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1. INTRODUCTION 
 
1.1 Relevance of posttranslational modifications in living cells 
Cells need to face and react to influences in their environment irrespective of being a 
protozoon or part of a higher organism to ensure their viability or to fulfill specialized 
tasks of a united cell-structure in a higher organism. 
Therefore highly organized interconnected signaling networks evolved sensing extra- or 
intracellular stimuli and induce diverse changes ranging from altered transcription to the 
activation or repression of protein functions. The bases of these signaling networks are 
small molecules that can be attached to other molecules such as proteins, RNA or lipids 
to induce altered affinities or binding properties for other molecules as well as to 
regulate functional aspects such as enzymatic activity or cellular localization. These so-
called posttranslational modifications permit much faster signaling and reaction than for 
example any altered transcription/translation modules could (Walsh, 2007).  
Posttranslational modifications of proteins also greatly extend the functional diversity 
and dynamics of the proteome. The usually transient attachment of small molecules 
such as phosphate, methyl or acetyl groups to certain proteins is well established 
(Cheung, 2000; Cohen, 2001; Walsh, 2007; Yang and Seto, 2008; Ng, 2009). Additionally, 
there are small proteins in eukaryotic cells that can be covalently attached to other 
proteins. The most prominent member of these modifiers is ubiquitin, after which this 
group is named. Other Ubiquitin-like modifiers (UBLs) are SUMO, NEDD8, ISG15, Fat10, 
Atg8 or Atg12 (Kerscher, 2006; Hochstrasser, 2009).  
1.2 Ubiquitin modification of proteins 
Since ubiquitin was discovered in 1975, it became apparent that posttranslational 
modification of proteins by ubiquitin plays an important role in diverse cellular 
processes, including cell division, differentiation, signal transduction, protein trafficking, 
and quality control (Schlesinger, 1975; Hershko, 1983; Ciechanover, 2005; 
Mukhopadhyay and Riezman, 2007). It is a highly conserved protein ubiquitously 
expressed in all eukaryotes with a size of 8,5 kDa and can be covalently attached to 
proteins by free lysine, cysteine, or N-terminal residues by specific enzymatic cascades. 
These cascades typically involve E1, E2 and E3 enzymes (see section 1.2.1). The most 
abundant attachment form of ubiquitin is the conjugation to lysine (K) residues in its 
substrate molecules (Glickman and Ciechanover, 2002; Bloom, 2003; Cadwell and 
Coscoy, 2005). Mono-ubiquitylation, the addition of a single ubiquitin moiety per 
targeting site, was shown to modulate protein endocytosis, intracellular transport, and 
DNA repair (see section 1.2.2.1; Haglund, 2003; Ulrich, 2005; Acconcia, 2009; Thompson 
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and Hinz, 2009). Attached mono-ubiquitin can be further modified to generate poly-
ubiquitin (polyUb) chains via linkages between several ubiquitin molecules, of which the 
most prominent is the K48-linked chain that targets the conjugated substrate for 
proteasomal degradation (see section 1.2.2.2; Hochstrasser, 2006). 
1.2.1 Mechanistic aspects of Ubiquitin conjugation 
Ubiquitin forms a stable β-grasp fold which is shared by all UBLs despite low sequence 
homologies. This suggests a common ancestry and indeed, the β-grasp fold may have 
arisen as an RNA-binding module in a primitive protein-translation system (Burroughs, 
2007). Furthermore, the UBL conjugation pathway shows some similarity to bacterial 
sulphur transfer enzymes within the biosynthesis pathways of the molybdenum cofactor 
and thiamine (Iyer, 2006; Hochstrasser, 2009). 
Four ubiquitin genes in humans encode a total of 14 copies of ubiquitin, so that it is 
synthesized as a linear poly-ubiquitin chain (Wiborg, 1985). To generate free cellular 
mono-ubiquitin molecules, theses chains require proteolytic processing by 
deubiquitylases (DUBs; Komander, 2009b). The single ubiquitin molecules then 
terminate with the typical Gly-Gly motif, which is common to all UBLs and which is 
indispensible for substrate modification (Hershko, 1981; Dye and Schulman, 2007).  
Mechanistically, the covalent attachment of ubiquitin to substrate proteins involves 
several enzymatic steps, carried out by three types of enzymes – E1, E2 and E3 (see 
Figure 1.1; Hershko, 1983). The E1 enzyme (Ubiquitin activating enzyme, e.g. Ube1) 
activates ubiquitin for transfer by adenylating its C-terminus in an ATP-dependent step. 
Ubiquitin is then coupled to the E1 active site cysteine, forming a reactive thioester 
between E1 and the C-terminal glycine of ubiquitin (Ciechanover, 1981; Hershko, 1981; 
Ciechanover, 1982). The activated ubiquitin is subsequently transferred to one of the 
distinct ubiquitin-conjugating enzymes (Ubc’s; E2s) by transthiolation to a conserved 
cysteine of the E2 (Pickart and Rose, 1985; Haas and Bright, 1988). The E2 proteins 
catalyze substrate ubiquitylation in conjunction with an ubiquitin-protein ligase (E3). The 
concerted action of different E2 and E3 enzymes provide substrate specificity to the 
ubiquitin conjugation reaction (Reiss, 1989; Sung, 1991; Pickart and Eddins, 2004; 
Hochstrasser, 2006; Christensen, 2007). During this last step of the enzymatic cascade, 
the ubiquitin molecule is usually transferred to an ε-amino group of a lysine side chain in 
the substrate, thereby forming a peptide-like amide bond (isopeptide bond; Goldknopf 
and Busch, 1977; Hershko, 1983; Pickart and Eddins, 2004). By adding activated ubiquitin 
moieties to internal lysine residues on the previously conjugated ubiquitin molecule, 
poly-ubiquitin chains are synthesized (see section 1.2.2.2; Chau, 1989; Hershko and 
Ciechanover, 1998).  
Whether ubiquitin chain assembly is mediated via a simple sequential addition of 
ubiquitin moieties to the nascent chain on the substrate or via pre-assembly on E2/E3 
active sites and subsequent transfer onto the substrate is currently under debate 
(Hochstrasser, 2006; Li, 2007; Ye and Rape, 2009).  
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Figure 1.1: ubiquitin conjugation cascade 
Ubiquitin is expressed as polyprotein; the C-terminal di-glycine motif of individual ubiquitin moieties is 
exposed after cleavage mediated by deubiquitylating enzymes (DUBs). Ubiquitin is activated by E1 
enzymes under ATP consumption and forms a thioester to the E1 active cysteine. Activated ubiquitin is 
then transferred to an E2 enzyme. E2 and E3 enzymes ubiquitylate the substrate in a concerted action. 
Attachment to other ubiquitin molecules forms poly-ubiquitin chains. Some types of ubiquitin chains are 
recognized by the proteasome that degrades the substrate. Modified from (Miteva, 2010). 
1.2.1.1 E1 enzymes  
There are two different E1 enzymes for ubiquitin activation in vertebrates, Ube1/UBA1 
and Ube1L2/UBA6. They share 40 % of sequence homology to each other (Ciechanover, 
1981; Ciechanover, 1982; Chiu, 2007; Jin, 2007; Pelzer, 2007). Ube1L2 was identified as 
an ubiquitin E1 in 2007, so before it was assumed that Ube1 is the only ubiquitin 
activating enzyme in vertebrates as it is in lower eukaryotes (Schulman and Harper, 
2009). Ube1 charges most known ubiquitin E2 enzymes whereas Ube1L2 has a selective 
ubiquitin E2 enzyme, Ube2Z/Use1 (Jin, 2007). Furthermore, Ube1L2 is capable to 
activate F-locus associated transcript 10 (FAT10), a UBL, in vivo and in vitro (Chiu, 2007).  
1.2.1.2 E2 enzymes  
Family members of the ubiquitin conjugating enzymes (E2s) all possess a highly 
conserved ubiquitin-conjugating (Ubc) catalytic fold (van Wijk and Timmers, 2009). 
These 14-16 kDa domains have an approx. 35 % sequence conservation among different 
family members and provide a binding platform for E1s, E3s, and the activated ubiquitin 
or UBL (Burroughs, 2008). The catalytic cysteine, which accepts the activated ubiquitin 
molecule, is embedded within this domain (van Wijk and Timmers, 2009).  
Until now, 38 E2s have been identified in humans and some of them promote 
specifically the conjugation of ubiquitin-like modifiers other than ubiquitin (Ye and Rape, 
2009). Together with the respective E1 enzymes, this specificity results in parallel 
conjugation pathways of ubiquitin and UBLs, although there are some cases of crosstalk 
(e.g. the ubiquitin E2 Ube2L6/UbcH8 is shared by ISG15 or the before mentioned use of 
Ube1L2 by ubiquitin as well as by FAT10; Kim, 2004; Zhao, 2004; Chiu, 2007). Several E2s 
play distinct roles in the ubiquitylation of a substrate. Although most E2s ubiquitylate 
substrates without any intrinsic selectivity for a specific acceptor lysine, some stimulate 
ubiquitin chain assembly through a defined lysine in ubiquitin. In these cases, the next 
INTRODUCTION 
4 
 
ubiquitin molecule being assembled is positioned in such a way that only the respective 
acceptor lysine side chain can attack the thioester bond to the E2 (Ye and Rape, 2009). 
Examples are the E2 MMS2/Ubc13 complex in the assembly of K63-linked chains 
(Hofmann and Pickart, 1999; Deng, 2000; VanDemark, 2001) or the UbcH10/Ube2S 
complex in the assembly of K11-linked chains (Williamson, 2009). 
Other E2s, such as UbcH5, catalyze the formation of ubiquitin chains that lack specificity 
for any lysine residue of ubiquitin (Brzovic and Klevit, 2006). 
1.2.1.3 Ubiquitin E3 ligases 
Approximately 600-1000 E3s exist in the human genome, some of which belong to a 
special class like the RING (really interesting new gene), the HECT (homologous to E6AP 
C-terminus) or the U-Box domain family (Hatakeyama and Nakayama, 2003; Li and Ye, 
2008; Deshaies and Joazeiro, 2009; Rotin and Kumar, 2009). 
For the HECT-domain family of E3s, ubiquitin is first transferred to a conserved cysteine 
of the E3 before it is finally transferred to a substrate group (Huibregtse, 1995; Rotin and 
Kumar, 2009). For most other ubiquitylation reactions, the E3 rather functions as an 
adaptor that positions the substrate in close proximity to the reactive E2~ubiquitin 
thioester. The majority of such E3s belong to the RING-based domain family (~616 
proteins; Freemont, 1991; Deshaies and Joazeiro, 2009). In addition to substrate 
recognition, E3s might have other roles in the catalytic cycle, such as allosteric activation 
of the E2 as well as mediating linkage-specific poly-ubiquitin chain assembly together 
with the respective E2 enzymes (Huang, 2004; Pickart and Eddins, 2004; Deshaies and 
Joazeiro, 2009).  
1.2.1.3.1 RING/U-Box ligases 
The RING domain was first described in 1991 and was thought to mediate DNA binding 
or protein dimerization (Freemont, 1991; Joazeiro and Weissman, 2000; Deshaies and 
Joazeiro, 2009). Only later it became clear, that many RING domain containing proteins 
serve as ubiquitin ligases and bind to E2 enzymes (Bailly, 1997; Zachariae, 1998; 
Joazeiro, 1999; Kamura, 1999; Lorick, 1999; Deshaies and Joazeiro, 2009). The consensus 
sequence of a RING domain is  
C-X2-C-X(9-39)-C-X(1-3)-H-X(2-3)-C-X2-C-X(4-48)-C-X2-C  
(where X is any amino acid). The conserved cysteine and histidine residues complex two 
zinc atoms while forming an interleaved globular structure, the RING domain (see Figure 
1.2; Barlow, 1994; Borden, 1995). RING domain E3 ligases are either part of a multi-
subunit complex or act as homo- or heterodimers to mediate substrate ubiquitylation 
(Sharp, 1999; Hashizume, 2001; Xia, 2003; Thornton and Toczyski, 2006; Kawai, 2007). 
Other domains such as the B-Box of the tripartite motif (TRIM) subfamily of RING 
proteins (see section 1.6; Tao, 2008) and the U-Box are structurally related to the RING 
(Aravind and Koonin, 2000).  
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Figure 1.2: RING domain – Dimer and cross-brace structure 
A) Structure of the RING heterodimer BARD1/BRCA1. The dimer interface is further stabilized through α-
helical interactions (Brzovic, 2001). 
B) Schematic representation of a RING domain. The primary sequence organization of the RING domain is 
folded in a cross-brace structure to coordinate the two zinc atoms. The first cysteine that coordinates zinc 
is labeled as C1, and so on. H1 denotes the coordinating histidine. Xn refers to the number of amino acid 
residues in the spacer regions between the zinc coordinating residues (modified from Deshaies and 
Joazeiro, 2009). 
1.2.1.4 Deubiquitylating enzymes  
Deubiquitylases (DUBs) exhibit three major functions: They generate the pool of free 
ubiquitin molecules by cleaving the newly translated linear ubiquitin chains into single 
molecules. Then, they can remove ubiquitin (chains) from modified substrates. 
Additionally, DUBs associated with the proteasome are responsible for ubiquitin 
recycling from proteins prone for degradation (Lam, 1997; Park, 1997; Borodovsky, 
2001; Verma, 2002; Komander, 2009b). Furthermore, some DUBs can edit the form of 
ubiquitin modification by trimming ubiquitin chains (Wertz, 2004). In the human 
genome, approx. 79 genes encode for deubiquitylases of which nearly all family 
members are cysteine proteases while the members of one subgroup are zinc 
metalloproteases (Nijman, 2005).  
1.2.1.5 Ubiquitin binding domains 
Diverse proteins in the ubiquitin signaling pathway need to recognize and distinguish 
ubiquitin and its diverse chained forms from each other and from other UBLs. Therefore, 
a range of ubiquitin binding domains (UBDs) exist (UIMs, UBXs, UBAs, etc.), most of 
which recognize a specific hydrophobic patch around ubiquitin’s Ile44.  The diverse UBDs 
differ in their structure and do not necessarily share a common motif (Dikic, 2009). 
Furhtermore, some UBDs have been shown to act as a cis-E3 mono-ubiquitin ligase, 
promoting self-ubiquitylation of the protein they are part of (Hoeller, 2007). 
 
A B 
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1.2.2 Mono-ubiquitylation and polymeric ubiquitin chains 
Ubiquitin can be attached to the substrates in multiple ways. 
The following scheme (Figure 1.3) gives an impression of the variety of signals achieved 
by different ubiquitylation types.  
 
 
Figure 1.3: Different forms of ubiquitylation 
A) The three general forms of ubiquitylation: mono-ubiquitylation, multiple mono-ubiquitylation and poly-
ubiquitylation. B) Forms of homotypic poly-ubiquitylation. Each ubiquitin chain contains a single linkage 
type which may lead to distinct ubiquitin chain conformations. Multiple homotypic ubiquitin chains on the 
same substrate are possible. C) Forms of heterotypic poly-ubiquitylation. In mixed linkages, a ubiquitin 
chain has alternating linkage types. In branched or forked poly-ubiquitin chains, a single ubiquitin is 
extended at two or more lysine residues. The scheme was modified from (Komander, 2009a). 
1.2.2.1 Mono-ubiquitylation 
Mono-ubiquitylation in general serves as a signaling module to confer additional 
protein-protein interaction properties to its substrate proteins. In the case of receptor 
endocytosis, it regulates the internalization and sorting of the modified receptor that is 
either recycled or further transported to the endo-lysosomal compartment for 
degradation (Levkowitz, 1998; Levkowitz, 1999; Joazeiro, 1999; Acconcia, 2009).  
In the case of the processivity factor “Proliferating cell nuclear antigen” (PCNA) 
monoubiquitylation results in the recruitment of a damage-tolerant polymerase and 
translesion synthesis while the modification of the same residue with a K63-linked chain 
results in an error-free damage avoidance pathway. Its modification with the small 
ubiquitin related modifier (SUMO) facilitates DNA damage tolerance upon replication 
fork stalling by recruitment of Srs2 (Hoege, 2002; Stelter and Ulrich, 2003; Kannouche, 
2004; Pfander, 2005; Ulrich, 2005).  
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1.2.2.2 Poly-ubiquitin chains 
Ubiquitin possesses seven lysine residues on its surface, namely K6, K11, K27, K29, K33, 
K48 and K63 that can all serve as acceptor sites for additional ubiquitin molecules in 
vitro and in vivo, thereby forming poly-ubiquitin chains (see Table 1.1; Arnason and 
Ellison, 1994; Johnson, 1995; Baboshina and Haas, 1996; Peng, 2003). Poly-ubiquitin 
chains consisting of four ubiquitin moieties attached through K48 linkages typically mark 
a protein for proteasomal degradation (Hershko, 1983; Chau, 1989; Hershko and 
Ciechanover, 1998; Pickart and Fushman, 2004). Chain formation through other lysine 
residues of various lengths and shapes results in various chain conformations and create 
a range of molecular signals in the cell (Kim, 2007; Ikeda and Dikic, 2008). In addition, 
linear chains are also assembled in vivo by head-to-tail arrangement of ubiquitin 
moieties through the α-amino group at the N-terminus (Kirisako, 2006). Recently, it has 
been postulated, that all non-K63-linked ubiquitin chains target proteins for degradation 
(Xu, 2009). 
 
Table 1.1: Relative cellular abundance and form of homotypic poly-ubiquitin chains 
Chain  via abundance Cellular functions  Chain form  
Lys48 29 % Protein degradation via the UPS (Pickart and 
Eddins, 2004) 
zig-zagged compact helix, 
lefthanded (Eddins, 2007) 
Lys63 17 % modulation of protein-protein interactions 
(Wang, 2008; Komander, 2009c) 
pseudo-linear; open, left-
handed helix  
(Komander, 2009c) 
Lys11 28 % Protein degradation in response of ER stress 
(Xu, 2009) 
tube or helix  (Bremm and 
Komander, 2009) 
Lys6 N.D. inhibits ubiquitin-dependent proteolysis 
(Shang, 2005) 
N.D. 
Lys33 3 % N.D. N.D. 
Lys29 3 % linked to lysosomal degradation 
(Chastagner, 2006) 
N.D. 
Lys27 9 % N.D. N.D. 
Met1 N.D. TNF/NFκB signaling (Haas, 2009; Iwai and 
Tokunaga, 2009) 
linear (Komander, 2009c) 
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1.2.2.2.1 K48-linked chains and the Ubiquitin-Proteasome system 
The majority of intracellular proteins are degraded via the ubiquitin proteasome system 
(UPS) (Lee and Goldberg, 1998). The ‘housekeeping’ 26S proteasomes are ATP-driven, 
multi-subunit proteolytic complexes that preferentially degrade proteins tagged with 
K48-linked poly-ubiquitin chains (Hershko, 1980; Chau, 1989; Hershko, 1991; Seufert and 
Jentsch, 1992; Hershko and Ciechanover, 1998; Voges, 1999; Elsasser and Finley, 2005). 
26S proteasomes are comprised of a 20S core component and two flanking 19S 
regulatory complexes that regulate substrate specificity and access to the catalytic 
chamber of the 20S core. The 20S core is highly conserved from yeast to humans; 
simpler prototypes are also found in prokaryotes (Löwe, 1995). Four α- and β-rings 
surround a barrel-shaped cavity in the 20S core (Groll, 1997). The two inner β-rings form 
a central chamber that harbors the proteolytic centers containing chymotryptic-, tryptic- 
and caspase-like activities (Marques, 2009). Tetra-ubiquitin is the minimum signal for 
efficient proteasomal targeting. The mechanism of targeting involves an increase in 
substrate affinity that is brought about by autonomous binding of the K48-linked tetra-
ubiquitin chain. Binding is mediated by the UBDs (see section 1.2.1.5) of the 19S 
subunits Rpn10/S5a and Rpn13 (Deveraux, 1994; Lam, 2002; Groll, 1997; Husnjak, 2008; 
Schreiner, 2008). Recognition of this signal is followed by substrate unfolding and 
translocation into the degradation chamber while ubiquitin itself is recycled. After 
degradation, the resultant peptides are released through the entry channel (Finley, 
2002; Hutschenreiter, 2004; Komander, 2009b). 
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1.3 Ubiquitin-like modifiers 
Ubiquitin is the most prominent and most abundant member of a diverse group of 
evolutionarily conserved small proteins that are covalently conjugated to target 
proteins, the ubiquitin-like modifiers (UBLs). Although the other members vary in their 
degree of sequence similarity to ubiquitin, they all share the typical β-grasp fold and 
seem to be conjugated through an analogous enzymatic cascade of specific E1, E2 and 
E3 enzymes (see table A.1; Kerscher, 2006). Each UBL contains one or two glycines at the 
C-terminus that is used to form the isopeptide bond with target proteins. Most UBLs 
(with the exception of FAT10, ATG12 and URM1) are synthesized as precursors whose 
conjugation requires C-terminal cleavage at this glycine through specific processing 
proteases (Groettrup, 2008). Barring ubiquitin, the so far best studied UBLs are the 
family members of small ubiquitin related modifiers (SUMO) which have a wide range of 
substrates and functions (Hochstrasser, 2009). As this thesis is mainly dealing with a new 
function for the SUMO modification of proteins, this group is described in more detail 
(see section 1.4). Functions of other UBL family members are summarized in Appendix 
table A.1; a phylogenetic tree for all human UBLs is displayed in Figure 1.4. 
 
 
Figure 1.4: Phylogenetic tree of human Ubiquitin-like modifiers  
The tree was derived through human UBL sequence comparison using MAFFT and virtualized with its 
associated software ArchaeopterixA (Katoh and Toh, 2008). Urm1 represents the closest relative to the 
ancestors of UBLs; the human Atg8 homologues as well as the human SUMOs are sub grouped.  
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1.4 SUMO modification of proteins 
An increasing number of proteins have been shown to be SUMO modified and many of 
them are tumor suppressor proteins, transcription factors or nuclear body proteins. 
SUMO is an ubiquitin-like protein and its conjugation to substrates (SUMOylation) is thus 
a reversible process including the typical enzymatic cascade with a SUMO-specific set of 
E1, E2 and E3 enzymes and a special set of proteases (see section 1.4.2 and Figure 1.7 
therein; Xu, 2009).  
SUMO is highly conserved in all eukaryotes, but lower eukaryotes like the yeasts 
S.cerevisiae and S. pombe as well as the nematode C. elegans possess only a single gene, 
while in mammalian cells four SUMO paralogs exist (Xu, 2009). Plants even have up to 
eight SUMOs (Kurepa, 2003; Lois, 2003). All SUMO paralogs are translated as precursors 
that need to be processed to produce the mature di-glycine motif at the C-terminus (Xu, 
2009). Compared to ubiquitin, all SUMOs possess a flexible N-terminal extension (see 
Figure 1.5; Bayer, 1998; Huang, 2004). 
 
 
Figure 1.5: Comparison of the three-dimensional structures of ubiquitin, SUMO-1 and SUMO-2 
NMR structures of human ubiquitin (PDB ID: 1D3Z), SUMO-1 (PDB ID: 1A5R) and SUMO-2 (PDB ID: 2AWT) 
as ribbon diagrams. Despite their low sequence homology, ubiquitin and the SUMO paralogues share the 
highly conserved three-dimensional structure of the β-grasp fold (α-helices are depicted in green, β-
strands in yellow). Structures were displayed using Cn3D 4.1. 
 
Out of the four mammalian SUMOs, SUMO-4 is probably not able to be conjugated to 
substrates (Owerbach, 2005), whereas SUMOs 1-3 are conjugated to lysines in their 
substrate proteins forming a covalent amide bond (SUMOylation; Johnson and Blobel, 
1997; Johnson, 1997; Sampson, 2001). SUMO-1 shares 44 % sequence identity with 
SUMO-2 and SUMO-3 which are 97 % identical in their processed and conjugatable form 
(see Figure 1.6). Therefore, they are commonly seen as entity (Lapenta, 1997; Chen, 
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1998; Maticvan Hagen, 2008). Yeast SUMOs (Bencsath, 2002; Bylebyl, 2003; Skilton, 
2009) as well as SUMO-2/3 harbor a consensus SUMOylation motif ΨKxE/D (where Ψ 
represents a hydrophobic and x any amino acid) and are able to form polymeric chains 
via a lysine residue in their N-terminus (K11) (Tatham, 2001). For SUMO-1 this has not 
been observed in vivo. 
 
 Ubiquitin   --------------------------------------------MQIFVKTLTGKTITLEVEPSD----21 
 Smt3-       MSDS-------------------EVNQEAKPEVK--PEVKPETHINLKV-SDGSSEIFFKIKKTT----43 
 Pmt3p       MSESPSANISDADKSAITPTTGDTSQQDVKPST---------EHINLKVVGQDNNEVFFKIKKTT----56 
 SUMO-1      MSD-----------------------QEAKPSTEDLGDKKEGEYIKLKVIGQDSSEIHFKVKMTT----42 
 SUMO-2      MAD-------------------------EKPKEG--VKTENNDHINLKVAGQDGSVVQFKIKRHT----38 
 SUMO-3      MSE-------------------------EKPKEG--VKTE-NDHINLKVAGQDGSVVQFKIKRHT----37 
 SUMO-4      MAN-------------------------EKPTEE--VKTENNNHINLKVAGQDGSVVQFKIKRQT----38  
 
 
 Ubiquitin TIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG--------------76 
 Smt3p      PLRRLMEAFAKRQGKEMDSLRFLYDGIRIQADQTPEDLDMEDNDIIEAHREQIGGATY----------101 
 Pmt3p       EFSKLMKIYCARQGKSMNSLRFLVDGERIRPDQTPAELDMEDGDQIEAVLEQLGGCTHLCL-------117 
 SUMO-1      HLKKLKESYCQRQGVPMNSLRFLFEGQRIADNHTPKELGMEEEDVIEVYQEQTGGHSTV---------101 
 SUMO-2      PLSKLMKAYCERQGLSMRQIRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQTGGVY------------95 
 SUMO-3      PLSKLMKAYCERQGLSMRQIRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQTGGVPESSLAGHSF--103 
 SUMO-4      PLSKLMKAYCEPRGLSVKQIRFRFGGQPISGTDKPAQLEMEDEDTIDVFQQPTGGVY------------95 
 
Figure 1.6: Multiple sequence alignment of human and yeast SUMO isoforms compared to ubiquitin 
All SUMOs display an N-terminal extension missing in ubiquitin. Additional residues C-terminally of the di-
glycine motif (which is highlighted in grey) have to be processed to form mature SUMOs. SUMO-4 cannot 
be processed to its mature form due to a proline residue (displayed in red) which prevents access to the 
catalytic center of the SUMO proteases (Owerbach, 2005). The SUMO-4 MV substitution at position 55 
associated with a higher susceptibility for type 1 diabetes is depicted in magenta. Conjugatable lysine and 
methionine residues are highlighted in green, boxes represent the main attachment sites for polymeric 
chain assembly. The K42, K41 and K54 attachment sites in SUMO-2, SUMO-3 and Smt3, correspondingly, 
as well as the respective SUMO1 lysines have been shown in vitro only (Pedrioli, 2006; Jeram, 2010). 
SUMO-1 was shown to be phosphorylated in vivo at S2 (depicted in blue). Sequences were aligned using 
MAFFT version 6 (Katoh and Toh, 2008). 
 
Non-covalent interactions of proteins with SUMO or SUMOylated proteins, respectively, 
are conferred via SUMO interaction motifs (SIMs) (Minty, 2000; Song, 2004; Hannich, 
2005; Song, 2005; Hecker, 2006; see section 1.4.3). The majority of SUMO targets is 
modified at very low steady state levels in vivo. However, SUMOylation-deficient 
mutants can have striking effects, probably due to dynamic 
SUMOylation/deSUMOylation cycles (Johnson, 2004). 
 
1.4.1 SUMO proteins 
1.4.1.1 Yeast SUMOs: Smt3 and Pmt3 
In S.cerevisiae, SUMO is encoded by a single gene that was originally isolated as a 
suppressor of mutations in a centromeric protein and was therefore named suppressor 
of Mif Two 3 (SMT3) (Meluh and Koshland, 1995; Mannen, 1996). The SMT3 gene is 
essential for viability while its orthologue pmt3 (for S. pombe homologue of SMT3) in 
S. pombe is not, although mutants lacking pmt3 grow poorly and display severe defects 
in genome maintenance (Tanaka, 1999).   
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1.4.1.2 Mammalian SUMO isoforms 
Human SUMO-1 was identified as a homologue to the S.c. Smt3 protein and shares only 
18 % sequence identity to ubiquitin. It was the first SUMO paralog discovered - 
independently from several groups - and therefore was also aliased as hSmt3, Ubiquitin-
like modifier 1 (UBL1), PML-interacting clone 1 (PIC1), Sentrin or GAP modifying 
protein 1 (GMP1) (Boddy, 1996; Mannen, 1996; Matunis, 1996; Okura, 1996; Shen, 
1996). 
It is expressed in many different cell types, predominantly localized to the nucleus, 
where it generally remains in the conjugated form (Kamitani, 1997; Saitoh and Hinchey, 
2000). The first identified and best characterized substrate is the Ran-GTPase activating 
protein (RanGAP1). Conjugation with SUMO-1 localizes RanGAP1 to the nuclear pore 
complex (NPC) where it is involved in nuclear import/export (Matunis, 1996; Mahajan, 
1997). Another prominent substrate in mammalians is the promyelocytic leukemia 
protein (PML), the scaffold protein for PML nuclear bodies (PML-NBs) which are large 
nuclear protein complexes (Sternsdorf, 1997; Müller, 1998; Ishov, 1999). SUMOylation 
of PML is a prerequisite for the formation of PML-NBs and many proteins that are 
localized to PML-NBs are also SUMOylated (Zhong, 2000; Matunis, 2006; Bernardi and 
Pandolfi, 2007). A more detailed description of PML-NBs is given in section 1.7. 
Additionally, many transcription factors and chromatin-associated proteins are transient 
SUMO substrates (as, for example the before mentioned modification of PCNA in DNA 
repair pathways), so that SUMOylation is required for a variety of cellular processes 
(Zhao, 2007; see also section 1.4.4). In some cases, SUMO-1 modification is thought to 
counteract ubiquitylation and subsequent degradation of the substrate, as the 
modifications occur on the same lysine residue and exclude each other. An example for 
that is the Inhibitor of NFκB alpha (IκBα) whose SUMOylation stabilizes the protein, 
thereby inhibiting nuclear factor kappa B (NFκB) transcriptional activity (Desterro, 1998). 
SUMO modification often occurs on specific lysine residues within the before mentioned 
consensus motif, ΨKxE/D, which can be directly recognized by the SUMO conjugating 
enzyme Ubc9/Ube2I (Sampson, 2001). SUMO-1 has also been shown to be 
phosphorylated in vivo at the very N-terminus (serine 2), but a function linked to that 
modification has not been identified yet (Matic, 2008).  
SUMO-1 deficient mice are viable despite a first observation in which SUMO-1 deletion 
was lethal (Alkuraya, 2006). They lack any apparent phenotype, due to a compensatory 
utilization of SUMO-2/3 for SUMOylation of SUMO1 targets (Evdokimov, 2008; Zhang, 
2008). However, on the cellular level, a decreased localization of SUMO-2/3 modified 
RanGAP1 to the nuclear pore was observed and PML nuclear body formation was 
reduced. Interestingly, the amount of PML protein as well as its modification by SUMO-
2/3 was significantly reduced (Evdokimov, 2008). 
Generally, SUMO-2/3 supply the main reservoir of free SUMO that is used for 
conjugation in response to certain stress stimuli like heat and ethanol as well as 
oxidative and osmotic stress, resulting in high molecular weight SUMO conjugates 
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(HMW-SCs). This response involves the modification of many proteins as well as SUMO 
chain formation and is reversed upon recovery; partly due to the action of SUMO-
specific proteases (see section 1.4.2.4; Saitoh and Hinchey, 2000; Haindl, 2008; 
Golebiowski, 2009). SUMO chain formation through the consensus lysine 11 in both 
SUMO-2 and SUMO-3 results in mixed chains in vivo (Matic, 2008). The exact roles of 
SUMO conjugation in the cellular stress response is not fully understood; it might help to 
eliminate otherwise toxic proteins as indicated by a newly discovered pathway (see 
section 1.5). 
The non-conjugatable SUMO-4 isoform was originally characterized as a susceptibility 
gene for type 1 diabetes (Guo, 2004; Owerbach, 2005). This susceptibility is somehow 
limited to Asian populations as it is not found in Caucasians (Ikegami, 2008). Correlated 
to that was a polymorphism in SUMO-4 at position 55, with an amino acid substitution 
from methionine to valine (as depicted in Figure 1.6).   
1.4.2 Mechanistic aspects of SUMO conjugation 
 
 
Figure 1.7: SUMOylation cascade 
Before SUMO can be conjugated it needs to be processed to its mature form by SUMO proteases 
(SENPs/Ulps). The SUMO-E1 heterodimer SAE1/SAE2 activates SUMO and transfers it from the active site 
cysteine in SAE2 to the SUMO-E2 enzyme Ubc9. Ubc9 either directly recognize substrates with the SUMO 
consensus site ΨKxE (Ψ, hydrophobic; x any amino acid) or in conjunction with a SUMO-E3 ligase. In 
contrast to SUMO-1, SUMO-2, SUMO-3 and yeast SUMOs are able to form chains that can be reversed by 
SENP/Ulp activity. Modified from (Miteva, 2010). 
1.4.2.1 SUMO E1 enzymes 
SUMO conjugation follows in principle the same mechanism as ubiquitin conjugation. 
The SUMO E1 enzyme is a heterodimer composed of the proteins activation of Smt3p 
and the ubiquitin activating protein 2, short AOS1/UBA2, in yeasts or its mammalian 
homologues SUMO activating enzymes 1 and 2 (SAE1/SAE2). AOS1/SAE1 as well as 
UBA2/SAE2 display sequence similarities to the N- and C-terminal parts, respectively, of 
ubiquitin-activating enzymes (Dohmen, 1995; Johnson, 1997; Azuma, 2001). Both AOS1 
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and UBA2 are essential for viability in S. c., consistent with an essential function for 
SUMO modification (Dohmen, 1995; Johnson, 1997). 
A specific binding of the SUMO E2 enzyme Ubc9 is mediated by a ubiquitin-like domain 
in UBA2/SAE2 and that this binding involves a folding-upon-binding process of 
unstructured parts within the E1 enzyme (Lois and Lima, 2005; Wang, 2009). UBE1DC1, 
the E1 enzyme for Ufm1 modification, has been reported to also activate SUMO-2 in 
vitro and to colocalize with overexpressed SUMO-2 in vivo (Zheng, 2008). 
1.4.2.2 E2 enzyme Ubc9 
The E2 enzyme Ube2I/Ubc9 is the specific conjugation enzyme for SUMO (Desterro, 
1997; Johnson and Blobel, 1997; Schwarz, 1998; Knipscheer, 2007).  
Ubc9 is able to directly recognize substrates harboring the SUMOylation consensus site 
ΨKxE/D, to which it can bind without the help of an additional E3 enzyme (Sampson, 
2001). An extended motif, ΨKxExxS/T(P) induces phosphorylation-dependent 
SUMOylation of substrates harboring this motif, also termed the phospho-SUMOyl-
switch or for phosphorylation-dependent sumoylation motif (PDSM) (Hietakangas, 2003; 
Hietakangas, 2006; Yang and Gregoire, 2006).  
To promote chain formation, Ubc9 has a non-covalent binding site for SUMO (around 
residue H20) that is used to recruit another Ubc9-SUMO thioester intermediate 
(Tatham, 2003; Knipscheer, 2007). Ubc9 is essential for viability in most species, 
probably because Ubc9 deficiency leads to a complete abrogation of SUMOylation 
(Seufert, 1995; Jones, 2002; Johnson, 2004). An exception is S. pombe where 
SUMOylation itself is also not essential (Ho and Watts, 2003).  
1.4.2.3 SUMO E3 ligases 
Only a few SUMO E3 ligases have been identified so far. Substrate specificity is partly 
linked to the distinct intracellular localization of the ligases and of the substrates, 
respectively. Ran binding protein 2 (RanBP2), for example is associated with the NPC 
(Wu, 1995; Yokoyama, 1995); the Polycomb protein 2 (Pc2) is mainly found in large 
complexes on chromatin (Wotton and Merrill, 2007). Some SUMO E3 ligases have dual 
functions, for instance the Class IIa histone deacetylases (HDACs). HDAC7 has been 
shown to promote SUMOylation of PML independently of its deacetylase activity 
(Gregoire and Yang, 2005; Zhao, 2005; Gao, 2008; Martin, 2009). TOPORS, a 
Topoisomerase I and p53 binding protein (Haluska, 1999; Zhou, 1999), is the first 
example of a protein that possesses both ubiquitin and SUMO E3 ligase activity. The 
ubiquitination activity maps to a conserved RING domain in the N-terminal region of the 
protein and is regulated by phosphorylation, both of which are not required for 
SUMOylation activity (Rajendra, 2004; Weger, 2005; Park, 2008).  
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1.4.2.3.1 PIAS proteins 
The protein inhibitors of activated STAT (PIAS) were initially named for their ability to 
interact with and inhibit the signal transducer and activator of transcription (STAT) 
factors (Chung, 1997; Liu, 1998). PIAS proteins are evolutionarily conserved in 
eukaryotes with mammals encoding four PIAS genes, PIAS1, PIAS2 (PIASx), PIAS3 and 
PIAS4 (PIASy). Homologues of mammalian PIAS proteins are found in non-vertebrates, 
plants and yeast, including the S. cerevisiae proteins Siz1 and Siz2/Nfi1 (Johnson and 
Gupta, 2001; Palvimo, 2007). 
The Siz/PIAS (SP)-RING displays structural similarity to RING and U-Box domains and is, 
together with the C-terminal SIM, required for activation of the Ubc9~SUMO thioester 
for conjugation to substrates (Yunus and Lima, 2009). Thus, similarly to the function of 
RING-type ubiquitin E3 ligases, PIAS proteins are likely to act as adaptors between the 
Ubc9~SUMO intermediate and the SUMO substrate. 
1.4.2.3.2 RanBP2 
In vertebrate cells, the nucleoporin 358 (Nup358)/Ran binding protein 2 (RanBP2) is a 
major component of the nuclear pore complex (Wu, 1995; Yokoyama, 1995). RanBP2 
forms a complex with SUMOylated RanGAP1, the GTPase activating protein for Ran, 
thereby tethering it to the cytoplasmic filaments of the NPC (Matunis, 1996; Mahajan, 
1997). Despite being equally well modified by SUMO-1 and SUMO-2 in vitro, RanGAP1 is 
primarily modified by SUMO-1 in vivo. This paralog-selective modification is due to a 
more stable, higher affinity complex of RanBP2 and SUMO-1-modified RanGAP1 that 
preferentially protects it from SUMO isopeptidases (Zhu, 2009). Moreover, RanBP2 
functions as SUMO E3 ligase for RanGAP1 as well as for many other proteins in vitro and 
in vivo and is itself SUMOylated (Saitoh, 1998; Pichler, 2002; Kirsh, 2002; Dawlaty, 2008). 
A C-terminal domain, which is characterized by the presence of two internal repeats, is 
sufficient to efficiently promote SUMOylation in the presence of E1, E2, SUMO-1 and 
ATP in vitro (Pichler, 2002; Kirsh, 2002).  
1.4.2.4 SUMO proteases 
The first SUMO-specific proteases, the distantly related Ubiquitin-like proteases Ulp1 
and Ulp2, were discovered in S. cerevisiae (Li and Hochstrasser, 1999; Li and 
Hochstrasser, 2000; Schwienhorst, 2000). Ulp1 is essential for the G2/M transition in the 
cell cycle and its inactivation as well as overexpression of its catalytic domain is lethal, 
pointing towards the essential function of a balanced SUMOylation/deSUMOylation (Li 
and Hochstrasser, 1999; Takahashi, 2000; Mossessova and Lima, 2000). Ulp1 functions 
both in SUMO maturation as well as in substrate deconjugation and is located at the 
NPC (Li and Hochstrasser, 1999; Takahashi, 2000). Ulp2 instead is localized 
predominantly in the nucleoplasm and functions in the disassembly of SUMO chains (Li 
and Hochstrasser, 2000; Schwienhorst, 2000; Bylebyl, 2003) with implications for the 
restart of the cell cycle after DNA repair and the checkpoint-induced metaphase arrest 
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(Schwartz, 2007). Ulp2 deletion strains are viable despite showing an abnormal 
phenotype including chromosome mis-segragation and hypersensitivity to DNA 
damaging agents (Li and Hochstrasser, 2000; Schwienhorst, 2000).  
To date, six human SUMO specific proteases (SUSPs) or Sentrin specific proteases 
(SENPs) - SENP1, 2, 3, 5, 6 and 7 - have been discovered with diverse activities and 
localizations within the cell (listed in Figure 1.8; Xu, 2009). An additional family member 
is SENP8, which has been shown to be a deNEDDylating enzyme (Gan-Erdene, 2003). All 
SUMO proteases share a C-terminal ~ 250 amino acid long catalytic domain and differ in 
their N-termini which probably confer substrate specificity and intracellular localization.  
 
 
Figure 1.8: Schematic representation of human SUMO proteases and their cellular distribution 
The conserved SENP catalytic domain is represented in grey with catalytic residues in circles. The dotted 
line illustrates insertions within the catalytic domains of SENP6 and SENP7 (aa, amino acids; NPC, nuclear 
pore complex). Modified from (Mikolajczyk, 2007 and Xu, 2009). 
 
SENP1 has been shown to mediate particularly the deconjugation of SUMO-1 modified 
substrates within the nucleus, while SUMO-2/3 substrates remain largely unaffected 
(Yamaguchi, 2005). Moreover, it exhibits the highest endopeptidase activity among the 
SENPs with its processing activity during SUMO maturation follows the order SUMO-1 > 
SUMO-2 > SUMO-3 (Xu and Au, 2005). SENP2 instead has the highest maturation 
efficiency for SUMO-2 (Reverter and Lima, 2004). Both SENP1 and SENP2 have been 
located to the nucleoplasm and to the NPC (Gong, 2000; Hang and Dasso, 2002; Bailey 
and O'Hare, 2004). SENP3 and SENP5 are localized in the nucleolus (Nishida, 2000; Di 
Bacco, 2006; Gong and Yeh, 2006), though SENP5 might also function within the cytosol, 
where it has been shown to deSUMOylate a dynamin related protein, DRP1 that is 
involved in mitochondrial fission (Zunino, 2007). SENP3 and SENP5 show a preference 
for SUMO-2/3 over SUMO-1 maturation and deconjugation (Di Bacco, 2006; Gong and 
Yeh, 2006).  
SENP6 and SENP7 both contain an insertion within the conserved catalytic domain and 
have been found to disassemble specifically SUMO-2/3 chains analogous to Ulp2 
cleaving SUMO chains in S. cerevisiae. Partly deletions of the insertion in SENP7 reduce 
the affinity of SENP7 to bind SUMO-2/3 chains (Lima and Reverter, 2008). 
Endopeptidase activity towards the SUMO precursors has not been detected for any of 
the both enzymes (Mikolajczyk, 2007; Lima and Reverter, 2008). SENP6 and SENP7 have 
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been both located to the nucleoplasm where they might exert overlapping functions. 
RNAi mediated knockdown of SENP6 resulted in a drastic increase of PML-NB size and 
number, suggesting a function for SENP6 in the disassembly of SUMO-2/3 chains in 
these structures (Mukhopadhyay, 2006).  
1.4.3 SUMO interaction motifs 
Similar to the ubiquitin system, SUMO binding proteins display a common motif 
recognizing SUMO non-covalently. Unlike the interaction of ubiquitin and UBDs, binding 
to SUMO is mediated through a short motif, the SUMO interaction motif (SIM) or SUMO 
binding motif (SBM) (see Figure 1.9.A; Minty, 2000; Song, 2004; Hannich, 2005; Song, 
2005; Hecker, 2006).  
Three types of SIMs have been identified so far (see Figure 1.9.B). SIMa is characterized 
by a core consisting of four hydrophobic residues, immediately followed by a mixed 
cluster of S/D/E residues, the so-called acidic stretch. The third hydrophobic position in 
SIMa motifs is less conserved than the other hydrophobic positions and instead, also 
non-hydrophobic, even acidic residues may be present (Song, 2004; Hannich, 2005; 
Miteva, 2010). 
In a reversed orientation of that motif, SIMr, the acidic stretch precedes the 
hydrophobic core (Song, 2005; Hecker, 2006). 
The type b SIM usually sticks to the consensus sequence V-I-D-L-T, with some variations 
in the first two hydrophobic amino acids (Uzunova, 2007; Miteva, 2010). 
Mixed SIM types are also present, the PIAS SIMs, for example are of type b, followed by 
an acidic stretch. Whether these types of SIMs have different binding capacities towards 
different SUMO isoforms remains to be elucidated, although there is a hint that SIM 
type b binds SUMO-2/3 with a higher affinity than SUMO-1 (Sekiyama, 2008).   
Binding occurs upon insertion of the hydrophobic SIM core into a hydrophobic cleft 
between the β2-strand and helix α1 of the SUMO molecule, forming a parallel β-sheet 
together with the β2-strand (Reverter and Lima, 2005; Song, 2005; Hecker, 2006; 
Sekiyama, 2008). An example is depicted in Figure 1.9.A; the SIMb from PIAS2 bound to 
SUMO-1. 
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Figure 1.9: SUMO interaction motifs (SIMs) 
A) Ribbon diagram of the SIMb from PIAS2 bound to human SUMO-1 (based on structure PDB ID: 2ASQ).      
B) Residue conservation of the three SIM types is shown in a sequence logo representation. Overall height 
of a position indicates its information content; height of individual residues indicates their frequency at 
that position (charged amino acids are displayed in black, polar in green and hydrophobic in blue). 
Pictures were taken from (Miteva, 2010). 
 
Furthermore, SIMs often contain serine and threonine residues that are able to be 
acidified by phosphorylation (Hecker, 2006). A recent publication showed that binding to 
SUMO by the SIM of PIAS1 is enhanced after Casein kinase II (CK2) phosphorylation of 
serine residues adjacent to the SIM core domain (Stehmeier and Müller, 2009). Serine 
residues in similar SIMs, for example within the PML protein, were also shown to be 
phosphorylated by CK2 after osmotic stress induction (Scaglioni, 2008; Stehmeier and 
Müller, 2009). This indicates an integrative crosstalk function for SIM motifs between 
the phospho- and SUMO-regulated signaling pathways within mammalian cells. 
In analogy to the activity of ubiquitin/substrate non-covalent interactions leading to 
mono-ubiquitylation (Hoeller, 2007), SIMs have also been shown to non-covalently 
recruit Ubc9~SUMO thioesters and serve as a cis-regulatory SUMO-E3 ligase modules 
(Lin, 2006; Knipscheer, 2008; Meulmeester, 2008; Cho, 2009).   
1.4.4 Cellular roles of SUMO modification 
Roles of SUMO modification in the cellular context are as multifaceted as the proteins 
subjected to SUMOylation. Some SUMO substrates are modified in the cytosol such as 
the inhibitor of NFκB, IκBα, thereby inhibiting cytokine or innate immune receptor 
signaling, or the mitochondrial fission GTPase DRP1 whose activity is linked to its 
SUMOylation (Figueroa-Romero, 2009). 
However, the vast majority of substrates are nuclear proteins, highlighting the primary 
nuclear functions of SUMOylation. As already mentioned above, SUMOylation is 
involved in DNA repair, transcriptional regulation, chromosome maintenance and 
mitosis, but also in inflammation, nuclear organization, protein localization and stress 
pathways, as reviewed in Gill, 2005; Ulrich, 2005; Matunis, 2006; Heun, 2007; Palvimo, 
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2007; Dasso, 2008; Tempe, 2008; Bergink and Jentsch, 2009; Garcia-Dominguez and 
Reyes, 2009. Deregulated SUMOylation may lead to cancer and is implicated in 
neurodegenerative diseases (Kim and Baek, 2006; Martin, 2007; Sarge and Park-Sarge, 
2009).  
Generally, SUMOylation is important for nuclear organization as many substructures as 
the nuclear envelope, Nucleoli and PML nuclear bodies are disrupted when the SUMO 
pathway is defective (Nacerddine, 2005; Heun, 2007).  
Proper protein localization upon SUMOylation is not only known for RanGAP1 and PML, 
but for many nuclear proteins and is mainly achieved by mono-SUMOylation or multiple 
mono-SUMOylation of a given protein and its interaction with SIM-containing partners 
(Matunis, 2006). Many transcription factors, for instance, relocalize to PML-NBs when 
SUMOylated (Johnson, 2004; Palvimo, 2007). Transcriptional regulation is also mediated 
through SUMOylation of transcriptional co-repressors or transcriptional activators 
(Palvimo, 2007; Garcia-Dominguez and Reyes, 2009).  
Dynamic SUMOylation/deSUMOylation events are also indispensable for sister 
chromatid separation in mitosis. The process is not fully understood but many 
centromeric proteins are SUMOylated, including yeast mif-2, whose mutant phenotype 
led to the discovery of SUMO (Dasso, 2008). Furthermore, many factors involved in DNA 
replication, telomere elongation and DNA repair are SUMOylation targets, thereby 
revealing also emerging connections between the SUMO and the ubiquitin pathways 
(Bergink and Jentsch, 2009; Galanty, 2009; Morris, 2009).  
A connection of the pathways was also discovered in the cellular response to stress.  
As already mentioned for SUMO-2/3 in humans (see section 1.4.1.2; Saitoh and Hinchey, 
2000), diverse stress stimuli upregulate SUMO-modification, generating HMW-SCs 
(Zhou, 2004). SUMO-targeted ubiquitin ligases (StUbLs) - or else - ubiquitin ligases for 
SUMO conjugates (ULS) recognize these HMW-SCs and target them for degradation via 
the proteasome. The next section will describe the discovery of these ligases in yeasts 
and their functional requirements. 
1.5 ULS proteins 
During the initial phase of this work, ULS proteins have been just identified in 
S. cerevisiae and in S. pombe.  
ULS proteins target SUMO-modified proteins for ubiquitylation and subsequent 
degradation. They contain a RING domain and one or several SIMs (as shown 
schematically in Figure 1.10).  
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 Slx5(S.c.)-- 20-NETVILIDSDKEEDASIRE   Slx5(S.c.)  111-SAHYVDLDQEPGQEPGSETLETPRTIQVDNTNG
 Slx5(S.c.)  473-KEETIIVTDDDLAKTLEDI   Slx8(S.c.)  158-KEQTVDLTADAIDLDAEEQQVLQISDDDFQEET 
 Slx8(S.c.)  174-EQQVLQISDDDFQEETKEA   Uls1(S.c.)  --2-AVPTIDLTLADSDNEDIFHSFSSSTSVDKIDIR 
 Uls1(S.c.) 1532-ANHVVIVDPFWNPYVEEQA   Rfp1(S.p.)  -10-ESSVIDLTRSPSPPVETSISSTNIIDLDAIPDD 
 Uls1(S.c.) -367-NSSIIILSDEDESGAGIND   Rfp2(S.p.)  -15-SPEVIDLTEDIEDD-GADVSEVTLLDLTRIPEF 
 Uls1(S.c.) -540-STQQILVDEAENQLNKLKE   Slx8(S.p.)  151-ISDMIDLTDETSYDPRKQKFEQGKNPSTTNAEI 
 
 
 
 
 
 
 
  
 
 
Figure 1.10: Yeast ULS proteins  
A) Alignment of proved and putative SUMO interaction motifs type a (boxed in dark grey) and type b 
(boxed in light grey) in ULS proteins from S. cerevisiae and S. pombe (hydrophobic residues within the SIM 
are displayed in blue, acidic in red and threonines in green).  
B) Schematic representation of yeast ULS proteins. Domains/Motifs are depicted relative to the total 
protein size (ULS, ubiquitin ligase for SUMO conjugates; SIM, SUMO interaction motif; aa, amino acids). 
1.5.1 S. cerevisiae Slx5-Slx8 and Uls1 
The S. cerevisiae ULS proteins, the RING containing proteins Slx5 (alias Hex3) and Uls1 
(alias Ris1 or Dis1) have been identified as non-covalent SUMO (Smt3) interacting 
proteins with each harboring several SIMs (for SIM type refer to Figure 1.10; Uzunova, 
2007). Slx5 was also isolated as a high-copy suppressor of a temperature-sensitive Ulp1 
mutant (Xie, 2007). Slx5 forms a RING dimer with Slx8 and the complex was shown to be 
an active ubiquitin ligase involved in genome stability (Mullen, 2001; Ii, 2007). Slx5-Slx8 
and ULS1 bind especially to HMW-SCs (Uzunova, 2007). Both Slx5-Slx8 and ULS1 target 
HMW-SCs for proteasomal degradation by a concerted action together with the 
redundant ubiquitin E2s Ubc4/Ubc5 (Uzunova, 2007). Further, an in vitro model 
substrate, a Rad52-SUMO fusion, was shown to be preferentially modified with ubiquitin 
by Slx5-Slx8 compared to Rad52 alone (Xie, 2007).  
1.5.2 S. pombe Rfp1/Rfp2-Slx8 
ULS proteins were also identified in S. pombe, where Slx8 forms a dimer with the 
redundant RING finger proteins Rfp1 and Rfp2. These are not related to Slx5 but also 
harbor several SIMs (see  
Figure 1.10) and were found to interact with S. pombe SUMO (Pmt3; Kosoy, 2007; 
Prudden, 2007; Sun, 2007). As Slx5, Rfp1 and Rfp2 lack intrinsic ubiquitin ligase activity 
but in a complex with Slx8 they form an active ubiquitin ligase targeting HMW-SCs and 
thus serve as functional homologues for Slx5. Cells lacking these complexes are sensitive 
to genotoxic stress and show genomic instability (Kosoy, 2007; Prudden, 2007; Sun, 
2007). Rfp1-Slx8 and Rfp2-Slx8 stimulate both the in vitro ubiquitylation of a GST-SUMO 
SIM type a SIM type b A 
B aa 
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fusion as well as of a di-SUMO mimicry, Rad60, which is involved in DNA repair 
(Prudden, 2007; Sun, 2007; Prudden, 2009). 
1.5.3 RNF4, a putative human ULS 
Proteasomal inhibition of HeLa cells showed a specific stabilization of SUMO-2/3 
conjugates while the SUMO-1 conjugate pattern appeared normal (Uzunova, 2007). 
Therefore, it was likely that also the ULS pathway is conserved to humans. Indeed, some 
of the before-mentioned ULS studies identified a small nuclear RING finger protein, 
RNF4, which could alone complement for the deletion phenotypes of the yeast ULS 
proteins (Kosoy, 2007; Prudden, 2007; Sun, 2007; Uzunova, 2007).  
RNF4 comprises 190 amino acids (aa) and contains a RING domain at its C-terminus and 
three to four putative SIMs in its short N-Terminus. It homodimerizes through its RING 
domain and undergoes self-ubiquitylation in vitro (Häkli, 2004). 
In human cells, RNF4 has been localized to the nucleus and there predominantly to PML 
nuclear bodies. Furthermore, it was shown to interact with PML when free SUMO-1 was 
added to the reaction, a behavior that is thought to be the basis of PML nuclear body 
formation (Häkli, 2005; for a detailed description of PML and PML-NBs refer to sections 
1.6 and 1.7). Altogether, these data point to a role for RNF4 as ULS but experimental 
data in a mammalian system as well as putative substrates are still missing. 
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1.6 The promyelocytic leukemia protein PML 
PML was first identified as part of an oncogenic fusion protein causing acute 
promyelocytic leukemia (APL, see section 1.8; Borrow, 1990; de The, 1990). It belongs to 
the TRIM family of proteins and is expressed in several isoforms (Jensen, 2001; 
Condemine, 2006). Post-translational modifications regulate PML stability, PML 
localization and PML nuclear body formation (see sections 1.6.1 and 1.7.1).  The PML 
gene is located on chromosome 15q22 and consists of nine exons (Fagioli, 1992). 
Alternative splicing of exons 5 to 9 yields in at least eleven isoforms, of which most are 
nuclear and only two are cytoplasmic (see Table 1.2 and Figure 1.11; Fogal, 2000; 
Jensen, 2001).  
   
Table 1.2: Human PML isoforms 
Name Alternative name(s)* Protein ID  
(NCBI database) 
Length 
[aa] 
Size 
[kD] 
Cellular 
localization 
PML1 PML I1, TRIM19 α2 NP_15023841 882 97.5 Nuclear 
PML2 PML V1, TRIM19 β2, PML12 NP_150243/48 611 67.4 Nuclear 
PML3 PML II1, TRIM19 γ2 NP_150245 824 90.2 Nuclear 
PML4 - - - - - 
PML5 PMLVI1; TRIM19 ε2 NP_150247 560 62.0 Nuclear 
PML6 PML IV1; TRIM19 ζ2; PML33 NP_002666 633 70.0 Nuclear 
PML7 PMLVIb1; TRIM19 η2 NP_150249 423 47.6 Cytoplasmic 
PML8 PML VIIb1; TRIM19 θ2 NP_150250 435 48.6 Cytoplasmic 
PML9 PML II1; TRIM19 κ2 NP_150242 829 90.7 Nuclear 
PML10 PMLIVa1; TRIM19 λ2 NP_150252 585 65 Nuclear 
PML11 - NP_150253 781 85.7 Nuclear 
PML-L3 PML III1 AAB19601 641 70.4 Nuclear 
*Alternative PML names from different publications: 1) Jensen, 2001; 2) Nisole, 2005; 3) Fogal, 2000 
 
At the N-terminus, coded by exons 1-3, all PML isoforms contain a tripartite motif that 
defines the TRIM family of proteins (see Figure 1.11; Condemine, 2006). It is 
characterized by a sequential arrangement of a RING domain, one or two B-Boxes and a 
coiled-coil domain, the RBCC motif (Reymond, 2001). PML (also aliased TRIM19) 
comprises two zinc-binding B-Boxes, B1 and B2, that are implicated in protein-protein 
interaction (Borden, 1998). The α-helical coiled coil domain has been shown to mediate 
PML multimerization (Kastner, 1992; Reddy, 1992). Exon 6 contains a nuclear 
localization signal that is not present in the alternatively spliced and therefore 
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cytoplasmic PML isoforms 7 and 8 (Jensen, 2001; Lin, 2004). A SIM ‘type a’ is coded by 
exon 7 and is not present in isoforms 5, 7 and 8 (see Figure 1.11; Shen, 2006). 
The differentially spliced C termini are relatively young in terms of evolution as mice 
only express two PML isoforms homologous to human PML1 and PML2 and might reflect 
the ability of different PML isoforms to interact with distinct binding partners 
(Condemine, 2006; Bernardi and Pandolfi, 2007).  
 
 
Figure 1.11: Human PML splice variants and domain organization 
Schematic representation of human PML gene (yellow), transcripts (blue) and protein (grey). The domain 
organization of the PML protein isoforms is exemplified for isoform 1; other isoforms vary in their C-
termini according to their alternatively spliced transcripts. Exons in frame (blue) represent translation in 
the same reading frame as isoform 1; out of frame (pale pink) the use of an alternative frame. Modified 
from (Nisole, 2005) and (Shen, 2006). 
 
The cellular expression levels vary between the different isoforms with PML1 and PML3 
being the most abundant ones (Condemine, 2006; Bernardi and Pandolfi, 2007). 
Overall PML expression is strongly induced by interferons (IFNs) type I and type II and 
the tumor suppressor p53 (Lavau, 1995; Stadler, 1995; de Stanchina, 2004). 
Furthermore, PML is frequently lost or downregulated in various solid tumors (Gurrieri, 
2004; Bernardi and Pandolfi, 2007). 
1.6.1 Posttranslational modifications of PML 
Apart from transcriptional control and alternative splicing, PML is highly regulated at the 
posttranslational level. The most prominent posttranslational modification of PML is the 
one with SUMO. PML colocalizes with and is covalently modified by all three 
conjugatable SUMOs: SUMO-1, SUMO-2 and SUMO-3 (Boddy, 1996; Sternsdorf, 1997; 
Kamitani, 1998a). PML contains three SUMOylation sites, namely K65 within the RING 
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domain, K160 at the end of B-Box 1 and K490 (K442 in PML 10 and 11) which is localized 
between the NLS and the SIM (see Figure 1.11; Kamitani, 1998b). The SUMO-1 
modification of PML is essential for PML nuclear body formation (see section 1.7.1; 
Müller, 1998; Duprez, 1999; Zhong, 2000). Other posttranslational modifications such as 
acetylation and phosphorylation have been shown to induce SUMOylation of PML upon 
diverse stimuli or to regulate other effects of PML (Hayakawa, 2008; Scaglioni, 2008; 
Stehmeier and Müller, 2009).  
PML can be phosphorylated by several kinases at multiple sites (Yang, 2002; Bernardi, 
2004; Scaglioni, 2008; Stehmeier and Müller, 2009). For instance, the extracellular 
signal-regulated kinase (ERK) has been shown to phosphorylate PML at several serine 
and threonine residues in the N-terminus and between the K442/490 SUMOylation site 
and the SIM after treatment with arsenic trioxide (As2O3, ATO), a therapeutic drug used 
in the treatment of APL (see section 1.8). This phosphorylation induces SUMO 
modification of PML and apoptosis (Hayakawa and Privalsky, 2004).  
1.6.2 PML functions 
PML is mainly seen as ‘the’ scaffold protein of PML nuclear bodies, sequestering the 
resident as well as the transient proteins to these structures through SUMO/SIM 
interactions as described in section 1.7 (Shen, 2006; Matunis, 2006). Therefore, most 
functions assigned to PML as the already mentioned one in apoptosis are mediated 
through the dynamic PML nuclear body network and are discussed in section 1.7.2. 
Additionally, PML might act as a SUMO E3 ligase, as PML self-SUMOylation was observed 
when expressed in S. cerevisiae (Quimby, 2006).  
Cytoplasmic PML has been found to be involved in the transforming growth factor 
(TGF) β signaling pathway as it interacts with the downstream regulators Smad2/3 and 
Smad anchor for receptor activation (SARA). PML deficient mice cells are resistant to 
TGFβ-dependent growth arrest, underlining the growth suppressive function of PML 
(Lin, 2004; Le Roy and Wrana, 2004).  
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1.7 PML Nuclear Bodies 
PML nuclear bodies are dynamic protein complexes within the nuclei of higher 
eukaryotic organisms with an average size of 0.2 µm to 1.0 µm diameter (see Figure 
1.12). They are defined by the presence of the PML protein that is thought to be the 
scaffold protein of these subnuclear domains (also aliased as nuclear domain 10, Kremer 
bodies or PML oncogenic domains; Bernardi and Pandolfi, 2007).  
 
 
 
 
Figure 1.12: PML nuclear bodies  
Fluorescent microscopy image of PML-NBs (red) in a HeLa cell nucleus. 
Chromatin is stained with DAPI (blue), the cytoplasmic microtubular network 
with anti-tubulin (green). 
 
To date, 166 proteins have been found to associate to PML nuclear bodies, constitutively 
or transiently in a dynamic interplay of the individual molecules (Weidtkamp-Peters, 
2008; Van Damme, 2010). Therefore, it is not surprising that they are implicated in the 
regulation of diverse cellular functions (see section 1.7.2). 
1.7.1 PML nuclear body formation 
The formation of PML-NBs is SUMO- and cell cycle dependent. Both, PML SUMOylation 
and the PML SIM are required for PML nuclear body formation (Müller, 1998; Zhong, 
2000; Shen, 2006). SUMO modification of many nuclear proteins results in the 
translocation to PML-NBs, for instance Sp100, Daxx, zinc finger proteins like ZNF198 or 
transcription factors like HSF2 (Sternsdorf, 1997; Goodson, 2001; Jang, 2002; Kunapuli, 
2006). However, mutant PML that lacks its SUMOylation sites fails to form the distinct 
PML-NB pattern. Moreover, other proteins usually located to PML-NBs do not 
accumulate in nuclear dots but display aberrant localization patterns (Zhong, 2000). 
Additionally, also the SIM of PML has been shown to be involved in PML-NB formation 
because a SIM-defective mutant localized in aberrant patterns that differed from the 
usual PML-NB pattern (Shen, 2006). The current model of PML nuclear body formation 
involves multiple SUMO-SIM interactions: First, between different PML dimers or 
multimers; second, between PML and other proteins and third between different PML-
NB proteins (Matunis, 2006; Shen, 2006). For instance, Daxx is recruited to PML-NBs 
through its C-terminal SIM (Lin, 2006). The interaction of Sp100 to the heterochromatin 
protein 1 (HP1) depends on the SUMOylation of Sp100 and both proteins are 
sequestered in PML-NBs (Seeler, 1998; Sternsdorf, 1999; Seeler, 2001). The association 
and dissociation of different proteins to and from the PML-NB network is a dynamic 
process with component exchange rates ranging from a few seconds, e.g. Daxx, to a 
minute. Most PML isoforms exchange every 10 minutes while isoform 2 exchanges at a 
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slower rate of about one hour. These observations point towards a special role for PML 
2 being the main scaffold form for PML-NBs (Weidtkamp-Peters, 2008). 
During mitosis, PML-NBs are disassembled due to PML deSUMOylation. The resulting 
PML accumulations contribute in G1 to the reestablishment of PML-NBs (Dellaire, 2006). 
Another factor that influences PML-NB integrity is chromatin. Several studies suggest 
that PML-NBs may have a direct connection with chromatin (Eskiw, 2003; Luciani, 2006; 
Lang, 2010). Upon radiation stress and nuclease treatments, PML-NBs increase their 
mobility immediately (Maul, 1995; Eskiw, 2004; Ching, 2005) and a recent study 
revealed that PML-NBs are formed de novo at telomeric DNA during interphase 
(Brouwer, 2009).  
1.7.2 Functions of PML nuclear bodies 
The PML nuclear body network has been implicated in a variety of functions due to the 
numerous associated proteins. They are involved in such diverse cellular processes as 
transcription, DNA repair, apoptosis, senescence, cell cycle and anti-viral defense 
(Dellaire and Bazett-Jones, 2004; Everett and Chelbi-Alix, 2007; Bernardi and Pandolfi, 
2007; Bernardi, 2008; Bourdeau, 2009). Deregulation of PML-NBs might induce 
carcinogenesis (Gurrieri, 2004). An overview of the functional distribution of PML-NB 
components is given in Figure 1.12.   
Despite the actual function of PML-NBs remains to be determined, three non-mutually 
exclusive hypotheses for the function of PML-NB network have been proposed:  
1) As ‘nuclear storage depot’ in which association to PML-NBs regulates the 
nucleoplasmic protein levels, for instance of transcription factors (Negorev and Maul, 
2001).  
2) As ‘sites of nuclear activity’ such as transcription and DNA repair (Ching, 2005).  
3) As a ‘nuclear platform for posttranslational modifications’ such as phosphorylation, 
acetylation, SUMOylation and ubiquitylation.  
Indeed, many kinases, phosphatases, acetylases, deacetylases and enzymes of the 
ubiquitin and SUMO pathway have been found to associate to PML-NBs (Boddy, 1996; 
Duprez, 1999; Engelhardt, 2003; Möller, 2003; Bailey and O'Hare, 2005; Saitoh, 2006; 
Yang, 2006; Bernardi and Pandolfi, 2007; Gao, 2008; Song, 2008; XuChan, 2009; Van 
Damme, 2010). 
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Figure 1.12: Functional distribution of PML-NB components 
For each category the number of proteins found to associate with PML-NBs during the given processes is 
plotted. The plot was generated by (Van Damme, 2010) and is based on the 166 proteins they identified to 
participate in the PML-NB network (PTM, posttranslational modification). The categories were merged to 
facilitate interpretation. 
 
PML-NBs are also involved in innate anti-viral mechanisms. This is already implicated by 
the IFN-induced upregulation of PML, Sp100 and Daxx which results in larger PML-NBs 
(Guldner, 1992; Lavau, 1995; Stadler, 1995; Shimoda, 2002). Further, many viruses 
evolved strategies to escape the PML-NB mediated defense and replicate slower when 
deficient for these factors (Everett and Chelbi-Alix, 2007). An example is the viral 
ubiquitin ligase ICP0 from Herpes simpex virus 1 (HSV-1). ICP0 targets PML and Sp100 for 
degradation (Chelbi-Alix and de The, 1999). With an ICP0-deficient HSV-1 mutant it was 
shown that PML-NB proteins Daxx, ATRX, PML and Sp100 relocate to the entry sites of 
viral DNA and are reorganized in putative PML-NBs at these DNA molecules (Everett and 
Murray, 2005; Everett, 2008; Lukashchuk and Everett, 2010). In analogy to PML-NB 
formation at sites of DNA repair and at telomeres (see section 1.7.1), it is tempting to 
speculate that some PML-NB proteins might somehow recognize naked DNA or DNA 
endings and relocate to these places, thereby initiating de novo PML-NB formation. 
Other viruses exploit PML-NBs through relocalization of PML-NB associated transcription 
factors to their genomes (Evans and Hearing, 2005; Everett and Chelbi-Alix, 2007).  
Together, PML-NBs might be an integrative network, sensing different cellular 
conditions and exerting many different functions by modulating the respective proteins 
in their activities through posttranslational modifications. That deregulation of such a 
INTRODUCTION 
28 
 
network might contribute to aberrant effects and cancerogenesis, is dramatically 
demonstrated in acute promyelocytic leukemia, in which PML-NBs are dispersed.  
1.8 Acute Promyelocytic Leukemia 
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) and is 
morphologically characterized by a differentiation block of the granulocytic lineage at 
the promyelocytic stage which results in faster cell divisions and cancer (de The, 1991; 
Goddard, 1991; Kakizuka, 1991; Pandolfi, 1991). In most cases, the genetic cause is a 
specific t(15;17) chromosomal translocation that results in a fusion of PML and the 
retinoid acid receptor alpha (RAR genes and proteins, the PML-RAR fusion (Rowley, 
1977; de The, 1990; Alcalay, 1991; Goddard, 1991; Kakizuka, 1991; Pandolfi, 1991; 
Chang, 1992). A proper assembly of PML-NBs is prevented in these cells and therefore, a 
large number of proteins mislocalize and contribute to the aberrant cell function in the 
leukemic cells (Melnick and Licht, 1999). 
Treatment of APL with chemotherapies used to have a poor prognosis, but over the past 
20 years, two novel agents, all-trans retinoic acid (ATRA)and ATO, have radically 
changed the prognosis of this disease. By now, APL is one of the rare malignancies that 
may be cured by targeted agents (Estey, 2006; Wang and Chen, 2008; Ravandi, 2009). 
1.8.1 Aberrant functions of the PML-RARα fusion protein 
PML-RARα possesses diverse oncogenic properties, which is due to the aberrant 
functions of both fusion partners. The oncogenic fusion protein PML-RARα is able to 
bind not only to the consensus RA response elements (RARE), but also to sites, in which 
the two AGGTCA half sites of the RARE can be in any orientation or spacing. This 
additional property is conferred by the homodimerization of its PML part (Perez, 1993; 
Grignani, 1998; Lin, 1998). PML-RARα also enhances co repressor recruitment (Melnick 
and Licht, 1999; Hoemme, 2008) and the transcriptional silencing involves also the 
SUMOylation of the PML part, RXR binding and the recruitment of the Polycomb 
complex (Zhu, 2005; Sternsdorf, 2006; Zhu, 2007). Moreover, off-target gene expression 
is altered due to binding of PML-RARα to other transcription factors (Reineke, 2007; van 
Wageningen, 2008).  
Apart from transcriptional regulation, the PML-RARα fusion disrupts the formation of 
PML nuclear bodies and therefore many cellular processes that are associated with 
these structures (Daniel, 1993; Dyck, 1994; Koken, 1994; Weis, 1994).  
1.8.2 Treatment of APL 
The target-directed treatment with ATRA leads to a cell differentiation of the myeloids 
along the granulocytic lineage as it releases the co-repressors from the complex and 
recruits transcriptional co-activators to the target genes (Ohnishi, 2007). However, with 
ATRA as a single agent, the majority of the patients experienced a relapse within a few 
months (Wang and Chen, 2008). This is probably due to the survival of Leukemia 
INTRODUCTION 
 
29 
 
initiating cells (LICs) that are then responsible for the relapses. LICs are a minority of 
tumor cells that are able to self-renew, but usually do not cycle (Wang and Dick, 2005).  
Another effective therapy of APL is the application of arsenic trioxide, which in low 
dosages renders the leukemic cells to differentiation or in higher dosages triggers their 
apoptosis (Chen, 1996; Chen, 1997; Shen, 1997). As one of the oldest drugs known, it 
was reintroduced as a drug against APL in the 1990’s (Zhu, 2002). It has improved the 
clinical outcome of APL with a complete remission rate of up to 90 % of patients with 
both newly diagnosed and relapsed APL or of patients resistant to ATRA (Wang and 
Chen, 2008).  
In contrast to ATRA, ATO targets the PML part of the PML-RARα fusion for degradation, 
while wild-type PML relocates from aberrant nuclear structures and reforms PML 
nuclear bodies (Chen, 1996; Zhu, 1997; Müller, 1998; Lallemand-Breitenbach, 2001). 
Treatment of cells with ATO resulted in an upregulated SUMO-1 modification of PML or 
PML-RARα at K160 and these SUMOylated forms were stabilized during proteasome 
inhibition (Lallemand-Breitenbach, 2001), pointing to a regulation of PML via the then 
unknown ULS pathway. The observed differences in degradation of the fusion protein 
and the wild-type (wt) copy are probably due to a slower turnover of wild-type PML 
(Müller, 1998).  
More recent clinical studies suggest that a combination therapy of ATRA and ATO has 
synergistic effects on APL, as it results in higher rates of complete remission as well as 
lower rates of relapse within a five year range as it occurred with traditional 
chemotherapy or either agent alone (Shen, 2004; Wang and Chen, 2008; Hu, 2009). This 
is accompanied by an effective down regulation of the PML-RARα transcript and protein 
(Jing, 2001; Zhu, 2001; Nasr, 2008) and can be explained by the fact that ATRA and ATO 
use different target sites within the fusion protein and act via distinct pathways (Benoit, 
2001; Zhu, 2002; Zhao, 2004; Tarkanyi, 2005; Tarrade, 2005; Zheng, 2005; Joe, 2006; 
Mathieu and Besancon, 2006; Leung, 2007). Furthermore, in an APL mouse model, it 
could be clearly shown that high ATRA dosages or an ATRA/ATO combinational therapy 
led to the eradication of LICs through the degradation of the PML-RARα fusion protein 
(Nasr, 2008).  
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1.9 Aims of this thesis 
There was evidence that the ULS pathway is conserved in humans as SUMO-2/3 
conjugation is generally upregulated after diverse cell stresses and conjugates are 
proteasomal targets in mammalian cells (Saitoh and Hinchey, 2000; Uzunova, 2007).  
However, a specialized ubiquitin ligase targeting these SUMO conjugates had not been 
identified yet. Therefore, the main aim of this thesis was to identify a mammalian 
ubiquitin ligase for SUMO conjugates (ULS). 
First, it should be investigated, whether SUMO-2/3 conjugates accumulate under 
proteasome inhibition at all and in which part of the cell. This attempt intended to 
minimize the candidates out of the numerous ubiquitin E3 ligases to those being 
localized to a certain cellular compartment or substructure. Also, it had already been 
shown that SUMO-1 conjugates accumulate around PML nuclear bodies under 
proteasome inhibition (Bailey and O'Hare, 2005) and it was tempting to speculate that 
this might also happen to SUMO-2/3. Possible candidate ULS proteins had to be 
investigated, however, for their ability to specifically recognize and ubiquitylate SUMO 
modified proteins in order to prove that they indeed act as ULS proteins. For that 
purpose, an in vitro ubiquitylation assay for SUMO conjugates should be developed.  
In order to obtain appropriate in vitro substrates – SUMO modified proteins – several 
known SUMO substrates should be SUMOylated in E. coli by making use of a trimeric 
vector system expressing the SUMOylation machinery in E. coli (Uchimura, 2004a; 
Uchimura, 2004b). This method should be optimized such that especially the SUMO 
modified species of a protein substrate would be enriched. 
Finally, the SUMO/SIM dependent recruitment of the identified ULS to its substrates 
should be investigated in more detail in order to specify the prerequisites for the 
recognition of SUMOylated proteins. This is especially interesting as most proteins are 
not targeted to degradation when conjugated by SUMO under normal cellular 
conditions. For some, even stabilization has been observed (Desterro, 1998). 
Experiments in yeast had already shown that specifically high molecular weight 
conjugates are targets of yeast ULS proteins, emphasizing a mechanism in which multi- 
or polySUMOylation serves as signal for ULS recruitment (Uzunova, 2007; Xie, 2007; 
Prudden, 2007).  
Knowing the prerequisites of mammalian ULS recruitment, it should also be possible to 
identify further cellular substrates regulated via the ULS pathway.  
As mentioned, earlier studies indicated that the promyelocytic leukemia protein PML 
might be a target of that SUMO-dependent degradation pathway in mammalian cells 
(Müller, 1998; Lallemand-Breitenbach, 2001). Indeed, PML is mainly conjugated by 
SUMO-2/3 upon ATO treatment. Isolated PML-SUMO-2/3-ubiquitin hybrid conjugates 
from ATO-treated cells further supported the idea that PML is regulated via the ULS 
pathway in mammalian cells upon ATO treatment (Weißhaar, 2008). PML was therefore 
an ideal substrate candidate for in vitro studies.  
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2. MATERIALS & METHODS 
2.1 Materials 
2.1.1 Chemicals & Solutions 
Chemicals used were graded p.A. and purchased from Merck (Darmstadt), Sigma (Sigma-
Aldrich, Seelze) or Roth (Karlsruhe) unless otherwise specified. All solutions and culture 
media were prepared with ultrapure water derived from a combined reverse 
osmosis/ultrapure water system equipped with UV and ultrafiltration (Milli-Q system; 
Millipore, Billerica, USA). 
2.1.2 Kits 
DNA purification and gel extraction were carried out using the NucleoBond PC 100 or 
the NucleoSpin Extract II Kits (Macherey-Nagel, Düren), respectively. 
Sequencing reactions were carried out using the BigDye Terminator v 3.1 Sequencing Kit 
from Applied Biosystems (Darmstadt).  
2.1.3 Plastic ware 
Plastic ware was purchased from Sarstedt (Nümbrecht) with exceptions for Cryotubes 
(Greiner Bio-one, Frickenhausen), 15 cm cell culture dishes (TPP; Trasadingen, 
Switzerland) and pipet tips (Starlab, Ahrensburg). Sterile filters (0,2 µm) were purchased 
from VWR (Darmstadt) or Whatman (Dassel), protein concentrators (Amicon Ultra) from 
Millipore (Billerica, MA, USA).  
2.1.4 Standards 
MassRuler Express DNA Ladder Mix #SM1283 Fermentas (St. Leon-Rot) 
PageRuler Prestained Protein Ladder #SM0671 Fermentas (St. Leon-Rot) 
Unstained Protein Molecular Weight Marker #SM0431 Fermentas (St. Leon-Rot) 
2.1.5 Enzymes  
Restriction enzymes, DNA polymerases and DNA ligases have been purchased from New 
England Biolabs (Ipswich, USA), Jena Biosciences (Jena) or AB Biosciences (Foster City, 
USA). 
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Other Enzymes: 
DNaseI Applichem (Darmstadt) 
Creatine phosphokinase Sigma (Sigma-Aldrich, Seelze) 
Trypsin Sigma (Sigma-Aldrich, Seelze) 
Thrombin Serva (Heidelberg) 
Ube1 BIOMOL (Enzo Life sciences, Lörrach) 
His6-UbcH5b BIOMOL (Enzo Life sciences, Lörrach) 
Ubc4 Kind gift of Maria Miteva and Jürgen Dohmen, Cologne 
Slx5-Slx8 Kind gift of Maria Miteva and Jürgen Dohmen, Cologne 
 
Further enzymes applied in in vitro assays have been purified from E. coli expression 
cultures (see section 2.2.4.3). 
2.1.6 Antibodies 
 
Primary antibodies: 
anti-GST (Z-5; sc-459) 1:2000 Santa Cruz Biotechnology  
(Santa Cruz, USA), rabbit polyclonal 
anti-His5 (Penta-His) 1:2000 Qiagen (Hilden), mouse monoclonal 
anti-myc (ab9106) 1:1000 Abcam (Cambridge, UK), rabbit polyclonal 
anti-PML (5E10)   1:100 kind gift of Roel van Driel,  
mouse monoclonal 
anti-PML (A301-167A, -168A) 1:2000 
   each 
Bethyl Laboratories  
(Montgomery, TX, USA), rabbit polyclonal 
anti-PML RING-B1 (3004) 1:1000 Biogenes (Berlin), rabbit polyclonal 
anti-RNF4 (3005)   1:100 Biogenes (Berlin), rabbit polyclonal 
anti-Sp100 (N-20; sc-16328)   1:500 Santa Cruz Biotechnology  
(Santa Cruz, USA), goat polyclonal 
anti-SUMO2 (ab22654) 1:2000 Abcam (Cambridge, UK), rabbit polyclonal 
anti-Tubulin (DM1A; T6199)   1:500 Sigma (Sigma-Aldrich, Seelze), 
mouse monoclonal 
anti-Ubiquitin (P4D1; sc-8017) 1:2000 Santa Cruz Biotechnology  
(Santa Cruz, USA), mouse monoclonal 
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Secondary antibodies: 
donkey-anti-mouse Alexa 488 1:1000 Molecular probes  
(Invitrogen, Karlsruhe) 
donkey-anti-goat Alexa 546 
1:1000 Molecular probes  
(Invitrogen, Karlsruhe) 
donkey-anti-rabbit Alexa 546 1:1000 Molecular probes  
(Invitrogen, Karlsruhe) 
goat-anti-mouse HRP 1:10000 BioRad (Munich) 
goat-anti-rabbit HRP 1:10000 BioRad (Munich) 
rabbit-anti-goat HRP 1:10000 Santa Cruz Biotechnology  
(Santa Cruz, USA) 
 
2.1.7 Plasmid vectors 
 
All listed plasmids have been generated during this work unless otherwise stated. 
  
Table 2.1: Constructs for transient expression in mammalian cells 
Construct Restriction sites used Resistance 
pCMV3b-myc-SUMO1† BamHI/XhoI  KanR 
pCMV3b-myc-SUMO2† BamHI/EcoRI KanR 
pCMV3b-myc-SUMO3† BamHI/ EcoRI  KanR 
 
† kindly generated by Christiane Horst 
 
 
Table 2.2: Expression constructs used in the E. coli SUMOylation system 
Construct Restriction sites used Resistance 
pACYCDuet-1-6H-hSAE1/hSAE2† BamHI/NotI and AflII/XhoI of 
pCDF-Duet-1-hSAE1/hSAE2  
CamR 
pRSFDuet-1-6H-hSUMO1/mUbc9 BamHI/NotI and NdeI/XhoI KanR 
pRSFDuet-1-6H-hSUMO2/mUbc9 BamHI/EcoRI and NdeI/XhoI KanR 
pRSFDuet-1-6H-hSUMO3/mUbc9 BamHI/EcoRI and NdeI/XhoI KanR 
pETDuet-1-GST-hPML 11 (50-179)† BamHI/EcoRI AmpR 
pETDuet-1-GST-hPML 11 (50-179)/ 
hPIAS3 (10-628) 
BamHI/EcoRI and NdeI/BglII AmpR 
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Construct Restriction sites used Resistance 
pETDuet-1-GST-hPML 11 (50-179)/ 
hPIAS4† 
BamHI/EcoRI and NdeI/BglII AmpR 
pETDuet-1-GST-hPML 11 (50-179)K65R/ 
hPIAS3 (10-628) 
BamHI/EcoRI and NdeI/BglII AmpR 
pETDuet-1-GST-hPML 11 (50-179) K65R/ 
hPIAS4 
BamHI/EcoRI and NdeI/BglII AmpR 
pETDuet-1-GST-hPML 11 (50-179) K160R/ 
hPIAS3 (10-628) 
BamHI/EcoRI and NdeI/BglII AmpR 
pETDuet-1-GST-hPML 11 (50-179) K160R/ 
hPIAS4 
BamHI/EcoRI and NdeI/BglII AmpR 
pETDuet-1-GST-hPML 11 (1-503)/ 
hPIAS4† 
BamHI/EcoRI and NdeI/BglII AmpR 
pETDuet-1-GST-hPML 11 (1-522)/ 
hPIAS4† 
BamHI/EcoRI and NdeI/BglII AmpR 
pETDuet-1-GST-hSp100 (1-332)† BamHI/EcoRI AmpR 
pETDuet-1-GST-hSp100 (1-332)/ 
hPIAS3 (10-628) 
BamHI/EcoRI 
NdeI/BglII 
AmpR 
pETDuet-1-GST-hSp100 (1-332)/hPIAS4† BamHI/EcoRI and NdeI/BglII AmpR 
pETDuet-1-GST-hSp100 (1-332)/ 
hRanBP2 (2553-2711)† 
BamHI/EcoRI and NdeI/BglII AmpR 
pETDuet-1-GST-hSp100 (1-332)/ 
hRanBP2 (2633-2711)† 
BamHI/EcoRI and NdeI/BglII AmpR 
pETDuet-1-GST-hSp100 (1-480)/hPIAS4† BamHI/EcoRI and NdeI/BglII AmpR 
pETDuet-1-GST-hSp100 (31-273)/hPIAS4† BamHI/EcoRI and NdeI/BglII AmpR 
 
* mUbc9 and hUbc9 share 100 % protein sequence identity 
† kindly generated by Christiane Horst 
 
 
Tabelle 2.1: E. coli expression constructs 
Construct Restriction sites used Resistance 
pET9d-TEV protease1 NcoI/PmlI KanR 
pGEX-TN-hSENP1 (415-643) 
EcoRI/NotI AmpR 
pGEX-TN-hSENP6 (625-1112) BamHI/XhoI AmpR 
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Construct Restriction sites used Resistance 
pGEX-4T2-hSUMO12 BamHI/HindIII AmpR 
pGEX-4T2-hSUMO22 BamHI/EcoRI AmpR 
pGEX-4T2-hSUMO32 BamHI/EcoRI AmpR 
pGEX-4T2-hSUMO1ΔN15 BamHI/XhoI AmpR 
pGEX-4T2-hSUMO2 ΔN11 BamHI/XhoI AmpR 
pGEX-4T2-hSUMO3 ΔN11 BamHI/XhoI AmpR 
pGEX-4T2-2 x hSUMO1ΔN15 BamHI/XhoI AmpR 
pGEX-4T2-2 x hSUMO2 ΔN11 BamHI/XhoI AmpR 
pGEX-4T2-2 x hSUMO3 ΔN11 BamHI/XhoI AmpR 
pGEX-4T2-3 x hSUMO1ΔN15 BamHI/XhoI AmpR 
pGEX-4T2-3 x hSUMO3 ΔN11 BamHI/XhoI AmpR 
pGEX-4T2-4 x hSUMO1ΔN15 BamHI/XhoI AmpR 
pGEX-4T2-4 x hSUMO2 ΔN11 BamHI/XhoI AmpR 
pGEX-TN-hUbiquitin (1x) 
(1st part of the human polyprotein) 
EcoRI/XhoI AmpR 
pET3a-hUbcH5B3 NdeI/EcoRI AmpR 
pGEX-TN-hRNF4 wt BamHI/EcoRI AmpR 
pGEX-TN-hRNF4 (1-105)† BamHI/EcoRI AmpR 
pGEX-TN-hRNF4 (1-125)† BamHI/EcoRI AmpR 
pGEX-TN-hPML SIM (419-522) wt BamHI/EcoRI AmpR 
pGEX-TN-hPML SIM (419-522) SA BamHI/EcoRI AmpR 
pGEX-TN-hPML SIM (419-522) SD BamHI/EcoRI AmpR 
pGEX-TN-hSp100 (274-332) BamHI/EcoRI AmpR 
pGEX-TN-hDaxx (625-740) BamHI/EcoRI AmpR 
pGEX-TN-hPIAS3 (394-470) BamHI/EcoRI AmpR 
pGEX-TN-hPIAS4 (445-570) BamHI/EcoRI AmpR 
pGEX-TN-hZNF198 wt†† BamHI/NotI AmpR 
pGEX-TN-hTIF1α wt†† NcoI/NotI AmpR 
 
1) kind gift of Ingrid Schwienhorst, 2) kind gift of Martin Scheffner, Konstanz;  
3) kind gift of Jörg Höhfeld, Bonn 
† kindly generated by Christiane Horst; †† kindly generated by Anke Krause 
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The cDNAs for SAE1, SAE2 and RanBP2 were kind gifts of Frauke Melchior. The mUbc9 
cDNA was kindly provided by Martin Scheffner, Konstanz. All other cDNAs have been 
obtained from the German Resource Center for Genome Research (RZPD), now 
ImaGenes (Berlin). 
2.1.8 Oligonucleotides 
Oligonucleotides for PCR and site-directed mutagenesis have been obtained from 
biomers (Ulm). A full list of oligonucleotides is given in the Appendix. 
2.1.9 E. coli strains and human cell lines 
 
Escherichia coli (E.coli) DH5α Ф80dlacZMΔM15, recA1,endA1,  
gyrA96, thi-1, hsdR17(rK
-, mK
+), supE44, 
relA1, deoR, Δ(lacZYA-argF)U169 
(Woodcock, 1989) 
E.coli BL21 (DE3) B, F-, dcm, ompT, hsdS (rB
- mB
-), galλ (DE3) 
(Weiner, 1994) 
E.coli Rosetta 2 (DE3) pLysS F-, ompT, hsdSB (rB
- mB
-), gal, dcm (DE3) 
pLysSpRARE (CamR) 
(Novagen, Schwalbach) 
  
HeLa B cells 
(ECACC No: 85060701) 
Human Negroid cervix carcinoma  
(European Collection of Cell Cultures; 
Health Protection Agency, Salisbury, UK) 
Hs27 cells 
(ECACC No: 94041901) 
Human foreskin, fibroblast 
(European Collection of Cell Cultures; 
Health Protection Agency, Salisbury, UK) 
2.1.10 Sorbents and FPLC columns 
 
Protino Glutathione Agarose 4B Macherey-Nagel (Düren) 
Ni-NTA Superflow Qiagen (Hilden) 
Q Sepharose Fast Flow GE Healthcare (Munich) 
SP Sepharose GE Healthcare (Munich) 
Superdex 75, 10/300 GL GE Healthcare (Munich) 
HiLoad 16/60 Superdex 75 prep grade GE Healthcare (Munich) 
HiLoad 26/60 Superdex 200 prep grade GE Healthcare (Munich) 
FPLC columns XK16 and XK26 GE Healthcare (Munich) 
200µL StageTips, C18 material Proxeon (Odense C, Denmark) 
MATERIALS & METHODS 
 
37 
 
2.1.11 Instruments 
 
Agarose gel electrophoresis chamber: 
Blue Marine 100 
 
Serva (Darmstadt) 
Balances Sartorius (Goettingen) 
Biacore T100 Biacore (GE Healthcare; Munich) 
Blotting Chamber TE 77 RWR Amersham Biosciences  
(GE Healthcare; Munich) 
Cary 100 Bio Spectrometer  Varian (Mulgrave, Victoria, Australia) 
Centrifuges:  
Eppendorf 5415R Eppendorf (Hamburg) 
Hermle Z383K Hermle (Gosheim) 
Avanti J-20 XP Beckman Coulter USA (Brae, CA, USA) 
Clean bench: LaminAir MA 2M 48 GS  Heraeus (Hanau) 
CO2 incubator C200 Labotect (Goettingen) 
Developing machine: AGFA Curix 60  AGFA (Mortsel, Belgium) 
Fluorescence microscope: Axioplan 2  (Zeiss, Jena) 
FPLC: Äkta purifier GE Healthcare (Munich) 
LTQ-Orbitrap Discovery  Thermo Fisher Scientific (Ulm) 
Milli-Q System Millipore (Billerica, USA) 
PCR-Thermocycler gradient  Eppendorf (Hamburg) 
Power Supply: Consort E835 Consort (Tournhout, Belgium) 
Protein gel systems: 
Mini-PROTEAN 
SE600-15-1.5 
 
Bio-Rad (Munich) 
Hoefer (San Francisco, CA, USA) 
Shaking incubators: innova 4230 & 4330 New Brunswick Scientific (Edison, NJ, USA) 
Stirrer:  
VS-C7 
IKAMAK RCT 
VWR (Darmstadt) 
IKA-WERKE (Staufen) 
Thermomixer Eppendorf (Hamburg) 
Ultrasonic Homogeniser: Sonifier 250 Branson (Danbury, CT, USA) 
UV agarose gel analyzer: BioDoc Analyze  Biometra (Goettingen) 
Vortex Genie 2 Scientific Industries (Bohemia, NY, USA) 
VP-ITC Microcalorimeter MicroCal (GE Healthcare; Munich) 
LTQ-Orbitrap Discovery  Thermo Fisher Scientific (Ulm) 
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2.2 Methods 
2.2.1 Buffers, Solutions and Media 
2.2.1.1 Buffers & Solutions 
SDS-PAGE running buffer:    25 mM Tris  
 190 mM Glycine 
0.1 % Sodium dodecyl sulfate (SDS) (w/v) 
 
5 x SDS-PAGE sample buffer:    50 mM Tris pH 6.8 
              10 % Glycerol (v/v) 
                1 % SDS (w/v) 
             0.1 % bromphenol blue 
    7 % β-Mercaptoethanol (β-ME) (v/v) 
 
Blotting buffer:      25 mM Tris 
190 mM Glycine  
  10 % MeOH (v/v) 
 
ECL1:     100 mM Tris pH 8.5 
      2.5 mM Luminol 
     400 µM p-Cumaric acid 
 
ECL2:     100 mM Tris pH 8.5 
      1.8 % H2O2 (v/v) 
 
PBS (phosphate buffered saline):  136.9 mM NaCl 
         2.7 mM KCl 
         8.1 mM Na2HPO4 
    1.76 mM KH2PO4 
 
PBST:      PBS  
0.1 % Tween 20 (v/v) 
 
IF fixation buffer:    PBS 
3 % Paraformaldehyde (PFA) (w/v) 
 
IF wash buffer:    PBS 
0.2 % Saponin (w/v) 
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IF block buffer:    IF wash buffer 
3 % bovine serum albumin (w/v) 
(BSA; Fraction V, protease free; Roth) 
 
RIPA buffer:       50 mM Tris pH 7.5 
150 mM NaCl 
    5 % Glycerol 
    1 % Triton X-100 (v/v) 
    1 % Sodium desoxycholate (w/v) 
 0.1 % SDS (w/v) 
    1 mM N-ethylmaleimide (NEM; freshly added) 
                                                               2 mM Dithiotreithol (DTT) 
     Complete protease inhibitor cocktail (Roche) 
 
GST1:       50 mM Tris pH 7.5 
150 mM NaCl 
    2 mM DTT 
 
GST2:       50 mM Tris pH 7.5 
300 mM NaCl 
    2 mM DTT 
 
GST Elution buffer:     50 mM Tris pH 8.0 
150 mM NaCl 
  20 mM Imidazole 
         5 mM β-ME 
 
Ni2+-NTA Binding buffer (BB)    50 mM Tris pH 8.0 
300 mM NaCl 
  20 mM Imidazole 
         5 mM β-ME 
      0.1 % Triton X-100 (v/v) 
 
Ni2+-NTA Elution buffer (EB)     50 mM Tris pH 8.0 
 300 mM NaCl 
                 1 M Imidazole 
          5 mM β-ME 
       0.1 % Triton X-100 (v/v) 
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‘Substrate buffer’:     30 mM Tris, pH 7.5 
100 mM KCl 
    5 mM MgCl2 
    2 mM DTT 
 
DnaK depletion buffer:     50 mM Tris, pH 7.5 
(modified from Rudolph, 1998)         150 mM NaCl 
  60 mM KCl 
  10 mM MgCl2 
    2 mM Adenosine triphosphate (ATP) 
    2 mM DTT 
          +/- 5 % Glycerol 
 
In vitro ubiquitylation buffer:    40 mM Tris, pH 7.5 
(Established final composition)    67 mM KCl 
     2 mM MgCl2 
     1 mM DTT 
     5 mM ATP 
 200 ng/µl BSA (NEB, Frankfurt)  
 200 µM Pefabloc 
     1 ng/µl Leupeptin  
      1 ng/µl Aprotinin  
      1 ng/µl Pepstatin  
    
All Tris based buffers with a defined pH were adjusted with HCl to their appropriate pH. 
To all buffers applied for protein purification from E. coli either 20 µM Pefabloc or 10 µM 
PMSF (for Ni2+-NTA buffers and purifications of zinc complexing proteins) were added 
with a combination of 0.1 µg/ml Leupeptin, 0.1 µg/ml aprotinin, 0.1 µg/ml pepstatin. 
2.2.1.2 Culture media for E. coli 
LB (Luria-Bertani)-Medium:   
     
   1 % Baktotryptone (w/v)    (Gibco/Invitrogen, Paisley, UK) 
0.5 % Yeast extract (w/v)    (Gibco/Invitrogen, Paisley, UK) 
   1 % NaCl (w/v) 
 
All media were sterilized for 20 min at 121 °C and stored at room temperature (RT). For 
LB Agar plates 2 % agar was added to LB medium before sterilization. 
The selection of antibiotic resistant bacteria was carried out by addition of the 
appropriate antibiotic to the medium after sterilization (100 µg/ml Ampicillin, 30 µg/ml 
Chloramphenicol or 30 µg/ml Kanamycin). 
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2.2.1.3 Culture media for human cells 
HeLa B medium: 
 
EMEM (Eagle's Minimal essentiell Medium)  (Gibco/Invitrogen, Paisley, UK)  
+ 10 % inactivated FCS (foetal calf serum)   (Sigma-Aldrich, Seelze) 
+ 1 % non-essential amino acids (NAA)   (Gibco/Invitrogen, Paisley, UK) 
+ 1 % Penicillin / Streptomycin   (Gibco/Invitrogen, Paisley, UK) 
 
Hs27 medium: 
 
DMEM (Dulbecco´s Modified Eagle Medium)  (Gibco/ Invitrogen, Paisley, UK) 
+ 10 % inactivated FCS (foetal calf serum)   (Sigma-Aldrich, Seelze) 
+ 1 % non-essential amino acids (NAA)   (Gibco/Invitrogen, Paisley, UK) 
+ 1 % Penicillin / Streptomycin   (Gibco/Invitrogen, Paisley, UK) 
+ 200 µM L-Glutamin     (Gibco/ Invitrogen, Paisley, UK) 
 
2.2.2 Biomolecular methods 
2.2.2.1 Standard techniques 
Molecular cloning, polymerase chain reactions (PCR) and DNA sequencing were carried 
out according to standard procedures (Ausubel, 2010) using enzymes purchased from 
New England Biolabs (Ipswich, USA), Jena Biosciences (Jena) and AB Biosciences (Foster 
City, USA). DNA Sequencing was carried out by the Cologne Center for Genomics 
sequencing facility. 
Site-directed mutagenesis was performed according to the “QuickChange Site-directed 
mutagenesis” (Stratagene, La Jolla, USA) protocol. 
2.2.2.2 Generation of artificial poly-SUMO chains 
Artificial SUMO chains have been generated by ligating PCR products encoding SUMO-
2ΔN11 or SUMO-1ΔN15 while simultaneously digesting with restriction enzymes specific 
for BamHI (N-terminal site) and BglII (C-terminal site) in T4 DNA ligase buffer, 150 mM 
NaCl, 0.1 mg/ml BSA at 22 °C o/n (Tatham, 2008). The next morning, additional units of 
all three enzymes were added for another 4 hours. This resulted in a range of cDNAs 
encoding SUMO-2ΔN11 or SUMO-1ΔN15 monomers and polymers that were separated 
by agarose gel electrophoresis and individually extracted into solution. 
These were then subjected to a second PCR for generating restriction sites for BamHI (N-
terminally) and XhoI (C-terminally) for cloning into pGEX-4T2 as well as a GG motif in 
front of a stop codon preceding the XhoI site. Expression from these plasmids resulted in 
GST-tagged artificial SUMO-2ΔN11 or SUMO-1ΔN15 monomers or linear chains with up 
to 4 monomers. Each monomer in these chains is separated from the other by Arg-Ser. 
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2.2.3 Cell biological methods 
2.2.3.1 Cell cultivation 
HeLa B (Cervix carcinoma) and Hs27 (primary human fibroblast) cells were cultivated in 
the respective media (see section 2.2.1) at 37 °C, 5 % CO2 and 99 % humidity in a C200 
incubator (Labotect, Göttingen). Long-term storage was carried out in inactivated 
FCS/10 % DMSO at around -110 and -150 °C in the vaporous phase of liquid N2. 
Cells were expanded at ~ 80 % confluency to other plates by incubating them with 
trypsin for 1-2 min after washing them twice with PBS. Usually, ~ 1 x 106 HeLa B or Hs27 
cells were plated per 10 cm dish.  
2.2.3.2 Cell lysis 
Hs27 cells were washed twice with ice-cold PBS before collected from plates with cell 
scrapers and transferred to 15 or 50 ml reaction tubes depending on the volume. Then, 
they were centrifuged at 300 g, washed once more with PBS and after another 
centrifugation lysed on ice with RIPA buffer (100 µl/1 x 107 cells) for 1 h. Cell debris was 
removed from lysate by centrifuging the lysed cells at 3000 g. Only the supernatant was 
used for isolation experiments (see section 2.2.4.13). 
2.2.3.3 Cell transfection  
HeLa B cells were transfected for fluorescent microscopy with pCMV-3b-SUMO 
constructs using Gene Juice transfection reagent (Novagen, Schwalbach) according to 
the manufacturer’s instructions. 
2.2.3.4 Preparation of cells for fluorescent microscopy 
HeLa B cells were grown on sterilized cover slips which were added to the usual culture 
plates and transfected as described in section 2.2.3.3. After 40 h, 20 µM MG 132 was 
added or not for additional 7 h. Cells on cover slips were fixed in PBS with 3 % 
paraformaldehyde. After permeabilization in PBS with 0.1 % saponin (Sigma-Aldrich, 
Seelze), cells were blocked in PBS, 3 % BSA, 0.1 % saponin. Primary and Alexa-labeled 
secondary antibodies (Invitrogen, Karlsruhe) as well as 4’,6-Diamidine-2’-phenylindole 
dihydrochloride (DAPI; Roche, Penzberg) were applied in blocking buffer. Cover slips 
were embedded in ProLong Gold antifade (Invitrogen, Karlsruhe) and examined using a 
Zeiss Axioplan2 fluorescence microscope (Zeiss, Göttingen). 
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2.2.4 Biochemical methods 
2.2.4.1 SDS-PAGE and Western Blotting  
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was applied to separate proteins 
according to their molecular size under reducing conditions unless otherwise stated 
(Laemmli, 1970). Table 2.4 summerizes the different SDS polyacrylamide (SDS-PA) gel 
compositions used. Two different protein gel systems from Bio-Rad and Hoefer have 
been utilized (see section 2.1.11). 
 
Table 2.4: SDS gel compositions 
 4 % stacking gel 10 % seperating gel 15 % seperating gel 
Acrylamide (37,5:1)  4 % 10 % 15 % 
Tris pH 8,8  - 390 mM 390 mM 
Tris pH 6,8  150 mM - - 
SDS  0.1 % 0.1 % 0.1 % 
Ammoniumperoxo-
disulfat (APS)  
0.1 % 0.1 % 0.1 % 
N,N,N‘,N‘-Tetra-
methylethylendiamine 
(TEMED)  
0.01 % 0.01 % 0.01 % 
H2O  add to final volume add to final volume add to final volume 
 
After SDS-PAGE, separated proteins have been either stained with Coomassie Brilliant 
Blue (Coomassie; Serva, Heidelberg) in 20 % Ethanol, 10 % Acetic acid directly in SDS-PA 
gels or transferred to 0,2 µm Polyvinylidene fluoride (PVDF) membranes (Millipore, 
Schwalbach) by western blotting using a semi-dry system from Amersham Biosciences 
(GE Healthcare, Munich) (modified from Renart, 1979; Towbin, 1979). 
2.2.4.2 Immunological detection of proteins on PVDF membranes 
Detection of proteins has been carried out by incubating the PVDF membranes with 
specific primary and horse-radish peroxidase (HRP)-coupled secondary antibodies (see 
section 2.1.6) diluted in PBST/5 % milk powder. HRP-initiated Enhanced 
Chemiluminescence (ECL) exposed X-ray films (Super RX; Fujifilm, Düsseldorf) at sites of 
bound antibodies. ECL solution was either self-mixed 1:1 from ECL1 and ECL2 or 
purchased from Roche (Penzberg).  
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2.2.4.3 Protein purifications 
Protein expression was usually carried out in E. coli Rosetta (DE3) pLys after induction 
with 0.1 mM Isopropyl-β-D-thiogalactopyranosid (IPTG) at individual temperatures. In 
some cases, E. coli BL21 (DE3) strains have been used to express proteins which is stated 
in the respective sections. Bacterial cultures (usually 6-10 l) were centrifuged at 6000 g 
for 10 min, resuspended in the buffers applied for the following first purification step 
and shock frozen in liquid nitrogen (liq. N2).  
Expressed proteins were isolated using different approaches (see the following 
sections). Lysis of bacteria was usually performed on ice with the following additives: 
100 µg/ml Lysozym (for BL21 lysis), DNase I, protease inhibitors (either 200 µM Pefebloc 
or a combination of 100 µM PMSF, 1 µg/ml Leupeptin, 1 µg/ml aprotinin, 1 µg/ml 
pepstatin) and 1.5 % Sarkosyl (v/v) unless otherwise stated. To obtain fully lysed bacteria 
and sheared DNA, lysates were sonified 3 x for 30 s on ice at maximal constant pulse 
(resulting in the raw lysate, RL). Then the lysate was centrifuged at 50000 g for 1 h at 
4 °C. The resulting supernatant (S) contained the expressed protein which was further 
purified. Supernatants containing Sarkosyl were substituted with 2 % Triton-X-100 (v/v) 
before subjected to following purification steps. Samples for RL, S, and Pellet (P) were 
taken for SDS-PAGE analysis. Usually, proteins were purified applying an affinity 
purification step followed by subsequent size exclusion chromatography. Fast Protein 
Liquid Chromatography (FPLC) was performed using an Äkta purifier (GE Healthcare). 
After gel filtration protein fractions of high purity were combined, concentrated using 
Amicon concentrators (Millipore) and aliquots were shock frozen in liq. N2. 
2.2.4.3.1 Affinity purification of GST-tagged proteins 
GST-tagged proteins were glutathione (GSH) affinity purified performing batch 
purifications in 50 ml tubes. Cleared lysates (Supernatant S) were applied to the beads 
and incubated for 1 h at 4 °C on a rotating wheel. Unbound proteins were washed away 
by several washing steps: usually 5 x with GST1 buffer, 3 x with GST2 buffer and 3 x with 
GST1 buffer or later including 3 wash steps with DnaK depletion buffer (refer to section 
2.2.4.6) before washing 3 x with GST1 buffer. Proteins that were purified from E. coli 
without the addition of Sarkosyl (like GST-SUMO-1, GST-SUMO-2, GST-SUMO-3, GST-
ubiquitin and GST-SENP1 (415-643)) were additionally washed 3 x with GST1 buffer/0.1 
% Triton X-100 (v/v). Elution was carried out using GST Elution buffer containing 10 -
20 mM GSH. When GST was cleaved off, instead of protein elution either TEV protease 
(for proteins expressed from pGEX-TN or pET-Duet vectors) or Thrombin (SERVA; for 
proteins expressed from pGEX-4T2 vectors) was added to the beads in appropriate 
buffers for following purification steps.  
 
Individual GST buffers were applied for the purification of GST-ubiquitin (GST1: 30 mM 
Tris pH 7.5, 100 mM KCl, 5 mM EDTA, 2 mM DTT; GST2: 30 mM Tris pH 7.5, 300 mM KCl, 
5 mM EDTA, 2 mM DTT), GST-SENP1 (415-643) (GST1: 20 mM Tris pH 8.0, 500 mM NaCl, 
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0.5 mM EDTA, 2 mM DTT; GST2: 20 mM Tris pH 8.0, 300 mM NaCl, 0.5 mM EDTA,  2 mM 
DTT) and GST-SIM constructs including all GST-RNF4 constructs purified (GST1 and GST2 
buffer supplemented with 5 % Glycerol (v/v)). 
The catalytic domain of SENP6 (aa 625-1112) was purified using 20 mM Tris pH 8.0,  
300 mM NaCl, 0.1 % Triton X-100 (v/v), 2 mM DTT as GST buffer. As this protein had the 
tendency to precipitate upon concentration, ion exchange chromatography using 
Q Sepharose (GE Healthcare) was applied instead of Superdex 75 (S75) gel filtration as a 
second purification step after TEV cleavage (Q1 buffer: 20 mM Tris pH8.0, 300 mM NaCl, 
0.1 % Triton X-100 (v/v), 2 mM DTT; Q2 buffer: 20 mM Tris pH 8.0, 1 M NaCl, 0.1 % 
Triton X-100 (v/v), 2 mM DTT). 
2.2.4.3.2 Affinity purification of His6-tagged proteins 
His6-tagged proteins were Ni
2+-NTA affinity purified by FPLC using a FPLC XK16 column 
(GE Healthcare) filled with a Ni2+-NTA superflow affinity matrix (Qiagen). Proteins were 
applied to in Ni2+-NTA BB, washed until baseline absorption and eluted with an 
Imidazole gradient from 20 mM in Ni2+-NTA BB to 1 M Imidazole in Ni2+-NTA EB. 
 
An individual Ni2+-NTA affinity purification protocol was applied for purifying His6-tagged 
TEV protease: The BB was composed of 20 mM Tris pH 8.0, 20 mM Imidazole, 150 mM 
NaCl, 0.02 % Sodium desoxycholate, 2 mM β-Mercaptoethanol. An additional wash step 
was included using the BB/1 M NaCl before an elution gradient in 20 mM Tris pH 8.0, 
20 mM Imidazole, 100 mM NaCl, 2 mM β-Mercaptoethanol, 20 % Glycerol was driven 
from 20 mM Imidazole to 300 mM Imidazole. Protein fractions of high purity were 
combined and added up to a final concentration of 50 % Glycerol. 
2.2.4.3.3 Size exclusion chromatography 
Size exclusion chromatography was carried out using a HiLoad 16/60 Superdex 75 prep 
grade gel filtration column (GE Healthcare). Before proteins were subjected to gel 
filtration, they were concentrated to a volume of 1-1.5 ml using Amicon protein 
concentrators (Millipore). Usually, proteins were filtrated into their respective GST1 
buffers with exceptions for proteins that were utilized as in vitro ubiquitylation 
substrates and therefore were filtrated into ‘substrate buffer’ and SENP1 (415-643) 
which was filtrated into its special GST2 buffer (see section 2.2.4.3.1). 
2.2.4.3.4 UbcH5b purification 
Untagged UbcH5b was expressed in E. coli BL21 (DE3) for 5 h from pET3a-UbcH5b at 
30 °C. Bacterial pellets were resuspended in 50 mM MES pH 6.0, 150 mM NaCl, 5 mM 
DTT, 100 µM PMSF, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 1 µg/ml pepstatin and shock 
frozen in liq. N2. Upon thawing, bacteria were stirred for 1 h at 4 °C and then centrifuged 
at 50000 g for 1 h at 4 °C. A classical lysis step was not performed, as UbcH5b leaks out 
from the bacterial periplasm into the buffer (the idea was taken from a purification 
protocol for Ubc9 by Frauke Melchior). Most E. coli proteins stay within the intact 
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bacterial membranes such that this step already yields in a fairly pure protein. It is 
therefore important not to use pLysS containing E. coli strains as, for instance, E.coli 
Rosetta 2 (DE3) pLysS. Further purification was achieved by applying the supernatant to 
ion exchange chromatography on SP sepharose (GE Healthcare) using a gradient from 
150 mM to 1 M NaCl. UbcH5B containing fractions were subjected to size exclusion 
chromatography in 30 mM Tris pH 7.5, 300 mM KCl, 15 % Glycerol, 20 µM Pefabloc using 
a Superdex 75 gel filtration column.   
2.2.4.4 Expression and purification of SUMOylated proteins from E. coli 
To generate appropriate substrates for in vitro ULS studies, it is of particular importance 
to produce and enrich the SUMO-modified forms of the respective protein. For that 
reason, an efficient method to purify the SUMO-modified forms of a protein from an 
‘E. coli SUMOylation system’ was established during this work using the trimeric Duet 
vector system from Novagen (Merck, Darmstadt). Each of the three different vectors 
possesses two open reading frames (ORFs) as well as distinct origins of replication and 
resistance genes (see Figure 2.1). 
Genes coding for the enzymes of the SUMOylation machinery, the SUMOs itself and 
possible GST-tagged substrates could therefore be introduced and expressed in parallel 
and in different combinations in E. coli such that the substrate is SUMOylated in E. coli.  
 
vector MCS1 MCS2 
pACYCDuet1 (CamR) 6His-SAE1  SAE2 
pRSFDuet1 (KanR) 6-His-SUMO (1/2/3) Ubc9 
pETDuet (AmpR) substrate SUMO-E3 
 
Figure 2.1: Trimeric vector system used to generate His6-SUMOylated proteins in E. coli 
Features of the trimeric vector system are shown in a schematic overview (Novagen /Merck, Darmstadt). 
All Duet vectors have two different Open Reading frames (ORFs) with inducible T7/lac promoters as well 
as distinct origins of replication (ori) and resitance markers (MCS, multiple cloning site). The table beneath 
summarizes the generated expression constructs for the production of SUMOylated proteins in E. coli.  
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The major advantage established here was to utilize His6-tagged SUMOs instead of 
untagged versions. It was therefore possible to purify the SUMO-conjugated forms of a 
substrate by consecutive affinity purifications. 
For each of the three conjugatable SUMOs, competent BL21 (DE3) strains were 
generated harboring two of the Duet vectors coding for the SUMO E1 enzyme and the 
E2 enzyme Ubc9 combined with one of the His6-SUMOs: pACYCDuet1-SAE1 (1. 
MCS)|SAE2 (2. MCS) and pRSFDuet1-His6-SUMO1/2/3 (1. MCS)|Ubc9 (2. MCS). These 
strains could then be transformed with a third vector coding for the GST-tagged 
substrate and occasionally for one of the tested SUMO E3 enzymes (pETDuet-GST-
substrate (1. MCS)|E3 enzyme (2. MCS).  
Expression in BL21 (DE3) cells was induced by 0.1 mM IPTG at 30 °C. His6-SUMO-
modified substrates were isolated by consecutive GSH and Ni2+-NTA affinity 
purifications, subsequent TEV protease cleavage of the GST-tag and size exclusion 
chromatography using a Superdex 75 gel filtration column. Residual GST was removed 
after TEV cleavage by binding to fresh GSH affinity beads. Buffers used for GSH affinity 
purifications are GST1 and GST2, for Ni2+-NTA affinity purifications Ni2+-NTA BB and EB as 
well as ‘substrate buffer’ for gel filtrations. TEV cleavage was performed in Ni2+-NTA BB 
at 4 °C o/n. Large scale purifications have been usually performed from 10 l E. coli 
expression cultures. Small scale (50 ml E. coli expression cultures) test purifications have 
been carried out similarly using each 50 µl affinity beads per lysate without subsequent 
cleavage and gel filtration. 
 
During this work several batches of SUMOylated PML (50-179) have been purified that 
differ (slightly) in purity or SUMOylation efficiency. 
2.2.4.5 PML (50-179) and RNF4 antibodies 
In order to obtain efficient antibodies for western blotting against PML (50-179) and 
RNF4, both proteins were highly purified applying consecutive gel filtrations on HiLoad 
16/60 Superdex 75 and 26/60 Superdex 200 prep grade columns after the described 
affinity purification (see section 2.2.4.3.1). PML (50-179) was sent in solution (native 
state) to a company producing antibodies (Biogenes). RNF4 had to be further purified 
from residual contaminants by SDS-PAGE and cut gel slices were sent to Biogenes. 
Therefore, the resulting polyclonal rabbit antiserum was directed against denatured 
RNF4. For both proteins, two antisera from different rabbits have been produced and 
were tested for application in Western Blots. One of each (serum 3004 for PML (50-179) 
and serum 3005 for RNF4) was efficiently and specifically recognizing its antigen (data 
not shown). 
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2.2.4.6 DnaK contamination and DnaK depletion 
Purified RNF4, PML (50-179) K65R and K160R (unmodified and SUMO-3 modified) were 
usually contaminated by an unspecific band at ~ 70 kDa. This band could be identified as 
bacterial DnaK by anti-DnaK staining (data not shown; anti-DnaK was a kind gift of 
Thomas Langer, Cologne). 
DnaK was also present in the sample sent for the PML (50-179) antibody production. 
Therefore, staining with anti-PML (50-179) often results in an additional band at ~ 70 kDa which represents DnaK and is thus unspecific for PML.  
In later protein purifications, a DnaK depletion step was added to the purification 
procedure (see section 2.2.4.3.1) which resulted in a reduction of DnaK contamination 
up to 100 %.  
2.2.4.7 In vitro ubiquitylation assays 
For in vitro ubiquitylation assays, only purified proteins and enzymes have been utilized 
that were mixed together under certain conditions. 
While establishing the in vitro ubiquitylation assay for SUMO conjugates, these 
conditions were varied in order to increase the specificity of the reaction. Therefore, at 
this place, the final reaction mixture is described that was used for all assays shown from 
Figure 3.17 B. All other in vitro ubiquitylation experiments shown were performed under 
varying conditions and are individually described beneath the according figures in 
section 3.4. When indicated, protease inhibitors were added in following 
concentrations: 200 µM Pefabloc, 1 ng/µl leupeptin, 1 ng/µl aprotinin and 1 ng/µl 
pepstatin. 
The established standard in vitro ubiquitylation reaction was performed the following: 
100 ng/µl unmodified or His6-SUMO modified forms of a substrate protein (PML or 
Sp100) were subjected to in vitro ubiquitylation by RNF4 in 40 mM Tris pH 7.5, 67 mM 
KCl, 2 mM MgCl2, 1 mM DTT, 200 ng/µl BSA (New England Biolabs, Frankfurt), protease 
inhibitors and 5 mM ATP containing 3 ng/µl Ube1, 3 ng/µl UbcH5b, 300 ng/µl ubiquitin 
+/- 30 ng/µl RNF4 for 7 h at 30 °C. Reactions were terminated by adding 2 x SDS sample 
buffer. Proteins were separated by SDS-PAGE, transferred to PVDF membranes and 
detected with the antibodies indicated.  
 
The ubiquitin E2 activity test for UbcH5B was carried out using a modified protocol from 
(Lorick, 2005): 0.2 µg/µl Ube1, 1 µg/µl UbcH5b and 3 µg/µl ubiquitin were incubated at 
RT for 5 min in 50 mM Tris pH 7.5, 50 mM NaCl, 10 mM MgCl2 +/- 5 mM ATP.  Reactions 
were divided and stopped by adding 2 x SDS sample buffer either containing the 
reducing agent β-Mercaptoethanol or not. E2~ubiquitin thioester formation was 
detected by anti-ubiquitin after SDS-PAGE in non-reduced samples only. 
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The ubiquitin E3 ligase activity of candidate ULS proteins was assessed under low salt 
conditions according to a modified protocol from (Joazeiro, 1999): 
7.5 nM Ube1 (Biomol), 150 nM UbcH5b or S. cerevisiae Ubc4, 5 µM ubiquitin and 
0.25 µM, 0.5 µM or 1 µM of the ULS candidates were mixed together in 50 mM Tris 
pH 7.5, 2 mM MgCl2, 1 mM DTT, 10 U Creatinphosphokinase, 1 mM Creatinphosphate 
+/- 1 mM ATP and incubated for 7 h at 30 °C. The reactions were terminated by adding 
2 x SDS sample buffer. Proteins have been separated by SDS-PAGE and detected with 
anti-ubiquitin. 
2.2.4.8 Isolation of SUMO-ubiquitin-PML hybrid conjugates after in vitro ubiquitylation 
reactions 
SUMO-ubiquitin-PML hybrid conjugates were isolated from the reaction mixture after 
RNF4-mediated in vitro ubiquitylation of His6-SUMO modified PML (50-179) by applying 
denaturing Ni2+-NTA affinity purification. The reaction mixture was diluted in 500 µl 
denaturing Ni2+-NTA buffer (8 M Urea, 100 mM Na2HPO4/NaH2PO4, 2mM DTT) pH 8.0 
and added to 50 µl Ni2+-NTA affinity beads for 30 min at RT. Bound proteins were 
washed 5 x with denaturing Ni2+-NTA buffer pH 6.3 and eluted with consecutive steps of 
50 µl denaturing Ni2+-NTA buffer pH 4.5 and 20 µl denaturing Ni2+-NTA buffer 
supplemented with 1 M Imidazole. Eluted fractions were combined; proteins have been 
separated by SDS-PAGE and detected with anti-ubiquitin. 
2.2.4.9 Assessing the ubiquitin attachment sites in His6-SUMO-3 modified PML (50-179) 
In order to investigate whether RNF4 attaches the ubiquitin molecules to SUMO, to PML 
or to both moieties of its substrate, the purified catalytic domains of SENP1 and SENP6 
were utilized to reverse the SUMOylated state of PML (50-179).  
After RNF4-mediated in vitro ubiquitylation of His6-SUMO-3 modified PML (50-179) (see 
section 2.2.4.7), reactions were divided. To one half, purified catalytic domains of 
SENP1, SENP6 or both (each or together ~ 30 ng/µl, respectively) were added to the 
reactions, to the other half 1 x reaction buffer only. All reactions were then further 
incubated at 30 °C o/n before being terminated by adding 2 x SDS sample buffer. 
Proteins were separated by SDS-PAGE and detected with according antibodies. 
 
Furthermore, a larger amount of ubiquitylated His6-SUMO-3 modified PML (50-179) was 
separated by SDS-PAGE in order to analyze the ubiquitylated bands by mass 
spectrometry. Therefore, this gel was stained with Coomassie and bands corresponding 
to the first three ubiquitylated bands in the western blots were excised and in-gel 
digested with trypsin (Promega). Peptides were extracted and desalted using StageTips 
(Proxeon), separated on a reverse-phase C18 capillary using an Eksigent nLC-System 
connected on-line to the mass spectrometer (LTQ-Orbitrap Discovery) equipped with a 
nanoelectrospray source. Survey full scan MS spectra (400-2000) were acquired in the 
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Orbitrap, top five ions were sequenced by CID in the LTQ. Orbitrap measurements were 
performed enabling the lock mass option for high mass accurancy, which allowed direct 
determination of charge states. Mass spectromic analysis was carried out by the 
proteomics facility of the Cellular stress responses in Aging-Associated Diseases (CECAD) 
University of Cologne Cluster of Excellence.  The individual peak lists have been searched 
in a ChopNSpice (Hsiao, 2009) data base generated from PML (50-179) and His6-SUMO-3, 
respectively, using the SEQUEST program (Eng, 1994). ChopNSpice created databases for 
the ubiquitin-specific GlyGly modification on lysine residues each of PML (50-179) and 
His6-SUMO-3. Data were double checked by searching the individual peak lists in the 
international protein index (IPI) database (IPIhuman 3.6.1; http://www.ebi.ac.uk/IPI/ 
IPIhuman.html) allowing a dynamic GlyGly modification in the search parameter settings 
of the SEQUEST program. 
2.2.4.10 Analytical gel filtrations of RNF4 (1-105) and artificial SUMO chains 
50 µM RNF4 (1-105) has been incubated with either 200 µM monoSUMO-1 or 
monoSUMO-2, 100 µM diSUMO-1ΔN15 or diSUMO-2ΔN11 or 50 µM tetraSUMO-1ΔN15 
or tetraSUMO-2ΔN11 o/n in GST1 buffer + 5 % Glycerol.  Proteins have been subjected 
to analytical gel filtrations performed at 0.5 ml/min in GST1 buffer + 5 % Glycerol using 
an analytical Superdex 75 (10/300). Eluted protein fractions were separated by SDS-
PAGE and stained with Coomassie. A special case represented the incubation of RNF4 (1-
105) with tetraSUMO-1ΔN15, as protein fell out directly while mixing them. Overnight 
incubation led to a clear solution, but high-speed centrifugation (13000 g at 4 °C) 
resulted in a small protein containing pellet (examined with addition of Bradford 
solution). The supernatant was applied to analytical gel filtration. 
2.2.4.11 ITC 
Isothermal titration calorimetry (ITC) was performed using a VP-ITC (MicroCal). All 
titrations were carried out using purified artificial polySUMOs and RNF4 (1-125) in de-
aerated GST1 buffer + 5 % Glycerol at 25 °C. All purified proteins were passed into the 
same buffer aliquot that was used for these experiments to avoid heat of dilution. 
Artificial polySUMOs were injected as ligands into the experimental cell containing the 
diluted RNF4 (1-125) solution. The ligand was injected into the cell in 7 µl steps (43 in 
total). After each individual injection, the released heat of binding was recorded for 
3.5 min. All results were analyzed using the ORIGIN software package (MicroCal). The 
curve fit to the data describes a single site binding model dq/dLt = H (1/2 + (1 − XR −r)/(2 
((XR + r +1)2 − 4XR)1/2)) V, with XR = [LT]/[MT] and r = 1/KA[MT] (Wiseman, 1989; Indyk 
and Fisher, 1998). This fit optimizes parameters of stoichiometry (N), association 
constant (KA), and the enthalpy of binding (ΔH). The dissociation constant (KD) is the 
inverse of KA. 
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2.2.4.12 Interaction of GST-SIM containing proteins with individual SUMO paralogs 
500 µg purified SUMO-1, SUMO-2 and SUMO-3 have been each subjected to an 
interactions study (pulldown (PD) assay) with freshly GSH affinity purified and equalized 
GST-SIM constructs of PML (419-522), PML (419-522) S512-514, 517A, PML (419-522) 
S512-514, 517D, RNF4 (1-105), Sp100 (274-332), DAXX (625-740), PIAS3 (396-479) or 
PIAS4 (445-570) in GST1 + 5 % Glycerol, respectively. GSH affinity purification is 
described in section 2.2.4.3.1. Purified ubiquitin served as negative control. Proteins 
were eluted in 2 x SDS sample buffer, separated by SDS-PAGE and detected by SUMO-1, 
SUMO-2/3 or ubiquitin antibodies, respectively. Input of GST-SIM constructs were 
equalized by comparison of Coomassie stained protein bands after SDS-PAGE and is 
displayed as GST-SIM input. 
2.2.4.13 Isolation of multi-/polySUMOylated proteins from cells treated with different 
stress stimuli by GST-RNF4 (1-105) 
2 x 107 Hs27 human fibroblasts were either treated with DMSO (-) or 20 µM MG132 
(Sigma-Aldrich, Seelze; solved in DMSO) (+) for 6 h, with 3 µM ATO -/+ 20 µM MG132 for 
6 h, with 1 M Sorbitol -/+ 20 µM MG132 for 4 h or with 7.5 mM Canavanine -/+ 20 µM 
MG132 for 6 h. 
While the Hs27 cells were treated with the different stress inducers, GST-RNF4 1-105 
was freshly GSH affinity purified from E.coli Rosetta cells as described in section 
2.2.4.3.1. Likewise, purified GST was bound in GST1 buffer + 5 % Glycerol as a control. 
Samples of all purification and binding steps were analyzed by SDS-PAGE. Equal amounts 
of GSH-bound GST and GST-RNF4 were prepared for isolation of cellular proteins in 
15 ml tubes (300 µl 1:1 suspension each). 
After stress treatment, Hs27 cells were lysed in RIPA buffer (1 x 107 cells/ml) as 
described in section 2.2.3.2.  
To shear DNA, cell lysates were additionally passed through a 20 Gauge needle before 
centrifuged to pellet cellular debris. Cleared lysates were divided equally and applied 
each to GST and GST-RNF4 1-105 beads in a 1/10 dilution in GST1 buffer + 5 % Glycerol. 
The isolation of possible RNF4 substrates was carried out over night at 4 °C. 
The next morning, Beads were washed once with 10 ml GST1 buffer/5 % Glycerol, 
followed by 2 wash steps with 5 ml GST1 buffer + 5 % Glycerol. Then, the beads were 
transferred to 1.5 ml tubes and further washed 5 x 1 ml GST1 buffer + 5 % Glycerol.  
Proteins were eluted with 150 µl 2 x SDS sample buffer. 1/5 (30 µl) and 4/5 (120 µl) were 
applied on SDS-PA gels (Hoefer system) for western blot analysis and Coomassie 
staining, respectively. Individual lanes were excised into 10 different slices from the 
Coomassie-stained gel (> 50 kDa, including stack) and in-gel digested with trypsin  
(Promega). Peptide extraction and Orbitrap measurements were carried out by the 
CECAD proteomics facility as described in section 2.2.4.9. 
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The individual peak lists have been searched in the IPI database (IPIhuman 3.6.1; 
http://www.ebi.ac.uk/IPI/IPIhuman.html) using the MASCOT program (Matrix Science; 
Boston, MA, USA). Resulting protein hits were merged individually for each condition in 
a multiconsensus file and compared to the hits obtained for the DMSO negative 
samples. Protein hits that were also present in DMSO samples were eliminated from the 
result files. Filter settings allowed hits > 2 peptides and Ion Scores > 20.  
The resulting proteins have been assessed for the presence of bona-fide SUMOylation 
sites using the SUMOplot SUMO site prediction program (Abgent; San Diego, CA, USA; 
accessible via the ExPASy proteomic tools server, http://www.expasy.ch/tools/) in order 
to increase the probability of the resulting proteins being regulated by the ULS pathway. 
Proteins that did not confer any predictable SUMOylation site were likewise eliminated 
from the result files. Proteins with low probability motifs were listed in grey. 
2.2.4.14 Surface Plasmon Resonance  
Surface Plasmon Resonance (SPR) is a technique to study binding affinities between a 
ligand which is immobilized on a sensor chip in a flow cell and an analyte which is 
injected in aqueous solution through the flow cell under continuous flow. SPR-based 
instruments use an optical method to measure the refractive index near (within ~ 300 nm) the sensor surface (given in response units, RU). 
SPR was performed at 25 °C on a Biacore T100 (Biacore). Roughly 2500 RU of ubiquitin, 
SUMO-1 and SUMO-2 were amino coupled to a CM5 sensor chip (CM5 matrix: 
carboxymethylated dextran covalently attached to a gold surface; Biacore). Several 
concentrations ranging from 25 µM-100 µM of PIAS3 (394-470) or RNF4 (1-105) were 
tested at 20 µl/min in 50 mM Tris pH 7.5/150 mM NaCl/5 % Glycerol. Association was 
recorded for 1 min followed by a dissociation period of 2 min. After this period, the 
surface was regenerated with a 5 s pulse injection of 50 mM NaOH. 
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3. RESULTS 
3.1 Proteasome inhibition induces accumulation of SUMO-2/3 
conjugates at PML-NBs 
There are several hints that the ULS pathway is conserved to humans and that the PML 
protein might be a substrate for this pathway (Kosoy, 2007; Prudden, 2007; Sun, 2007; 
Uzunova, 2007; Weißhaar, 2008). In order to identify the according ULS enzyme, the first 
experiment attempted to test the hypothesis that SUMO-2/3 conjugates accumulate at 
PML-NBs under proteasome inhibition. That would limit the possible ULS candidates to 
proteins localizing to PML-NBs. Therefore, HeLa cells were transiently transfected with 
constructs expressing mature myc-tagged SUMO-1, SUMO-2 or SUMO-3 and treated 
with the proteasome inhibitor MG132. Figure 3.1 shows exemplarily the effects of 
proteasomal inhibition for cells expressing myc-SUMO-3. 
 
 
Figure 3.1: SUMO-3 conjugates accumulate at PML-NBs upon proteasome inhibition 
Fluorescent microscopy image of HeLa cells transfected with an expression plasmid for mature myc-
SUMO-3 40 h before treated with 20 µM MG132 for 7 h. Chromatin is stained with DAPI (blue), PML with 
the PML antibody 5E10 and the secondary donkey anti-mouse Alexa 488 (green). Myc-SUMO-3 is stained 
with anti-myc and the secondary donkey anti-rabbit Alexa 546 (red). Bar represents relative units. 
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The experiment demonstrated that upon proteasome inhibition, all three conjugatable 
SUMO paralogs accumulated at PML-NBs (data not shown for myc-SUMO-1 and myc-
SUMO-2). Note that the general PML-NB size seems to increase upon proteasome 
inhibition, regardless of the size of the respective nuclei (bigger nucleus in the middle 
panel, smaller ones in the lower panel compared to the control nucleus without MG132 
treatment). Cells transiently transfected with constructs expressing the chain-forming 
deficient myc-SUMO-2 K11R or myc-SUMO-3 K11R displayed a similar accumulation of 
SUMO conjugates at PML-NBs and as well an increase in PML-NB size and number (see 
exemplarily Figure 3.2 for myc-SUMO-3 K11R). 
 
 
Figure 3.2: SUMO-3 K11R also accumulates at PML-NBs upon proteasome inhibition 
Fluorescent microscopy image of HeLa cells transfected with an expression plasmid for mature myc-
SUMO-3 K11R 40 h before treated with 20 µM MG132 for 7 h. Immunofluorescent staining was carried 
out as described in Figure 3.1. Bar represents relative units. 
 
However, cells transiently transfected with the non-conjugatable myc-SUMOΔGG 
mutants had normal to small PML-NBs but the transfected SUMOΔGG mutants did not 
localize to them (data not shown). Therefore, the observed accumulation of mature 
SUMOs at PML-NBs was probably due to the accumulation of SUMOylated substrates. 
Together with the data from Bailey and O’Hare (2005), who observed the recruitment of 
SUMO-1 conjugates and moreover of proteasome subunits, it is reasonable to speculate 
that possible ULS substrates might accumulate at PML-NBs and that possible ULS 
proteins might be recruited to these structures in human cells.  
 
In order to verify possible substrates and identify mammalian ULS proteins, it was 
necessary to reconstitute the ubiquitylation of SUMOylated conjugates in vitro. 
Therefore, the efficient production and purification of SUMOylated proteins as well as 
the development of an in vitro ubiquitylation assay for SUMO conjugates was 
established and represents the main part of this work (see sections 3.2, 3.3 and 3.4). 
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3.2 Establishment of an efficient method to produce and purify 
SUMO-modified proteins from E. coli  
Generating SUMO-modified proteins requires the enzymatic cascade of E1, E2 and E3 
enzymes (as described in section 1.4). This process can be reproduced in E. coli (see 
section 2.2.4.4). First attempts to generate SUMO-modified proteins in E. coli have 
shown that the process is quite inefficient and the majority of the purified substrate is 
not SUMOylated (Uchimura, 2004a; Uchimura, 2004b; Weißhaar, 2008).  
In order to obtain appropriate possible ULS substrates for in vitro studies, this part of the 
work aimed to improve the production and isolation for the SUMO-modified forms of 
possible substrates (all GST-tagged).  
The major advantage established here was to utilize His6-tagged SUMOs instead of 
untagged versions. It was therefore possible to purify the SUMO-conjugated forms of a 
substrate by consecutive affinity purifications (as described in section 2.2.4.4).    
To test this method, several known SUMO substrates, e.g. the PML nuclear body 
proteins PML and Sp100, were subjected to small scale purifications.  
 
 
Figure 3.3: Small scale purification of His6-SUMOylated GST-PML11 truncation variants  
Different GST-PML truncation constructs were subjected to E. coli SUMOylation and then to subsequent 
GSH (A) and Ni2+-NTA (B) affinity purification. PIAS4 was coexpressed as SUMO E3 enzyme. 
Eluted proteins were separated by SDS-PAGE and detected with anti-GST or anti-His5, respectively.  
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Three PML11 constructs were tested: PML11 (50-179), which consists of the RING and 
B1 domain with the first two SUMOylation sites, PML11 (1-503), which comprises all 
features common to all nuclear isoforms except of the SIM and PML11 (1-522) which 
additionally contains the SIM (see Figure 3.3).  
E. coli preferentially expressed the smallest construct tested, GST-PML (50-179). Also, 
the SUMOylation of this protein was more efficient compared to the longer PML 
variants. Note that after GSH affinity purification most of the expressed GST-PML (50-
179) was not modified with SUMO as the band migrating at ~ 43 kDa is only present in 
the anti-GST Blot (see Figure 3.3 A). SUMOylated forms were enriched upon Ni2+-NTA 
affinity purification (compare respective ratios of Figure 3.3 A and B).  
 
For Sp100 A, the full length construct (1-480), a truncated version that ends behind the 
SIM (1-332) and one that lacks the K297 SUMOylation site and the SIM (1-274) were 
tested (see Figure 3.4).  
 
 
Figure 3.4: Small scale purification of His6-SUMOylated GST-Sp100 truncation variants 
Different GST-Sp100 truncation constructs were subjected to E. coli SUMOylation and then to subsequent 
GSH (A) and Ni2+-NTA (B) affinity purification. PIAS4 was coexpressed as SUMO E3 enzyme. 
Eluted proteins were separated by SDS-PAGE and detected with anti-GST or anti-His5, respectively.  
 
Upon the conditions applied, Sp100 (1-480) was not expressed in large amounts in E. coli 
and its SUMOylation was moderate. The shortest Sp100 construct (1-274) showed only 
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residual SUMOylation and demonstrated that the lost attachment site K297 is indeed 
the major one. Sp100 (1-332) is expressed and efficiently well SUMOylated.  
Furthermore, although detection was limited with the anti-GST after Ni2+-NTA affinity 
purification, SUMOylated forms were enriched; there is basically no band visible for 
unmodified Sp100 (1-332) which runs at ~ 72 kDa (compare protein running behavior 
between Figure 3.4 A and B). 
In comparison to the test SUMOylation of PML constructs, it becomes apparent, that 
E. coli expressing the SUMO-2 system had difficulties not only to SUMOylate the 
substrates efficiently but in overall substrate expression which was always lower 
compared to the SUMO-1 and SUMO-3 expressing systems. Therefore, large scale 
purifications have been only performed for SUMO-1 or SUMO-3 conjugated substrates 
(see sections 3.2.1 and 3.2.2). 
 
Additionally to PML and Sp100, non-PML-NB proteins, the NFκB essential modulator 
(NEMO) and the cytoplasmic-nuclear shuttling protein Huntingtin interacting protein 1 
alpha (HIP1α) were subjected to small scale E. coli SUMOylation for comparison (see 
Figure 3.5 and Figure 3.6). NEMO has been shown to be specifically SUMO-1 modified by 
PIAS4 (Huang, 2003; Mabb, 2006). HIP1α displays several possible SUMOylation sites 
and was tested whether it could be a SUMO substrate in cooperation with Ian Mills 
(Cambridge). 
 
Figure 3.5: Small scale purification of His6-
SUMOylated GST-NEMO 
GST-NEMO was subjected to E. coli 
SUMOylation and to subsequent GSH affinity 
purification. As SUMO E3 enzyme, PIAS4 was 
coexpressed. 
Eluted proteins were separated by SDS-PAGE 
and detected with anti-GST or anti-His5, 
respectively.  
 
 
NEMO was not efficiently SUMO modified in E. coli. The only detectable SUMOylation 
occurred in the SUMO-1 system and is in line with the before mentioned literature. 
 
For HIP1α, several possible SUMOylation sites exist (see Figure 3.6 A). To assess whether 
HIP1α is a SUMO substrate, two domains that comprise these sites were expressed 
separately in the SUMOylation systems (see Figure 3.6 B). 
The HIP1α domain (722-974) was efficiently SUMOylated by SUMO-1 and to a lesser 
extent by SUMO-2 and SUMO-3 in the E. coli SUMOylation systems. Most likely, several 
sites in this domain served as SUMO acceptors. Notably, this substrate was also 
SUMOylated without the help of a SUMO E3 ligase. The other HIP1α domain (303-727) 
was probably not SUMOylated although there were slower migrating bands detected 
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with anti-GST compared to the non-modified form running at ~ 43 kDa. However, as 
these bands were not detected with the His5-antibody, it is unlikely that they contain 
SUMO.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: HIP1α is a SUMO substrate in the E. coli SUMOylation system 
A) HIP1α harbors several possible SUMOylation sites. HIP1α sequence was subjected to SUMOplot analysis 
(Abcam; San Diego, USA), a SUMOylation site prediction program. Motifs marked in red have a high 
probability to be SUMOylated (> 50 %), motifs marked in blue a lower one (< 50 %). The domain which is 
predominantly SUMOylated in E. coli (refer to point B) is boxed in red.  
B) Small scale purification of His6-SUMOylated GST-HIP1α domains. GST-HIP1α domains (303-727) and 
(722-974) were subjected to E. coli SUMOylation without an additional E3 ligase and to subsequent GSH 
affinity purification. Eluted proteins were separated by SDS-PAGE detected with anti-GST or anti-His5, 
respectively. 
A 
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Together, these data demonstrated that the E. coli SUMOylation systems are functional 
tools for a range of substrates. Furthermore, it seems that substrate and SUMO variant 
specificity are maintained (compare SUMOylation of PML and Sp100 to NEMO and 
HIP1α).  SUMOylation of the respective substrates likely occurs with some specificity at 
previously identified sites (e.g. Sp100 K297) or predictable sites (compare HIP1α 
domains). 
The efficiently SUMOylated GST-fusions of PML (50-179), Sp100 (1-332) and HIP1α (722-
974) have been subsequently purified in large scale. Purified proteins either contained 
the GST tag or it was cleaved off during purification.  
3.2.1 PML & Sp100 
The purification of SUMOylated PML (50-179) and Sp100 (1-332) has been established 
during this work and is described in section 2.2.4.4. As the method is the same for both 
proteins, the single steps are illustrated only for SUMO-3 modified PML (50-179) in 
Figure 3.7.  
During purification, the proportion of SUMOylated forms of the substrate is massively 
enriched compared to the non-modified form; GST-PML (50-179) migrates at ~ 38 kDa, 
SUMOylated forms above. After GSH affinity purification strikingly only a small 
proportion of the GST-tagged substrate is SUMOylated (see Figure 3.7 A). This 
proportion is then enriched by Ni2+-NTA affinity purification as it only binds the 
SUMOylated forms of the substrate (see Figure 3.7 B). PML as well as Sp100 dimerizes 
and therefore, a smaller proportion of non-conjugated substrate cannot be removed 
under native conditions and elute in the same fractions from gel filtration (see Figure 
3.7 C; untagged PML (50-179) migrates at ~ 15 kDa, SUMOylated forms at ~ 30 kDa or 
slower).  
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Figure 3.7: Purification steps for SUMOylated proteins  
Purification steps are exemplified by showing the Coomassie-stained SDS-PA gels of the SUMO-3 modified 
PML (50-179) purification.  
A) The raw E. coli lysate (RL) was cleared by centrifugation and the resulting supernatant (S) was applied 
on GSH-beads (B). After extensive washing, GST-tagged proteins were eluted with buffer containing GSH 
(E; P, pellet; FT, flow through). 
B) Ni2+-NTA affinity purification of eluted GST-tagged proteins. SUMOylated GST-tagged proteins were 
bound and eluted at Imidazole concentrations around 200 mM (FT, flow through). Elution fractions were 
pooled and subjected to o/n TEV cleavage. 
C) TEV cleaved SUMOylated proteins (TEV cleavage) were applied on fresh GSH beads (GST clearance) to 
remove GST or residual GST-tagged proteins from the SUMOylated proteins. These are finally subjected to 
size exclusion chromatography on a HiLoad 16/60 Superdex 75 column and eluted in the respective 
fractions.  
 
For in vitro studies, PML (50-179) as well as Sp100 (1-332) have been purified either non-
conjugated, SUMO-1 modified or SUMO-3 modified. PML K65 and K160 mutants have 
also been subjected to large scale SUMOylation and purification. Usually, from 10 l 
expression cultures, 1-10 mg SUMOylated proteins have been obtained per purification. 
Purification of non-conjugated substrates has been conducted in a similar way, except 
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that the Ni2+-NTA affinity purification was not necessary. Figure 3.8 summarizes the 
purified non-conjugated forms and SUMO-3 conjugated forms of the respective proteins 
and provides an impression of their migration in SDS-PA gels. 
 
 Figure 3.8: Migration of 
SUMOylated and non-conjugated 
proteins purified in large scale 
Purified proteins were separated by 
SDS-PAGE and stained with 
Coomassie. Arrows indicate non-
conjugated PML (50-179) or Sp100 
(1-332), respectively. SUMOylated 
forms migrate at different sizes and 
likely represent either different 
SUMO attachment sites and/or 
SUMO chains (S3, SUMO-3). The 
asterisk marks a contaminating 
protein, meanwhile identified as 
bacterial DnaK (see section 2.2.4.6). 
 
3.2.2 HIP1α 
The purification of SUMO-1 modified HIP1α (722-974) basically followed the same 
protocol as described above for PML (50-179). Further studies have been performed by 
Ian Mills group in Cambridge. Figure 3.9 shows the purified non-conjugated and 
SUMOylated domain in comparison. 
 
Figure 3.9: Comparison of purified HIP1α (722-
974) non-conjugated and SUMO-1 modified. 
This HIP1α domain is efficiently SUMO-1 (S1) 
modified when subjected to the E. coli 
SUMOylation system and SUMO-1 modified HIP1α 
(722-974) could be purified in large scale. Shown is 
a Coomassie stain after separating the purified 
proteins by SDS-PAGE. It is depicted here as an 
example of how efficient the SUMOylated forms of 
a protein can be separated by the consecutive 
affinity purifications applied. As this domain 
probably does not dimerize, the non-modified 
substrate has been completely removed from the 
purified SUMO-1 conjugated forms. The asterisk 
marks a prominent degradation band. 
 
3.2.3 Analysis of different SUMO-E3 ligases on substrate SUMOylation  
To improve the SUMOylation efficiency of PML (50-179) and Sp100 (1-332) the influence 
of several SUMO E3 ligases has been tested (see Figure 3.10 and 3.11). 
All four tested SUMO E3 ligases promoted SUMO-1 modification of Sp100 (1-332) in 
comparable amounts (see Figure 3.10). 
RESULTS 
62 
 
 
Figure 3.10: Impact of different SUMO E3 ligases on Sp100 (1-332) SUMOylation efficiency 
GST-Sp100 (1-332) was subjected to E. coli SUMOylation with coexpression of different E3 enzymes 
(RanBP2short, aa 2633-2711; RanBP2long, aa 2553-2711) and subsequent GSH affinity purification. 
Proteins were separated by SDS-PAGE and detected with anti-GST or anti-His5, respectively. SUMO 
conjugates (SUMOc.) are indicated. 
 
For SUMO-3, only PIAS4 seems to generate poly-SUMO chains efficiently on the 
substrate (note the typical ladder in the respective lane). PIAS3 and the short RanBP2 
promoted chain formation to a minor extend whereas it is nearly completely abrogated 
with the long RanBP2 form which only allows mono-SUMOylation of Sp100 (1-332). 
Sp100 (1-332) alone was also efficiently SUMOylated in E. coli (data not shown). 
 
 
Figure 3.11: Impact of different SUMO E3 ligases on PML (50-179) SUMOylation efficiency 
GST-PML (50-179) and its KR mutants were subjected to E. coli SUMOylation with coexpression of PIAS3 
or PIAS4 and subsequent GSH affinity purification. Proteins were separated by SDS-PAGE and detected 
with anti-GST or anti-His5, respectively. SUMO conjugated forms (SUMOc.) are indicated at the right. 
 
SUMO-1 modification of PML (50-179) was most efficient with PIAS4 coexpression. PML 
(50-179) SUMOylation also occurred without the coexpression of an additional E3 ligase 
in E. coli. In the case of SUMO-3 modification, it was even the most efficient strategy to 
form polymeric chains and indicated a SUMO E3 ligase activity for PML as neither PIAS3 
 RESULTS 
 
63 
 
nor PIAS4 were as efficiently SUMOylating PML (50-179). By using lysine mutants of PML 
(50-179), differences in migration through SDS-PAGE could be observed for the SUMO 
conjugated forms depending on the SUMO attachment site. SUMO attached to K160 
resulted in protein species migrating faster than the ones where it is attached to K65 
(compare running behavior of mono-SUMOylated PML (50-179) K65R and K160R 
mutants as indicated by arrows in Figure 3.11). A reduction of self-SUMOylation 
efficiency was not observed in PML (50-179) lysine mutants (data not shown). 
 
Together, particularly the SUMO-3 conjugation was strongly influenced by the choice of 
the coexpressed SUMO E3 ligase and differed between substrates. In light of the 
following data shown, SUMO-3 modified PML (50-179) was purified several times, either 
when coexpressed with PIAS4 or without the coexpression of an additional ligase. 
SUMO-1 modified PML (50-179) was purified after coexression with PIAS4. SUMOylated 
Sp100 was generated by coexpression with PIAS4 and subsequent purification.  
3.3 Establishment of an in vitro ubiquitylation assay 
In vitro ubiquitylation requires purified active ubiquitin E1, E2 and E3 enzymes as well as 
a substrate and ubiquitin itself. For the special case of SUMO-dependent ubiquitylation, 
the substrate has to be SUMOylated. Furthermore, the appropriate E3 enzyme that 
recognizes SUMOylated proteins needs to be identified and then tested for its ability to 
act as a ULS (see section 3.3.2 and following ones). 
3.3.1 E2 purification & activity test 
To establish SUMO-dependent ubiquitylation in vitro, the appropriate E2 enzyme had to 
be purified. Yeast ULS proteins use the E2 members Ubc4 and Ubc5 that are 
homologous to the human UbcH5 family (Uzunova, 2007). Together with the fact that 
these proteins consists simply of the ‘E2 core’ and therefore accept a huge variety of 
ubiquitin E3 ligases (Ye and Rape, 2009), it was tempting to speculate that they might 
also act in conjunction with possible human ULS proteins. Therefore, UbcH5b was 
chosen and purified (as described in section 2.2.4.3.4). 
Enzymatic activity was analyzed by thioester formation to purified ubiquitin (see Figure 
3.12). Thioesters between purified untagged UbcH5b (~ 16 kDa) and ubiquitin (~ 8 kDa) 
have been formed in comparable efficiency to the purchased His6-tagged UbcH5b 
(Biomol, Hamburg). Note that the thioester between the tagged UbcH5b and ubiquitin 
migrated slower than the one between the self-made untagged UbcH5b and ubiquitin. 
The use of untagged (and not His6-tagged) UbcH5b for in vitro ubiquitylation studies 
avoided cross detection as the SUMOs in the SUMOylated putative ULS substrates were 
His6-tagged and were supposed to be detected with anti-His5. 
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Figure 3.12: UbcH5b activity test 
Activity of self-made UbcH5b was tested in comparison to the commercial available His6-tagged UbcH5b 
(Biomol, Hamburg) by assessing thioester formation with ubiquitin. 0,2 µg/µl Ube1, 1 µg/µl UbcH5b and 
3 µg/µl ubiquitin were incubated at RT for 5 min in 50 mM Tris pH 7.5, 50 mM NaCl and 10 mM MgCl2 +/- 
5 mM ATP. Reactions were divided and terminated by adding 2x SDS sample buffer either containing the 
reducing agent β-Mercaptoethanol or not. Proteins were separated by SDS-PAGE and detected with anti-
ubiquitin.  
 
3.3.2 Identification of putative ULS proteins for PML 
As SUMOylated substrates accumulate predominantly at PML-NBs (see section 3.1), 
putative human ULS proteins could also localize to these structures. The nuclear protein 
database (http://npd.hgu.mrc.ac.uk/user/) provided a list of 76 proteins that had been 
localized to PML-NBs until 2007 (start of search). 
Out of these, several candidate ULS proteins have been identified by complying with the 
two requirements for putative ULS proteins: domains that might confer ubiquitin ligase 
activity (such as HECT, RING or U-Box) and putative SIMs for substrate recognition. 
PML itself has a RING domain and a SIM and although it has been published to promote 
SUMOylation in S. cerevisiae (Quimby, 2006), it was tested here for ubiquitin ligase 
activity. Also, during the initial phase of this work PML was not known to be a ULS 
target.  
Furthermore, two other TRIM proteins with ubiquitin ligase activity, TRIM23/ARD1 
(Vichi, 2005) and TRIM24/TIF1α (Allton, 2009) harbour putative SIMs. Additionally, the 
zinc finger protein ZNF198 and the RING finger protein RNF4 have been found to meet 
the defined requirements. ZNF198 can be SUMOylated, possesses at least two SIMs and 
localizes to PML-NBs (Hecker, 2006; Kunapuli, 2006), but a ubiquitin ligase activity has 
not been identified yet. RNF4 is a homologue to the S. pombe ULS proteins Rfp1 and 
Rfp2 and has been introduced in section 1.5.3. Figure 3.13 gives an overview of the 
candidate ULS proteins. 
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 Domain organization of putative human ULS proteins 
  
     SIM type a -                    SIM type r 
 
 PML1 ---546-SGAGEAEERVVVISSSEDSDAEN    RNF4 ----26-PEISLEAEPIELVETAGDEIVDL 
 
 ARD1 ---497-LTEKELRDALLLIFANKQDVAGA 
 ARD1 ---560-LSRQLVAAGVLDVA  
 TIF1α --412-WAQNIINLGSLVIEDKESQPQMP SIM type b 
 TIF1α --727-GPPENYDFPVVIVKQESDEESRP 
 
 ZNF198---50-NSSVEDDDDVVFIEPVQPPPPSV RNF4 ----36-ELVETAGDEIVDLTCESLEPVVV 
 ZNF198 -106-ASQKGSVSETIVIDDEEDMETNQ RNF4 ----48-LTCESLEPVVVDLTHNDSVVIVD 
 ZNF198 1082-VKTRQLDEDLLVLDELKSSKSVK 
 ZNF198 1348-NTLENMLVRVLLVKDIYDKDNYE 
 
 RNF4 ----57-VVDLTHNDSVVIVDERRRPRRNA 
 
 RNF4’s complete SIM domain 
 
 RNF4 ----26-PEISLEAEPIELVETAGDEIVDLTCESLEPVVVDLTHNDSVVIVDERRRPRRNA 
 
 RING domains 
 
 PML1 ----52-FLRCQQCQAEAKC-------PKLLPCLHTLCSGCLEAS---GMQCPICQAP 
ARD1 ----27-VLECGVCEDVFSLQGDKV--PRLLLCGHTVCHDCLTR--PLHGRAIRCPFD 
 TIF1α –--52-LDTCAVCHQNIQSRA-----PKLLPCLHSFCQRCLPAP//GVIRCPVCSQE 
 RNF4 ---128-TVSCPICMDGYSEIVQNGRLIVSTECGHVFCSQCLRDSLKNANTCPTCRKK 
 
Figure 3.13: Domain organization and sequence homology of putative human ULS proteins 
All identified possible human ULS proteins possess at least one SIM and a RING/U-Box like domain (see 
scheme). Diverse additional domains of ARD1, TIF1α and ZNF198 are not depicted here to focus on the 
requirements for ULS proteins. SIM types and sequences are given as well as the RING sequences (the 
RING of TIF1α has an extension compared to the others which is not depicted here due to space problems 
and is indicated by //). The zinc fingers of ZNF198 resemble in part a U-Box and are depicted in Appendix 
Figure A.1. SIM relevant hydrophobic amino acids are depicted in blue, acidic amino acids in red and 
threonine residues in green. The SIM cores are boxed. Zinc chelating residues in the RING domains are 
depicted in gold. 
 
In light of the homology of RNF4 to the S. pombe ULS proteins Rfp1/Rfp2 and its ability 
to complement for yeast ULS deletion phenotypes (see section 1.5.3), made it the most 
promising among the candidates. Moreover, its domain organization shows that it more 
or less consists of a SIM ‘domain with up to four SIMs, the NLS and the RING domain. 
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3.3.3 Activity test for putative ULS proteins 
The possible human ULS proteins were cloned and expressed as GST fusion proteins in 
E. coli with the help of Anke Krause. Expression and purification of ARD1 was not 
successful and it was therefore not further analyzed. 
To assess their potential as ubiquitin ligases, the candidate ULS proteins were subjected 
to a typical E3 assay in low salt conditions (2 mM MgCl2; Joazeiro, 1999) in order to 
promote ‘self-ubiquitylation’ (which results in most cases in formation of ubiquitin 
chains, either free, or on E2 or on the respective E3 enzyme; see Figure 3.14).  
 
 
Figure 3.14: Ubiquitin ligase activity of potential human ULS proteins 
Potential ULS proteins were analyzed for their self-ubiquitylation activity in comparison to the known 
S. cerevisiae ULS proteins Slx5-Slx8 (a kind gift of Maria Miteva and Jürgen Dohmen, Cologne; the asterisk 
indicates that the protein concentration is not further determined). Reactions have been carried out for 
7 h at 30 °C using 7.5 nM Ube1, 150 nM UbcH5b or S. cerevisiae Ubc4, 5 µM ubiquitin and 0.25 µM, 
0.5 µM or 1 µM of the ULS candidates in 50 mM Tris pH 7.5, 2 mM MgCl2, 1 mM DTT, 10 U creatine 
phosphokinase, 1 mM creatine phosphate +/- 1 mM ATP. The reactions were terminated by adding 
2 x SDS sample buffer. Proteins were separated by SDS-PAGE and detected with anti-ubiquitin. 
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Except for the active Slx5-Slx8 complex (analyzed as well for the purpose of comparison), 
only RNF4 exhibited ubiquitylation activity in this assay which was demonstrated by the 
increase of ubiquitin conjugates with increasing RNF4 concentrations and its strict ATP 
dependence (compare lanes 1-4 of the blot at upper right). Furthermore, both the 
S. cerevisiae Slx5-Slx8 complex and RNF4 could promote ubiquitylation in conjunction 
with either UbcH5b or yeast Ubc4 which underlines the conservation of RING-E2 
interfaces across species borders. 
As RNF4 seemed to fulfill all set requirements and displayed ubiquitylation activity, it 
was next tested for its ability to act as a ULS. 
3.4 In vitro ubiquitylation of SUMOylated PML demonstrates a 
function of RNF4 as a mammalian ULS 
3.4.1 ULS assay development 
The first substrate chosen for assessing RNF4’s capability as ULS enzyme was the in 
E. coli His6-SUMOylated GST-PML (50-179) introduced in section 3.2. It has been shown 
previously that RNF4 physically interacts with PML in a SUMO-dependent manner (Häkli, 
2005) and that SUMOylated PML species are stabilized during proteasome inhibition 
(Lallemand-Breitenbach, 2001).  
First, GST-tagged PML (50-179) or its SUMOylated forms were subjected to RNF4-
mediated ubiquitylation reactions (see Figure 3.15 A). The anti-GST blot suggested that 
higher SUMOylated species decrease when RNF4 is present. Unfortunately, this also 
happened without the addition of ATP, suggesting that some residual ATP or ADP might 
have been present in the purified protein fractions and was recycled with the help of the 
added ATP regenerating system (creatine phosphokinase and creatine phosphate). 
Nonetheless, RNF4 had some influence to the higher SUMOylated species of GST-PML 
(50-179) running at ~ 55 kDa that vanish (marked with a red circle), though slower 
migrating species could not be detected with anti-GST (no additional bands above 55 
kDa). The appearance of such species in presence of RNF4 and ATP would strongly 
suggest an additional modification of the respective substrate with ubiquitin. This could 
be due to a detection problem: when the substrate is modified by both, ubiquitin and 
SUMO, it simply could disturb the antibody-antigen binding on the membrane. The same 
problem arose when the blot was subjected to immunodetection with anti-His5 to detect 
the SUMOylated species (data not shown). By testing several variants, the first time that 
additional bands appeared in presence of RNF4 and ATP was an assay with PML (50-179) 
or its SUMOylated variants where the GST-tag was cleaved off. Instead, GST-tagged 
RNF4 was used in that reaction and substrates were detected with anti-His5 (see Figure 
3.15 B). 
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Figure 3.15: RNF4 dependent ubiquitylation of SUMOylated PML (50-179) in vitro 
A) GST-tagged PML (50-179) or its His6-SUMO conjugated forms (SUMO-1c. or SUMO-3c.) were subjected 
to a ubiquitylation reaction containing RNF4 or not. Reactions have been carried out for 16 h o/n at 30 °C 
in 50 mM Tris pH 7.5, 2 mM MgCl2, 1 mM DTT, 10 U creatine phosphokinase, 1 mM creatine phosphate 
and protease inhibitors +/- 5 mM ATP containing 3 ng/µl Ube1, 3 ng/µl UbcH5b, 300 ng/µl ubiquitin, 100 
ng/µl GST-PML (50-179) or its SUMOylated forms +/- 30 ng/µl RNF4. Reactions were terminated by adding 
2 x SDS sample buffer. Proteins were separated by SDS-PAGE and detected with anti-GST or anti-ubiquitin. 
B) Untagged PML (50-179) or its His6-SUMOylated forms (SUMO-1c. or SUMO-3c.) were subjected to a 
similar reaction as in A, containing each 100 ng/µl substrate and 30 ng/µl GST-RNF4. All other parameters 
were unchanged. Detection was carried out using antibodies recognizing His5 or ubiquitin. The arrow 
indicates a probably mono-ubiquitylated form of SUMOylated PML (50-179), whereas the brace indicates 
a smear which might represent poly-ubiquitylated substrates. 
 
 
The SUMOylated forms of PML (50-179) migrating at ~ 43 kDa seemed to decrease and 
instead, an additional band (indicated by an arrow) appeared slightly higher together 
with some faint smear above it (indicated by a brace). Assuming that these bands are 
ubiquitylated forms of SUMOylated PML (50-179) – either mono-ubiquitylated (arrow) 
or poly-ubiquitylated (brace), this strongly suggests that RNF4 is indeed a ULS protein, 
predominantly recognizing and ubiquitylating the slower migrating, higher SUMOylated 
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species of PML (50-179). Both SUMO-1 and SUMO-3 modified PML (50-179) served as 
substrate for ubiquitylation through RNF4. Of course, with the His5-antibody, the non-
conjugated PML (50-179) control could not be detected, so that a simple recognition of 
RNF4 and PML (50-179) with subsequent PML ubiquitylation could not be ruled out. An 
antibody efficiently recognizing PML itself in Western blots was not available at that 
time. 
Also, any conclusions could be drawn from the anti-ubiquitin blot because ‘self-
ubiquitylation’ was detected in all lanes where RNF4 and ATP had been added to the 
reaction. This uncontrolled formation of ubiquitin chains was so strong that there 
weren’t any detectable changes between the provided PML substrates (Figure 3.15, 
left). 
 
To increase specificity towards the SUMOylated substrate, several steps have been 
taken to render the reaction more stringent. 
First, untagged RNF4 was purified again in a higher purity than the old batch which 
greatly reduced unspecific ubiquitylation (see protocol in section 2.2.4.3.1).  
Second, the salt concentration was elevated; as unspecific ubiquitylation occurs in low 
salt conditions (see ubiquitin E3 activity test and Figure 3.16). Out of 33 mM, 50 mM, 67 
mM and 100 mM KCl, ubiquitylation specificity was achieved at 67 mM KCl while 
keeping an adequate efficiency which was lost at higher salt concentrations (data are 
not shown for 33 mM, 50 mM and 100 mM KCl). 
 
 
Figure 3.16: Comparison of RNF4-mediated (self-) ubiquitylation in dependence of salt concentration 
Exemplarily, low salt conditions containing only 2 mM MgCl2 and no additional KCl (0 mM KCl) are 
compared to the chosen assay conditions containing 67 mM KCl. Different RNF4 concentrations have been 
added as indicated to ubiquitylation reactions containing 3 ng/µl Ube1, 3 ng/µl UbcH5b and 300 ng/µl 
ubiquitin in 50 mM Tris, 2 mM MgCl2, 1 mM DTT, protease inhibitors and 5 mM ATP +/- 67 mM KCl. 
Reactions were incubated at 30 °C and terminated after 7 h by adding 2 x SDS sample buffer. Proteins 
were separated by SDS-PAGE and detected with anti-RNF4 or anti-ubiquitin. At the RNF4 concentration 
used for substrate ubiquitylation (30 ng/µl), uncontrolled ubiquitylation was prevented in conditions with 
67 mM KCl.  
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Third, in order to block unspecific activity, addition of bovine serum albumin (BSA) to the 
assay was tested and found to further increase specificity without changing the 
efficiency of ubiquitylation towards the SUMOylated PML (50-179).  
Together, these improvements made the reaction specific towards the SUMOylated PML 
(50-179) (compare ubiquitin blots in Figure 3.17 and see Figure 3.19). 
 
 
Figure 3.17: Improvement of assay conditions results in RNF4 specificity towards SUMO conjugates 
100 ng/µl PML (50-179) or its His6-SUMOylated forms (SUMO-1c. or SUMO-3c.) were subjected to in vitro 
ubiquitylation by RNF4 in 50 mM Tris pH 7.5, 2 mM MgCl2, 1 mM DTT, protease inhibitors and 5 mM ATP 
containing 3 ng/µl Ube1, 3 ng/µl UbcH5b, 300 ng/µl ubiquitin +/- 30 ng/µl RNF4 (A) or in 40 mM Tris 
pH 7.5, 67 mM KCl, 2 mM MgCl2, 1 mM DTT, 200 ng/µl BSA, protease inhibitors and 5 mM ATP containing 
3 ng/µl Ube1, 3 ng/µl UbcH5b, 300 ng/µl ubiquitin +/- 30 ng/µl RNF4 (B). Reactions were terminated by 
adding 2 x SDS sample buffer. Proteins have been separated by SDS-PAGE and detected with anti-
ubiquitin. 
 
Furthermore, under the chosen conditions, ULS activity of RNF4 seemed to be restricted 
to appropriate SUMOylated substrates: Ubiquitylation of a GST-SUMO fusion which 
occured under low salt conditions (Sun, 2007) was prevented (see Figure 3.18). Note 
that also GST alone was slightly ubiquitylated under low salt conditions. 
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 Figure 3.18: RNF4 in vitro ubiquitylates GST-SUMO fusion proteins only under low salt conditions 
GST, GST-SUMO-1 or GST-SUMO3 linear fusions (each 100 ng/µl) were subjected to in vitro ubiquitylation 
by RNF4 either under low salt conditions as described in Figure 3.17 A or in the advanced assay conditions 
described in Figure 3.17 B. Proteins were separated by SDS-PAGE and detected with anti-GST or anti-
ubiquitin. Ubiquitylated species are indicated. 
 
3.4.2 RNF4 is a ULS and prefers SUMO3-modified PML as substrate 
By subjecting PML (50-179) or its SUMO-conjugated forms to the more stringent in vitro 
conditions, it became apparent, that RNF4 indeed acts as a ubiquitin ligase for SUMO 
conjugates: Figure 3.19 A shows the RNF4-dependent ubiquitylation of SUMO-modified 
PML in vitro analyzed by SDS-PAGE and subsequent detection by anti-His5 and anti-
ubiquitin after Western blotting. Since unspecific ubiquitylation was prevented, the 
intensity of ubiquitin conjugates revealed a RNF4-dependent ubiquitylation of PML (50-
179) modified with SUMO-1 and -3 while RNF4 mediated ubiquitylation of unmodified 
PML (50-179) was negligible.  
Additionally, RNF4-dependent ubiquitylation of both types of SUMO-modified PML were 
detected by anti-His5. Slower migrating bands are visible for both, His6-SUMO-1 and His6-
SUMO-3. However, His6-SUMO-3 modified PML (50-179) was ubiquitylated more 
efficiently which is also demonstrated by a stronger ubiquitin signal.   
Note that SUMO-1 and SUMO-3 modified PML (50-179) forms migrated at comparable 
heights (input on the right, Figure 3.19 A). 
In order to directly show that ubiquitin was attached to His6-SUMOylated PML (50-179), 
a Ni2+-NTA affinity isolation was performed after the in vitro ubiquitylation reaction (see 
Figure 3.19 B). His6-tagged SUMOs were isolated from the reaction mixture under 
denaturing conditions such that only proteins covalently attached to could be extracted 
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as well. Detected ubiquitylated species are therefore most likely PML-SUMO-ubiquitin 
hybrid conjugates. This isolation also underlined the preference of RNF4 towards SUMO-
3 modified PML (50-179) already observed in Figure 3.19 A. Although the anti-His5 blot 
shows that comparable amounts of SUMO-1 and SUMO-3 conjugated PML (50-179) 
were isolated from RNF4 containing reactions, there were more ubiquitin conjugated 
species detected for SUMO-3 modified PML (50-179). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19: SUMO-3-modified PML is the preferential target of RNF4-dependent in vitro ubiquitylation 
Unmodified (non-conj.) PML (50-179) or its His6-SUMO conjugated forms (SUMO-1c. or SUMO-3c.) were 
subjected to in vitro ubiquitylation by RNF4 as described in Figure 3.17 B. Reactions were divided and 
further treated as described in A and B. 
A) Reactions were terminated by adding 2 x SDS sample buffer, proteins were separated by SDS-PAGE and 
detected with anti-His5 or anti-ubiquitin (left and middle). Input of purified PML (50-179) species is given 
in the right panel (Coomassie). Residual His6-tagged TEV protease is marked with an asterisk. 
B) Reactions were subjected to denaturing Ni2+-NTA affinity purification as described in 2.2.4.8. Proteins 
were separated by SDS-PAGE and detected with anti-His5 or anti-ubiquitin. 
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Together, these data demonstrated a highly specific ubiquitin ligase activity of RNF4 
towards SUMOylated PML, suggesting that RNF4 is indeed a ULS protein. Furthermore, it 
confirmed with in vitro data that PML is a substrate for the ULS pathway in mammalian 
cells. The following experiments focused on SUMO-3 modified PML (50-179) due to the 
observed preference of RNF4 towards these forms. 
3.4.3 The SUMOylation site of the PML substrate is not important for 
recognition by RNF4 in vitro 
To circumvent the detection problems for PML itself, highly purified PML (50-179) was 
used to generate a specific rabbit antibody (see section 2.2.4.5). It became a very useful 
tool as it detected the unmodified and the modified PML (50-179) species so that they 
could be compared directly (see Figure 3.20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20: Newly generated antibody against PML (50-179) allowed comparison of PML species 
Unmodified (non-conj.) PML (50-179) or its His6-SUMO-3 conjugated form (SUMO-3c.) were subjected to 
in vitro ubiquitylation by RNF4 as described in Figure 3.17 B. Reactions were terminated by adding 2 x SDS 
sample buffer, proteins were separated by SDS-PAGE and detected with anti-His5 or anti-PML (50-179). 
Rabbit-anti-PML (50-179) (serum 3004) specifically recognizes unmodified, SUMO-modified and 
ubiquitylated SUMO-modified PML. Anti-PML (50-179) detection sensitivity of the latter two is 
comparable to that of anti-His5.  
 
This antibody also recognized PML (50-179) lysine mutants K65R and K160R and was 
used to dissect the influence of the substrate SUMOylation site for RNF4-dependent 
ubiquitylation. In human cells, ATO stimulates the ubiquitylation of SUMOylated PML 
and the PML-RARα fusion protein. PML K160 seems to be required for this process 
(Lallemand-Breitenbach, 2001). 
However, RNF4-dependent in vitro ubiquitylation of the PML (50-179) K160R mutant is 
still very efficient (see Figure 3.21). In fact, huge differences in ubiquitylation efficiency 
depending on the substrate SUMOylation site could not be observed. Although 
ubiquitylation of SUMOylated PML (50-179) wt was relatively inefficient in this assay 
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(compared for example with the one shown in Figure 3.20), the SUMOylated K65R and 
K160R mutants were well ubiquitylated.  
 
 
Figure 3.21: RNF4-dependent in vitro ubiquitylation of site-specific SUMOylated PML (50-179) 
Unmodified (non-conj.) and His6-SUMO-3 (SUMO-3c.) modified PML (50-179) wt, K65R or K160R were 
subjected to in vitro ubiquitylation by RNF4 as described in Figure 3.17 B. Reactions were terminated by 
adding 2 x SDS sample buffer, proteins were separated by SDS-PAGE and detected with anti-PML (50-179). 
The asterisk marks residual DnaK from E. coli. 
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3.4.4 RNF4 preferentially ubiquitylates the SUMO moiety of its substrate 
The preceding experiment suggested that at least under in vitro conditions, RNF4 does 
not discriminate between SUMOs attached to different sites in the substrate protein. 
RNF4 thus seems to be directed to its substrate via the SUMO moieties. A question 
arising from this observation – apart from a general interest – was the following: are the 
ubiquitin molecules attached to lysines in the conjugated SUMOs or to lysines in the 
modified substrate PML? 
A first attempt to address this question was the reversal of SUMOylation after subjecting 
His6-SUMO-3 modified PML (50-179) to RNF4-dependent ubiquitylation. For that 
purpose, the catalytic domains of the SUMO proteases SENP1 and SENP6 were purified. 
Then, after subjecting unmodified or His6-SUMO-3 modified PML (50-179) to RNF4-
dependent ubiquitylation, reactions were either left untreated or incubated with SENP1, 
SENP6 or both catalytic domains. SDS-PAGE analysis followed by anti-PML (50-179), anti-
His5 and anti-ubiquitin detection (see Figure 3.22) revealed that the ubiquitin molecules 
are most likely attached to the SUMO moieties, not to PML (50-179).  
 
 
Figure 3.22: SENP treatment of in vitro ubiquitylated SUMO-modified PML  
Unmodified (nc.) and His6-SUMO-3 (SUMO-3c.) modified PML (50-179) were subjected to in vitro 
ubiquitylation by RNF4 as described Figure 3.17 B. Modified species have been produced without the 
coexpression of a SUMO E3 ligase. Purified catalytic domains of SENP1, SENP6 or both (each or together ~ 30 ng/µl, respectively) were added or not to the reactions as indicated. 
Reactions were terminated by adding 2 x SDS sample buffer, proteins were separated by SDS-PAGE and 
detected with anti-PML (50-179), anti-His5 or anti-ubiquitin. Asterisks on the right of the respective blots 
mark cross-reactive bands. Black boxed blot parts are enlarged beneath the total blot view. Green boxes 
highlight ubiquitylated His6-SUMO-3.  
 
RESULTS 
76 
 
The resulting blots show that both, SENP1 and SENP6 catalytic domains were active in 
deSUMOylating PML (50-179) (compare western blots decorated with anti-PML (50-179) 
and anti-His5 in Figure 3.22). The anti-ubiquitin blot shows that the ubiquitylation 
reaction was not as specific as in the experiments before (compare RNF4-dependent 
ubiquitylated unmodified to modified PML). Reactions without substrate displayed a 
similar ubiquitylation pattern (data not shown). That problem occurred independently 
from salt or protein concentration and could be linked to the use of a new Tris batch 
(data not shown). A small fraction of unmodified PML (50-179) was also ubiquitylated by 
RNF4 (see faint band beneath 26 kDa). However, after ubiquitylation of SUMO-modified 
PML (50-179) and subsequent SENP treatment, additional bands migrating slower than 
the single moieties were only detected for His6-SUMO-3, not for PML (50-179). 
Moreover, these bands were also recognized with anti-ubiquitin (green boxed bands in 
the enlarged blot pictures). Although a minor ubiquitylation of the PML moiety cannot 
be excluded due to the limits of detection, RNF4 obviously preferred to ubiquitylate the 
SUMO moiety of its substrate.  
In order to identify the lysine residues for ubiquitin attachment, ubiquitylated His6- 
SUMO-3 modified PML bands visible in a Coomassie stained SDS-PA gel were subjected 
to mass spectrometry (MS) analysis (see section 2.2.4.9, Table 3.1 and Figure 3.23). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23: Coomassie stained SDS-PA gel for MS analysis to identify the 
ubiquitin attachment sites of in vitro ubiquitylated His6-SUMO-3 
modified PML (50-179) 
His6-SUMO-3 modified PML (50-179) was subjected to in vitro 
ubiquitylation by RNF4 and subsequently separated by SDS-PAGE.  
Ubiquitylated bands visible after Coomassie-staining (indicated by arrows) 
were excised from the gel and analyzed by mass spectrometry (see Table 
3.). 
 
Table 3.1: Ubiquitin attachment sites of in vitro ubiquitylated His6-SUMO-3 modified PML (50-179)  
 SUMO-3 PML (50-179) Ubiquitin 
1 K11/K32/K41 none detected K48 
2 K11 none detected K48 
3 K11/K41 none detected none detected 
 
Summary of MS analysis; samples 1, 2, 3 correspond to the ubiquitylated bands excised from the 
Coomassie-stained gel depicted in Figure 3.23. Residues depicted in bold represent the modified lysine 
most abundantly detected. The sequence coverage of detected peptides ranged between 50-55 % for 
SUMO-3, 15 % for PML (50-179) and 97 % for ubiquitin. 
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MS analysis revealed that indeed the SUMO moiety of His6-SUMO-3 modified PML is 
ubiquitylated by RNF4 while ubiquitylation of PML (50-179) was not detectable. 
Moreover, some detected peptides corresponded to ubiquitin-ubiquitin linkages at 
lysine 48, indicating that ubiquitin chains were attached to the SUMO molecules. 
3.4.5 Sp100 - a second substrate of RNF4-dependent ubiquitylation? 
As RNF4 seems to recognize SUMOylated proteins and to ubiquitylate the SUMO moiety, 
it should display its ULS function for any multi- or polySUMOylated protein. To test this 
hypothesis, unmodified and SUMO-3 modified Sp100 (1-332) were subjected to RNF4-
dependent ubiquitylation (see Figure 3.24). SUMO-3 modification of Sp100 resulted in 
species that are most probably modified with SUMO chains as Sp100 possesses only one 
consensus SUMOylation site (compare also Figure 3.8 and Figure 3.10). 
 
 
Figure 3.24: RNF4 dependent in vitro ubiquitylation of Sp100 (1-332) compared to PML (50-179) 
Unmodified (non-conj.) and His6-SUMO-3 (SUMO-3c.) modified Sp100 (1-332) or PML (50-179) were 
subjected to in vitro ubiquitylation by RNF4 as described in Figure 3.17 B. Reactions were terminated by 
adding 2 x SDS sample buffer, proteins were separated by SDS-PAGE and detected with anti-Sp100, anti-
His5 or anti-PML (50-179). Asterisks mark cross-reactive bands of anti-PML (50-179). Poly-SUMOylated 
Sp100 species are boxed in red.  
 
Again, the ubiquitin blot was not very conclusive (data not shown) and the antibody 
recognizing Sp100 seemed to detect only unmodified and mono-SUMOylated Sp100 (left 
panel). Nonetheless, detection with the His5-antibody showed that Sp100 species 
modified with a minimum of two SUMOs seemed to vanish upon RNF4-mediated 
ubiquitylation (red box in the middle panel). However, additionally appearing bands 
could not be detected. For comparison, RNF4-dependent ubiquitylation of unmodified 
and His6-SUMO-3 modified PML (50-179) was performed in parallel (right side). 
Thus, whether SUMOylated Sp100 could be a second target for RNF4-dependent 
ubiquitylation is - due to the detection limits - not conclusively clear. 
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3.5 The RNF4 SIMs bind preferentially to SUMO chains 
In vitro ubiquitylation assays presented in the last section 3.4 show that the human 
RNF4 is a SUMO-dependent ubiquitin ligase. The next two sections are dealing with the 
binding properties of RNF4 to SUMOs.  
The purified His6-SUMO-1 and His6-SUMO-3 modified PML (50-179) species displayed a 
similar running behavior in SDS-PAGE analysis (refer to Figure 3.19 A), suggesting that 
the respective PML (50-179) species were either modified on K65, K160 or on both sites. 
Beyond that, His6-SUMO-3 chains on PML (50-179) do not seem to be present to a 
detectable extend at least when coexpressed with PIAS4 used for most assays shown 
except the one depicted in Figure 3.22. However, RNF4 still seemed to prefer His6-
SUMO-3 modified PML (50-179) for ubiquitylation (see Figure 3.19).  
The analysis of His6-SUMO-3 modified Sp100 (1-332) hints towards a chain recognizing 
mechanism by RNF4: only those species vanished that contained a minimum of two 
SUMOs in the His6-SUMO-3 chain formed on Sp100 (1-332). 
The RNF4 sequence contains up to four possible SIMs and thus it is likely that RNF4 
binding to substrates is triggered by multiple SUMOs as for example provided by a 
SUMO chain. In order to investigate RNF4 binding to SUMO chains, only the part of RNF4 
containing the SIMs (aa 1-105) was purified. Furthermore, SUMO chains were generated 
artificially. A special cloning strategy (see section 2.2.2.2) and subsequent protein 
purification resulted in linear SUMO chains lacking the first 11 amino acids (SUMO-
2ΔN11 and SUMO-3ΔN11), mimicking a natural SUMO chain (Tatham, 2008). Likewise, 
for SUMO-1, the corresponding N-terminal extension including the first 15 amino acids 
was deleted to produce artificial SUMO-1 chains when several SUMO-1ΔN15 were 
cloned linearly. 
As SUMO-2 and SUMO-3 are nearly identical and do not differ in their SIM binding 
region, binding studies to the RNF4 SIM domain were performed with SUMO-2 chains. 
First, RNF4 binding to SUMO and SUMO chains was investigated by analytical gel 
filtrations on a Superdex 75 (10/300 GL) column (see Figures 3.25 and 3.26). For that 
purpose, 50 µM RNF4 (1-105) was incubated with 200 µM mono-SUMOs, 100 µM di-
SUMOs or 50 µM tetra-SUMOs overnight. Assuming all presumed SIMs are capable of 
binding to SUMOs, these concentrations chosen should result in a 1:1 binding 
stoichiometry.  
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Figure 3.25: Gel filtration of RNF4 SIM domain and artificial SUMO-1 chain complexes  
50 µM RNF4 (1-105) has been incubated with either 200 µM monoSUMO-1 (1 x SUMO-1), 100 µM 
diSUMO-1ΔN15 (2 x SUMO-1) or 50 µM tetra-SUMO-1ΔN15 (4 x SUMO-1) o/n in GST1 buffer + 5 % 
Glycerol.  Proteins have been subjected to analytical gel filtrations performed at 0.5 ml/min in GST1 buffer 
+ 5 % Glycerol and eluted protein fractions were separated by SDS-PAGE and stained with Coomassie. 
Fractions from 9.0 to 13.2 ml are depicted here after the respective runs indicated. The incubation of 
RNF4 (1-105) with tetra-SUMO-1ΔN15 represented a special case, as protein precipitated directly while 
mixing them. Overnight incubation led to a clear solution, but high-speed centrifugation (13000 g at 4 °C) 
resulted in a small protein containing pellet (examined with addition of Bradford solution). The 
supernatant was applied to analytical gel filtration. 
 
For RNF4 (1-105) mixed with tetra-SUMO-1ΔN15, proteins precipitated upon mixing. Gel 
filtration of the remaining supernatant completely lacks RNF4 (1-105) in the respective 
elution fractions and tetra-SUMO-1ΔN15 is also reduced. It seems that under the chosen 
conditions, RNF4 (1-105) binding to artificial tetra-SUMO-1ΔN15 results rather in protein 
aggregation than in proper protein complex formation. 
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In contrast to that, binding of di-SUMO-1ΔN15 to RNF4 (1-105) could be observed since 
formed complexes were stable during gel filtration and eluted earlier than each 
component alone. The amount of di-SUMO-1 and RNF4 (1-105) in the elution fractions 
containing the complexes seemed to be the same as estimated from Coomassie staining 
which would point to a 1:1 stoichiometry. Mono-SUMO-1 did not bind efficiently to 
RNF4 (1-105) and complexes between the both could not be observed after analytical 
gel filtration. 
 
 
Figure 3.26: Gel filtration of RNF4 SIM domain and artificial SUMO-2 chain complexes  
50 µM RNF4 (1-105) has been incubated with either 200 µM single SUMO-2 (1 x SUMO-2), 100 µM di-
SUMO-2ΔN11 (2 x SUMO-2) or 50 µM tetra-SUMO-2ΔN11 (4 x SUMO-2) o/n in GST1 buffer + 5 % Glycerol.  
Proteins have been subjected to analytical gel filtrations performed at 0.5 ml/min in GST1 buffer + 5 % 
Glycerol and eluted protein fractions were separated by SDS-PAGE and stained with Coomassie. Fractions 
from 9.0 to 13.2 ml are depicted here after the respective runs indicated. 
 
In the case of RNF4 (1-105) mixed with tetra-SUMO-2ΔN11, a proper complex formation 
between the two proteins could be observed since both elute earlier after size exclusion 
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chromatography than during their respective single runs. Basically the whole amount of 
both proteins seemed to be engaged in complexes, pointing to a 1:1 stoichiometry. 
Analytical gel filtration of RNF4 (1-105) mixed with di-SUMO-2ΔN11 resulted in a similar 
elution profile as observed for RNF4 (1-105) mixed with di-SUMO-1ΔN15. A complex 
formation of mono-SUMO-2 with RNF4 (1-105) could not be observed after size 
exclusion chromatography. 
Together, these data suggested that RNF4 is capable to bind to SUMO chains containing 
at least two SUMOs. A difference between SUMO-1 and SUMO-2 during di-SUMO 
binding could not be observed. However, artificial tetra-SUMO-1 chains induced protein 
aggregation when mixed with the RNF4 SIM domain while tetra-SUMO-2 chains formed 
proper complexes with RNF4 (1-105). 
 
In order to investigate these complex formations in a more detailed fashion including 
binding constants, Isothermal Titration Calorimetry (ITC) was performed. For this 
method it is crucial to know the exact protein concentration. Since the RNF4 (1-105) 
construct does not include any aromatic residue and other methods for the 
determination of the protein concentrations yielded variable results, the protein was 
unsuitable to be investigated by this method. Therefore, a longer construct was 
generated, RNF4 (1-125), which contains a tyrosine residue and for which the protein 
concentration could be determined by measuring the absorbance at 280 nm. ITC 
experiments were carried out by injecting artificial polySUMOs as ligands into the 
experimental cell containing the RNF4 (1-125) solution (see Figures 3.27, 3.28 and 3.29). 
 
 
Figure 3.27: Interaction of 
artificial tetra-SUMO chains and 
RNF4 (1-125)  
The interaction of tetra-SUMO 
chains and the SIM containing N-
terminus of RNF4 was followed by 
isothermal titration calori-metry. 
The upper panel shows the heat of 
binding measured by stepwise 
injection of 60 µM tetra-SUMO-
1ΔN15 into 3.3 µM RNF4 (1-125) 
and of 100 µM tetra-SUMO-2ΔN11 
into 6.6 µM RNF4 (1-125) at 25 °C. 
The lower panel shows the 
integrated heating powers of the 
upper panel normalized to the 
concentrations of the artificial 
tetra-SUMOs. Fitting of a single 
binding side model yielded a KD of 
1.7 µM for tetra-SUMO2 and RNF4 
(1-125). 
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For the interaction of tetra-SUMO-2ΔN11 and RNF4 (1-125), a one site binding model 
could be fitted with a KD = 1.7 µM (see alsoTable 3.2). Due to the low available amounts 
of tetra-SUMO-1 ΔN15 to RNF4 (1-125) and several artefactual perturbations the binding 
could not be fitted. However, a trend for binding is indicative.  
 
Figure 3.28: Interaction of 
artificial di-SUMO chains and 
RNF4 (1-125)  
The interaction between di-SUMO-
1ΔN15 or di-SUMO-2ΔN11 and the 
SIM containing N-terminus of 
RNF4 (aa 1-125) was followed by 
isothermal titration calorimetry. 
The upper panel shows the heat of 
binding measured by stepwise 
injection of 300 µM di-SUMO-
1ΔN15 or di-SUMO-2ΔN11 into 
20 µM RNF4 (1-125) at 25 °C. The 
lower panel shows the integrated 
heating powers of the upper panel 
normalized to the concentrations 
of the artificial di-SUMOs. Fitting 
of a single binding side model for 
the interaction to RNF4 yielded a 
KD of 5.2 µM for di-SUMO-1 and of 
3.9 µM for di-SUMO-2. 
 
The interaction of both, di-SUMO-1ΔN15 or di-SUMO-2ΔN11 and RNF4 (1-125) were 
nearly as strong as the interaction of RNF4 (1-125) and tetra-SUMO-2ΔN11 with KD 
values of 5.2 µM or 3.9 µM, respectively.  
 
 Figure 3.29: Interaction between 
mono-SUMOs and RNF4 (1-125)  
The interaction between mono-
SUMO-1ΔN15 or mono-SUMO-
2ΔN11 and RNF4 (aa 1-125) was 
followed by isothermal titration 
calorimetry. The upper panel 
shows the heat of binding 
measured by stepwise injection of 
1.8 mM mono-SUMO-1ΔN15 or di-
SUMO-2ΔN11 into 120 µM RNF4 
(1-125) at 25 °C. The lower panel 
shows the integrated heating 
powers of the upper panel 
normalized to the concentrations 
of the artificial mono-SUMOs. 
Fitting of a single binding side 
model for the interaction to RNF4 
yielded a KD of 92 µM for mono-
SUMO-1 and of 125 µM for mono-
SUMO-2. 
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Mono-SUMOs were poor binding partners of RNF4 (1-125). When injected at a 
concentration of 300 µM into 20 µM RNF4 hardly any interaction was detectable (data 
not shown). However, when protein concentrations were increased to 1.8 mM mono-
SUMOs and 120 µM RNF4 (1-125), interaction could be detected with KD values of 92 µM 
in the case of mono-SUMO1ΔN15 and 125 µM for mono-SUMO2ΔN11.  
Table 3.2 summarizes the binding constants obtained after one site modeling of the 
fitted binding curves.  
 
Table 3.2: Binding constants of artificial (poly)SUMOs and RNF4 (1-125) SIMs 
 KD [µM] N ΔH [kcal/mol] TΔS [kcal/mol] 
mono-SUMO-1ΔN15            92  1.4 -2.3 3.2 
mono-SUMO-2ΔN11          125  1.4 -3.4 1.9 
di-SUMO-1ΔN15    5.2  1.00 -4.8 2.4 
di-SUMO-2ΔN11   3.9  1.1 -6.1 1.3 
tetra-SUMO-1ΔN15          N.D. N.D. N.D. N.D. 
tetra-SUMO-2ΔN11  1.7  0.8 -18.3 -10.4 
 
KD is the inverse of the association constant KA obtained from the binding experiments performed at 25 °C. 
N represents the calculated stoichiometry. The values for ΔH and TΔS are given for the association 
reaction.   
 
The comparison shows that the RNF4 SIM domain displayed a ~ 25 fold increase in 
binding affinity towards a di-SUMO chain and a ~ 50 to 70 fold increase towards the 
tetra-SUMO2ΔN11 compared to the binding affinities towards the mono-SUMOs.  
Furthermore, it seems that for binding of the mono-SUMOs more than one binding site 
in RNF4 (1-125) is used although a fit for more than one site was not possible.   
3.6 Mammalian SUMOs might discriminate between different 
SIM types 
The observed preference of RNF4 for His6-SUMO-3 modified PML (50-179) in in vitro 
ubiquitylation reactions may hint towards a SIM-type specific SUMO recognition 
mechanism. In contrast to this, no significant difference of the binding was observed by 
ITC measurements. The four putative SIMs in RNF4 belong to different types: SIM1 
might be a SIMr, SIM2 and 3 are type b SIMs and SIM4 is a conventional SIMa (see Figure 
3.13). In order to analyze the binding properties of different SIM types to different 
SUMO paralogs, several SIMs from different proteins were cloned as GST-fusions in their 
natural sequence environment of about 80-100 amino acids around it (see Figure 3.30). 
The RNF4 SIM domain (1-105) was used for comparison. Furthermore, the PML SIM has 
been shown to be phosphorylated at several serine residues next to the SIM core which 
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enhances SUMO binding (Stehmeier and Müller, 2009). In order to investigate the 
influence of a phosphorylated SIM in binding of SUMO paralogs, PML11 SIM mutants 
were generated which either mimic phosphorylated serines (S512-514, 517D) or in 
which the respective serines were mutated to alanines (S512-514, 517A). 
 
 
RNF4 SIM domain (1-105): 
1–MSTRKRRGGAINSRQAQKRTREATSTPEISLEAEPIELVETAGDEIVDLTCESLE 
  PVVVDLTHNDSVVIVDERRRPRRNARRLPQDHADSCVVSSDDEELSRDRD–105 
 
SIM type a: 
 
PML11 (419-522)wt: 
419-DVSNT…GEAEERVVVISSSEDSDAENS–522 
 
PML11 (419-522) S 512-514,517A: 
419-DVSNT…GEAEERVVVIAAAEDADAENS–522 
 
PML11 (419-522) S 512-514,517D: 
419-DVSNT…GEAEERVVVIDDDEDDDAENS–522 
 
Sp100 (274-332): 
274–SPEA…NQASDIIVISSEDSE–332 
 
Daxx SIM2 (625-740): 
625–SGPP…TQCDPEEIIVLSDSD–740 
 
SIM type b: 
 
PIAS3 (394-470): 
394–DEIQ…KKKVEVIDLTIESSSDEEDLPPTKKHCSV–470 
 
PIAS4 (445-510): 
445–GSTG…PGADVVDLTLDSSSSSEDEEEEEEEEEDEDEEGPR…LVPAC–510 
 
 
Figure 3.30: SIMs chosen to study type-specific binding properties to SUMO paralogs 
Shown are the SIM sequences of different proteins; GST-constructs of these SIMs used in the following 
experiment comprise the amino acids given in brackets. SIM relevant hydrophobic amino acids are 
depicted in blue, acidic amino acids in red and type b specific threonine residues in green. 
 
The resulting proteins were subjected to GSH affinity purification and were left 
associated to the GSH beads to perform interaction studies with purified SUMO-1, 
SUMO-2 and SUMO-3 (see Figure 3.31).  
SUMO-1 interacted with all tested SIM constructs. In the case of the PML SIM, the 
phosphomimic PML11 (419-522) S512-514,517 D construct displayed indeed a 
stronger binding to SUMO-1 compared to its non-phosphorylated wt or phosphorylation 
defective S512-514,517 A mutant form. 
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SUMO-2 and SUMO-3 only bound to the RNF4 (1-105) SIM domain, PIAS3 (394-470) and 
PIAS4 (445-510). In the experiment shown, binding of PIAS4 to SUMO-3 was not 
detectable, probably due to the low amount of SUMO-3 input. In other experiments, it 
bound equally well to SUMO-3 as to SUMO-2 (data not shown). Intriguingly, all three 
SIM constructs binding to SUMO-2 and SUMO-3 contain a type b SIM, in the case of 
RNF4 even two.  
  
 
Figure 3.31: SUMO binding to different SIM types 
Purified SUMO-1, SUMO-2 and SUMO-3 have been subjected to a pulldown (PD) assay with the GST-SIM 
constructs introduced in Figure 3.30 as bait. Purified ubiquitin served as negative control. Proteins were 
eluted in 2 x SDS sample buffer, separated by SDS-PAGE and detected by SUMO-1, SUMO-2/3 or ubiquitin 
antibodies, respectively. Input of GST-SIM constructs are displayed as Coomassie staining after SDS-PAGE. 
 
Thus it seems that the binding properties of SIM type a are restricted to SUMO-1 
whereas SIM type b is able to bind to SUMO-1 and to SUMO-2/3. In other words, SUMO-
2 and SUMO-3 discriminate between type a and type b SIMs. 
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Whether type b SIMs have a higher affinity to SUMO-2/3 than to SUMO-1 - which would 
explain the preference of RNF4 for SUMO-3 conjugated PML (50-179) - could not be 
detected with this type of interaction study.  
Therefore, Surface Plasmon Resonance (SPR) was performed to measure the 
interactions between PIAS3 (394-470) or RNF4 (1-105) SIMs and either SUMO-1 or 
SUMO-2 (the analysis focused on PIAS3 and RNF4 as they displayed the strongest 
binding to SUMO-2 and SUMO-3; see Figure 3.32).  
 
  
 
Figure 3.32: Surface plasmon resonance curves for the interaction of SUMOs to PIAS3 and RNF4 SIMs 
SPR was performed at 25 °C on a Biacore T100. SUMO-1, SUMO-2 and ubiquitin (as a negative control) 
were coupled to a CM5 surface of a SPR biosensor chip (Biacore) and subsequently probed for the binding 
of ~ 25 µM PIAS3 (394-470) or RNF4 (1-105). RU, response units. 
 
Though overall binding was weak, in both cases, binding to SUMO-2 was indeed stronger 
than binding to SUMO-1, suggesting that type b SIMs have a higher affinity for SUMO-
2/3 (SUMO-3 does not differ from SUMO-2 in respect to the SIM binding sites). For 
PIAS3 (394-470), binding to SUMO-1 was not detectable with this method above the 
level of binding to the negative control ubiquitin. RNF4 (1-105) displayed binding to 
both, SUMO-1 and SUMO-2 while binding to SUMO-2 was approximately twice as strong 
as binding to SUMO-1 with respect to the relative response units remaining during the 
dissociation period.  
3.7 Possible RNF4 substrates upon diverse cellular stresses 
In the preceding sections of this work, it could be conclusively shown that RNF4 is a 
human ubiquitin ligase for SUMOylated PML in vitro and that RNF4 binds preferentially 
to SUMO-2/3 chains. Overall cellular SUMO-2/3 conjugation is upregulated upon diverse 
cellular stress stimuli like proteasomal inhibition, ATO treatment, unfolded protein 
stress or (slightly) upon osmotic stress (Saitoh and Hinchey, 2000; Weisshaar, 2008; 
Meyer-Teschendorf, 2010). Therefore, ULS substrates other than PML might also be 
regulated by RNF4 (or similar, yet to be identified ULS proteins) after these types of 
stress. These possible substrates should be either multi- or polySUMOylated upon the 
respective stress stimuli and further stabilized upon proteasomal inhibition. 
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As the RNF4 N-terminus comprises up to four SIMs, isolation of specifically multi- or 
polySUMOylated proteins from stress induced cells should be possible by making use of 
the GST-RNF4 (1-105) SIM domain construct. This construct should bind RNF4 substrates 
due to its SIMs but is not an active ubiquitin ligase as the RING domain is deleted. 
Recently, tandem-repeated ubiquitin-binding entities (TUBEs) that are based on the 
linear tandem-repeated fusion of several ubiquitin-associated (UBA) domains could be 
shown to recognize tetra-ubiquitin with a markedly higher affinity than single UBA 
domains (Hjerpe, 2009). This allowed poly-ubiquitylated proteins to be efficiently 
purified from cell extracts in native conditions. In order to identify further possible ULS 
substrates, an analogous method was established using the GST-RNF4 (1-105) SIM 
domain construct bound to GSH-beads as a bait to isolate multi- or polySUMOylated 
proteins binding to it (see section 2.2.4.13).  
First, the method was tested for isolation of SUMOylated proteins with cell extracts from 
MG132-treated Hs27 primary human fibroblast cells (see Figure 3.33). 
 
Figure 3.33: Isolation of multi-/ 
polySUMOylated proteins from 
MG132-treated cells  
Hs27 cells were treated or not 
with 20 µM MG132 for 6 h and 
lysed in RIPA buffer. SUMO-
conjugated proteins were 
isolated using purified GST-RNF4 
(1-105) bound to GSH beads as a 
bait. Purified GST served as 
negative control. Bound proteins 
were eluted by adding 2 x SDS 
sample buffer, separated by SDS-
PAGE and detected with anti-
SUMO-2/3 or anti-PML (A301-
167A, -168A), respectively (PD, 
pull down assay). 
 
 
GST-RNF4 (1-105) could indeed be utilized to efficiently isolate SUMOylated proteins 
from the extracts of MG132-treated Hs27 cells, among them the already identified ULS 
substrate PML.   
In order to identify further possible ULS substrates, this method was applied to isolate 
SUMOylated proteins after a range of cellular stresses, namely after proteasomal 
inhibition with MG132, ATO treatment, osmotic stress induced by the addition of 
sorbitol or after unfolded protein stress induced by the addition of the arginine analogue 
canavanine (see Figure 3.34). The samples were subjected to SDS-PAGE and several gel 
slices with a defined molecular weight range were excised to perform subsequent MS 
analysis (see section 2.2.4.13).  
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Figure 3.34: Isolation of multi-/polySUMOylated proteins from cells treated with different stress stimuli 
Hs27 cells were either treated with DMSO (-) or 20 µM MG132 (+) for 6 h, with 3 µM ATO -/+ 20 µM 
MG132 for 6 h, with 1 M sorbitol -/+ 20 µM MG132 for 4 h or with 7.5 mM canavanine (Canavan.)                
-/+ 20 µM MG132 for 6 h (input at the left shows the respective cell lysates after SDS-PAGE and detection 
with anti-SUMO-2/3). Isolation of proteins binding to GST or GST-RNF4 (1-105) was performed as 
described in section 2.2.4.13. The majority of these isolated proteins was subjected to SDS-PAGE with 
subsequent Coomassie-staining and MS analysis (see Table 3.3 and Appendix Tables A.2-A.8). A small 
fraction of the isolated proteins was subjected to SDS-PAGE and detected with anti-SUMO-2/3 (right). 
 
The resulting proteins were assessed for the presence of bona-fide SUMOylation sites 
using the SUMOplot SUMO site prediction program (accessible via the ExPASy proteomic 
tools server, http://www.expasy.ch/tools/) in order to increase the probability that the 
resulting proteins are regulated by the ULS pathway. Proteins that possess high 
probability SUMOylation sites are listed in black, those with low probability motifs in 
grey. Internal positive controls represented peptides found for PML, SUMO-2, SUMO-3 
and ubiquitin. A complete list of proteins interacting with GST-RNF4 (1-105) is provided 
in Appendix tables A.2 – A.8.  
The table below (Table 3.3) comprises a selection of interacting proteins that might be 
regulated by SUMO-dependent ubiquitylation. The proteins listed are either found in a 
higher molecular weight (MW) range as their individual calculated MW and/or show 
stabilization upon proteasomal inhibition. As the isolation of proteins from ATO- or 
sorbitol-treated cells was not very successful (see Figure 3.34), individual protein hit 
results from these isolations must be regarded as preliminary results.  
MS analysis indicated that many signaling molecules are interacting with the RNF4 N-
terminus.. For instance, IKK-1 and Nmi are found in all stressed samples and for some, a 
stabilization upon treatment with MG132 can be observed.  Further, many other kinases 
and transcription factors could be isolated by GST-RNF4 (1-105). 
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Table 3.3: Selection of RNF4 (1-105) interacting proteins after diverse cellular stress stimuli 
Possible RNF4 substrates after MG132 stress Peptides Accession Mw [kDa] Mw range [kDa] 
5'-AMP-activated protein kinase subunit gamma-2  2 Q9UGJ0 63.0         170 - stack 
Caspase-8 precursor (CASP-8) 2 Q14790 55.4 170 - stack 
Centrosomal protein of 131 kDa (Cep131) 19 Q9UPN4 122.0 > 170 incl. 
stack 
E3 SUMO-protein ligase PIAS2  3 O75928 68.2 90 - 120 
F-box only protein 11 (Vitiligo-associated protein VIT-1) 2 Q86XK2 103.5 170 - stack 
I kappa-B kinase alpha (IKK-alpha; IKK1) 7 O15111 84.6 stack 
N-myc-interactor (Nmi) (N-myc and STAT interactor) 13 Q13287 35.0 > 170 incl. 
stack 
Promyelocytic leukemia protein PML (TRIM 19)  12 P29590 97.5 > 170 incl. 
stack 
Serine/threonine-protein kinase 36  5 Q9NRP7 143.9 stack 
Serine/threonine-protein kinase SRPK2  3 P78362 77.5 90 - 120 
Serine/threonine-protein phosphatase PP1-alpha 
catalytic subunit (PP-1A) 
2 P62136 37.5 stack 
Transcriptional-regulating factor 1 (TReP-132) 5 Q96PN7 132.2 > 170 incl. 
stack 
Possible RNF4 substrates after ATO stress Peptides Accession Mw [kDa] Mw range [kDa] 
5'-AMP-activated protein kinase subunit gamma-2  4 Q9UGJ0 63.0 90 - 120 
Chromobox protein homolog 8 (Polycomb 3 homolog)  10 Q9HC52 43.4 120 - 170 
I kappa-B kinase alpha (IKK-alpha; IKK1) 12 O15111 84.6 70 - stack 
Mitogen-activated protein kinase kinase kinase 6  2 O95382 112.4 stack 
Myristoylated alanine-rich C-kinase substrate (MARCKS) 2 P29966 31.5 70 - 90 
N-myc-interactor (Nmi) (N-myc and STAT interactor)  5 Q13287 35.0 > 70 incl. 
stack 
Serine/threonine-protein kinase PLK2  8 Q9NYY3 78.2 stack 
Wiskott-Aldrich syndrome protein family member 1  4 Q92558 61.6 90 - 120 
Zinc finger and BTB domain-containing protein 43  11 O43298 52.6 90 - 170 
Possible RNF4 substrates after ATO/MG132 stress Peptides Accession Mw [kDa] Mw range [kDa] 
5'-AMP-activated protein kinase subunit gamma-2  8 Q9UGJ0 63.0 > 170 incl. 
stack 
Centrosomal protein of 131 kDa (Cep131) 3 Q9UPN4 122.0 stack 
COUP transcription factor 1 (COUP-TF1)  2 P10589 46.1 70 - 90 
I kappa-B kinase alpha (IKK-alpha; IKK1) 11 O15111 84.6 90 - stack 
N-myc-interactor (Nmi) (N-myc and STAT interactor)  2 Q13287 35.0 120 - 170 
Serine/threonine-protein kinase PLK2  4 Q9NYY3 78.2 120 - 170 
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Possible RNF4 substrates after sorbitol stress Peptides Accession Mw [kDa] Mw range [kDa] 
150 kDa oxygen-regulated protein precursor (Orp150) 
(Hypoxia up-regulated 1)  
8 Q9Y4L1 111.3 170 - stack 
5'-AMP-activated protein kinase subunit gamma-2  25 Q9UGJ0 63.0 50 - 90 
Centrosomal protein of 131 kDa (Cep131 protein)  10 Q9UPN4 122.0 > 50 incl. 
stack 
E3 SUMO-protein ligase PIAS2 2 O75928 68.2 120 - 170 
Forkhead box protein D1 (Forkhead-related 
transcription factor 4) (FREAC-4)  
4 P55854 11.6 stack 
I kappa-B kinase alpha (IKK-alpha; IKK1) 39 O15111 84.6 > 50 incl. 
stack 
Mitogen-activated protein kinase kinase kinase 8  2 P41279 52.9 170 - stack 
N-myc-interactor (Nmi) (N-myc and STAT interactor)  8 Q13287 35.0 90 - stack 
Serine/threonine-protein kinase PLK2  12 Q9NYY3 78.2 90 - 120 
Transcription intermediary factor 1-alpha (TIF1-alpha) 
(TRIM 24)  
2 O15164 116.8 170 - stack 
Possible RNF4 substrates after sorbitol/MG132 stress Peptides Accession Mw [kDa] Mw range [kDa] 
5'-AMP-activated protein kinase subunit gamma-2  32 Q9UGJ0 63.0 > 50 incl. 
stack 
Centrosomal protein of 152 kDa (Cep152 protein)  4 O94986 147.3 170 - stack 
Homeobox prospero-like protein PROX1 (PROX 1)  16 Q92786 83.2 > 90 incl. 
stack 
I kappa-B kinase alpha (IKK-alpha; IKK1) 18 Q92786 83.2 > 90 incl. 
stack 
N-myc-interactor (Nmi) (N-myc and STAT interactor)  13 Q13287 35.0 > 170 incl. 
stack 
Retinoic acid receptor alpha (RAR-alpha)  2 P10276 50.7 70 - 90 
Serine/threonine-protein phosphatase PP1-alpha 
catalytic subunit (PP-1A)  
2 P62136 37.5 stack 
Transcription factor HES-5  3 Q5TA89 18.2 170 - stack 
Possible RNF4 substrates after canavanine stress Peptides Accession Mw [kDa] Mw range [kDa] 
150 kDa oxygen-regulated protein precursor (Orp150) 
(Hypoxia up-regulated 1)  
9 Q9Y4L1 111.3 170 - stack 
5'-AMP-activated protein kinase subunit gamma-2  16 Q9UGJ0 63.0 90 -120 
Centromere protein H (CENP-H)  2 Q9H3R5 28.5 120 - 170  
Creatine kinase M-type  2 P06732 43.1 170 - stack 
DNA topoisomerase 2-beta  4 Q02880 183.2 stack 
E3 SUMO-protein ligase PIAS2  10 O75928 68.2 > 170 incl. 
stack 
ELAV-like protein 3 (Hu-antigen C)  9 Q14576 39.5 stack 
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Possible RNF4 substrates after canavanine stress Peptides Accession Mw [kDa] Mw range [kDa] 
Homeobox prospero-like protein PROX1 (PROX 1)  5 Q92786 83.2 > 70 incl. 
stack 
I kappa-B kinase alpha (IKK-alpha; IKK1) 27 O15111 84.6 > 170 incl. 
stack 
Kelch repeat and BTB domain-containing protein 10  10 O60662 68.0 90 - 170 
Myristoylated alanine-rich C-kinase substrate (MARCKS) 4 P29966 31.5 70 - 90 
Serine/threonine-protein kinase 36  3 Q9NRP7 143.9 170 - stack 
Serine/threonine-protein kinase PLK2 4 Q9NYY3 78.2 70 - 90 
Serine/threonine-protein kinase SRPK2  2 P78362 77.5 90 - 120 
Serine/threonine-protein phosphatase PP1-alpha 
catalytic subunit (PP-1A)  
13 P62136 37.5  50 - 70             
and stack  
Signal transducer and activator of transcription 2 
(p113) (STAT2) 
2 P52630 97.9 120 - 170 
Transcriptional-regulating factor 1 (TReP-132) 3 Q96PN7 132.2 stack 
WD repeat protein 13 (WDR13) 4 Q9H1Z4 53.7 stack 
Possible RNF4 substrates after Canavan./MG132 stress Peptides Accession Mw [kDa] Mw range [kDa] 
5'-AMP-activated protein kinase subunit gamma-2  16 Q9UGJ0 63.0 > 120 incl. 
stack  
Centrosomal protein of 131 kDa (Cep131 protein)  5 Q9UPN4 122.0 120 - 170 
DNA topoisomerase 2-beta  3 Q02880 183.2 stack 
Dual specificity protein phosphatase 16 (DUS16)  
(MAP kinase phosphatase 7) (MKP-7)  
2 Q9BY84 73.1 170 - stack 
GABA(A) receptor-associated protein (GABARAP) 7 O95166 13.9 70 - 90 
Homeobox prospero-like protein PROX1 (PROX 1) 12 Q92786 83.2 > 70 incl. 
stack 
I kappa-B kinase alpha (IKK-alpha; IKK1) 50 O15111 84.6 > 50 incl. 
stack 
Kelch repeat and BTB domain-containing protein 10  22 O60662 68.0 120 - stack 
Mitogen-activated protein kinase 14 (MAP kinase p38)  3 Q16539 41.3 170 - stack 
N-myc-interactor (Nmi) (N-myc and STAT interactor)  5 Q13287 35.0 170 - stack 
Probable transcription factor PML (TRIM 19)  4 P29590 97.5 170 - stack 
Serine/threonine-protein kinase 36  5 Q9NRP7 143.9 170 - stack 
Serine/threonine-protein kinase PLK2  7 Q9NYY3 78.2 > 120 incl. 
stack 
Serine/threonine-protein kinase TAO3  3 Q9H2K8 105.3 120 - 170 
Serine/threonine-protein phosphatase PP1-alpha 
catalytic subunit (PP-1A)  
18 P62136 37.5 > 50 incl. 
stack 
WD repeat protein 13 (WDR13) 8 Q9H1Z4 53.7 > 70 incl. 
stack 
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4. DISCUSSION 
 
This work aimed to identify a human ubiquitin ligase targeting SUMO conjugates (ULS) 
for degradation. In order to demonstrate that possible candidates are ULS proteins, an in 
vitro ubiquitylation assay for SUMO conjugates has been developed. For that purpose, 
SUMOylated proteins were generated and purified as in vitro substrates from E. coli. 
While establishing an efficient method for modifying proteins with SUMO in E. coli and 
their purification, an intrinsic SUMO E3 activity was observed for PML (discussed in 
section 4.1). 
SUMOylated PML was efficiently in vitro ubiquitylated by RNF4, a human RING finger 
protein which complements yeast ULS deletion phenotypes (discussed in section 4.3). 
Binding of RNF4 to its substrate and substrate ubiquitylation was strictly SUMO 
dependent such that RNF4 was indeed identified as a human ULS protein. Investigation 
of the SUMO binding properties of RNF4s SIM domain revealed that the interaction was 
specifically enhanced by the presence of SUMO chains of more than two SUMOs. 
Further, a SIM type specific binding mode was noticed for different SUMO paralogs 
(discussed in section 4.2). Finally, in an attempt to find other ULS regulated cellular 
proteins, an RNF4 SIM domain construct was used to isolate poly- or multi-SUMOylated 
proteins from cells subjected to diverse cell stresses (see outlook section 4.3.4).  
4.1 PML might act as a SUMO-E3 ligase 
PML is mainly known to promote PML nuclear body formation (Shen, 2006). However, 
besides this important function, a role for PML as SUMO E3 ligase was speculated due to 
a observed stimulation of SUMOylation in yeast. This activity was first detected while co-
transformed with SUMO-1 and depended on an intact PML RING domain as the C72A 
mutant failed to self-SUMOylate efficiently (Quimby, 2006). Additionally, endogenous 
SUMOylation of Smt3 was also stimulated by PML transformation (Quimby, 2006; 
Weisshaar, 2008).  
While testing several SUMO E3 ligases for efficient PML (50-179) SUMOylation in the 
E. coli SUMOylation system established during this work, it became apparent that PML 
(50-179) modification with SUMO-3 is most efficient without the coexpression of an 
additional SUMO E3 ligase (see Figure 3.11). Contrary, SUMO-1 modification was most 
efficient during coexpression of PIAS4. The simplest explanation for SUMOylation in 
absence of an additional E3 ligase would be that Ubc9 can directly bind to the 
SUMOylation consensus motifs in its substrate proteins (Sampson, 2001; Bernier-
Villamor, 2002). However, another possibility could be that Ubc9~SUMO is recruited to 
the PML RING by forming an E2-E3 complex, thereby leading to SUMOylation of PML 
(50-179). An additionally expressed SUMO E3 ligase would then compete for 
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Ubc9~SUMO binding leading to a decrease of PML (50-179) SUMOylation. As this was 
observed in the case of SUMO-3 modification, PML may act as a SUMO E3 ligase, 
probably with a preference for SUMO-2/3. 
This finding confirms the observations made in yeast (Quimby, 2006; Weisshaar, 2008) 
and is further supported by a study which showed that Ubc9 indeed interacts with the 
RING domain of PML (Duprez, 1999). This interaction depends on the structural integrity 
of the PML RING but not on an intact K65 SUMOylation site. In line with this study, an 
overall reduction of SUMOylation in E. coli of the single PML (50-179) lysine mutants 
K65R and K160R was not observed, suggesting that the intrinsic SUMO E3 ligase activity 
is neither dependent on single consensus motifs nor influenced by SUMO modification 
of the RING or the B1 domain in this short construct. However, in full length PML-L, 
these two sites have been shown to influence the SUMO conjugation of each other 
(Lallemand-Breitenbach, 2008). These contradicting results may reflect a regulatory 
mechanism which is either mediated by additional proteins in cells or by inter-
/intramolecular interactions of full length PML. An accelerated self-SUMOylation via a 
SIM-mediated SUMOylation in cis (Lin, 2006; Knipscheer, 2008; Meulmeester, 2008; Cho, 
2009) can be excluded as well in the case of the construct PML (50-179) which does not 
contain a SIM. 
Other TRIM proteins have been already shown to display E3 ligase activity, in most cases 
mediating ubiquitylation. For instance, TRIM5α monoubiquitylates itself (Yamauchi, 
2008), TRIM11 is implicated in the turnover of the neuroprotective Humanin (Niikura, 
2003), TRIM18/MID1 targets the phosphatase 2A for degradation (Trockenbacher, 2001) 
and TRIM25/Efp has a dual role as ubiquitin and ISG15 ligase (Urano, 2002) (Zou and 
Zhang, 2006). For TRIM23/ARD1, in vitro polyubiquitylation has been shown (Vichi, 
2005) and TRIM24/TIF1α has been shown to ubiquitylate p53 (Allton, 2009).  
In the case of PML, a ubiquitin ligase activity has not been published yet and could 
neither be observed in the in vitro ULS candidate activity test (see Figure 3.14). 
Therefore, the observed stimulation of SUMOylation by PML in yeast and E. coli seems 
to be a specific process and not a matter of forced RING/E2 interactions. 
Whether PML might exert SUMO E3 activity towards other proteins has to be further 
analyzed either in vitro or by using the E. coli SUMOylation system, which lacks other 
SUMO E3 ligases compared to the alternative systems of human cell cultures or trans-
vivo systems in yeast. As negative control, a mutant defective in Ubc9 binding could be 
used analogous to the RING mutants already investigated to abolish E2 binding in the 
ubiquitin system (for instance the W408 or I383 mutants of c-Cbl; Joazeiro, 1999; Zheng, 
2000). 
As this work concentrated on the identification of human ULS proteins and the 
reconstitution of ULS activity in vitro, a final conclusion concerning the SUMO E3 ligase 
activity of PML as well as putative substrates remain to be elusive. 
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Of note, while performing the last corrections of this thesis, another group reported that 
the PML RING interacts to Ubc9 and that this interaction is enhanced by the 
replacement of the zinc atoms within the PML RING and B2 zinc fingers with arsenic 
after treatment with ATO. This replacement triggered a conformational change of the 
PML RBCC motif which enhanced PML oligomerization (Zhang, 2010). A modeled 
structure of the PML RING-Ubc9 binding interface is depicted in Figure 4.1. An increased 
Ubc9 binding to PML triggered by direct binding of arsenic to the PML RING also solves 
the mechanism by which ATO leads to enhanced SUMOylation of PML thereby inducing 
the SUMO-dependent ubiquitylation of PML mediated by RNF4. 
 
 
 
 
 
 
Figure 4.1: Predicted structural model of the Ubc9/PML 
RING complex 
Computational simulation of a Ubc9/PML RING binding 
mode on the basis of the UbcH7/c-Cbl structure (PDB ID: 
1FBV). UBC9 is shown in cyan; the PML RING is displayed 
as a blue cartoon structure. The two zinc ions in the PML 
RING are indicated by two red balls. The cysteines and 
histidine coordinated with zinc ions are shown as 
colored sticks. The model was taken from (Zhang, 2010). 
 
4.2 Specificities in SUMO/SIM interactions 
In section 3.6, several SIMs of different proteins have been analyzed for their ability to 
interact with different SUMO paralogs in comparison to the RNF4 SIM domain construct 
(1-105). Under the chosen conditions in an in vitro binding assay, all tested SIMs (type a 
or type b) were found to bind to SUMO-1 while only proteins containing type b SIMs also 
bound to SUMO-2 and SUMO-3 (see Figure 3.31). This suggests that SUMO-2 and SUMO-
3 are able to discriminate between different SIM types with a strong preference for 
type b SIMs. Although this preliminary conclusion needs a more detailed investigation, 
several hints in the literature support this notion. Most type a SIMs investigated so far 
for direct interactions with SUMO were only analyzed for SUMO-1 binding, including the 
SIMs of PML and Daxx (Lin, 2006; Shen, 2006). In contrast, type b SIMs have been shown 
to directly interact with SUMO-1 as well as with SUMO-2/3, including SIMs of the PIAS 
proteins, MCAF1 and Usp25 (Song, 2004; Song, 2005; Meulmeester, 2008; Sekiyama, 
2008).  
NMR spectroscopy or X-ray crystallography structural studies are only available for the 
type b SIMs of PIAS2 bound to SUMO-1 and MCAF1 bound to SUMO-2 (see Figure 4.2) as 
well as for a type r SIM of RanBP2 bound to SUMO-1 (Song, 2005; Reverter and Lima, 
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2005; Sekiyama, 2008). These structures show that the type r SIM is indeed binding 
SUMO in a reversed orientation compared to the type b SIMs. The closely related type b 
SIMs of PIAS2 and MCAF1 display similar binding interfaces while interacting to SUMO-1 
and SUMO-2, respectively. The highly conserved aspartate residue at position three of 
the SIM type b core contacts a lysine residue conserved in all human SUMO paralogs. 
This lysine residue (K32 in SUMO-3) is one of the in vitro ubiquitylation targets of RNF4 
identified which emphasizes the idea that only the terminal SUMO moiety in the 
targeted SUMO chain is modified with ubiquitin as the K32 residues of other SUMO 
moieties might be masked by the SIMs of RNF4.  
 
 
Figure 4.2: Molecular interfaces between type b SIMs and different SUMO paralogs 
Molecular interfaces between the type b SIM of MCAF1 (magenta) and SUMO-2 (cyan) (PDB ID: 2RPQ) as 
well as between the type b SIM of PIAS2 (orange) and SUMO-1 (green) (PDB ID: 2ASQ). Amino acid 
residues that are involved in the interactions are shown in stick representation. The images were taken 
from (Sekiyama, 2008).  
 
In an attempt to assess the binding properties towards different SUMO paralogs of the 
RNF4 (1-105) SIM domain construct in comparison to the type b SIM of PIAS3, a slight 
binding preference for SUMO-2 was observed in both cases (see Figure 3.32). This is 
supported by several studies in which type b SIMs seem to prefer binding to SUMO-2/3 
over SUMO-1 (Song, 2004; Meulmeester, 2008; Sekiyama, 2008). 
A SUMO E3 ligase encoded by Kaposi’s sarcoma associated herpesvirus (KSHV), K-bZIP, 
harbors a type b SIM that seems to only recognize SUMO-2/3 and not SUMO-1 (Chang, 
2010). This SIM displays the archetypical V-I-D-L-T sequence of most type b SIMs. The 
only obvious difference to other SUMO-1 binding SIMs is the lack of the acidic stretch 
behind the core motif. However, deletion of this stretch in Usp25 lowered the affinity to 
SUMOs, especially to SUMO-1, dramatically but binding was still detectable 
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(Meulmeester, 2008). Previously, it has already been suggested that the acidic stretch in 
human SIMs supports mainly SUMO-1 binding, while SUMO-2/3 binds both to SIMs with 
and without acidic regions (Hecker, 2006). This was based on the unusual type b SIM of 
TTRAP (I-V-D-V-W) that lacks an acidic stretch and the deletion mutants of acidic 
stretches of type a and b SIMs. This study is also the only one that detected a direct 
interaction of a type a SIM with SUMO-2 and SUMO-3 in an in vitro binding assay which 
is contrasting the results shown in Figure 3.31. However, this paradigm might be due to 
different experimental setups and in order to elucidate this question, more 
investigations concerning this matter are needed. Direct binding measurements by ITC 
might help to dissect different binding affinities for different SIM/SUMO combinations. 
Nonetheless, these biochemical studies need to be analyzed also in terms of functional 
consequences of these findings. One such example is the SUMOylation of Usp25 which 
depended on its type b SIM. This in cis E3-like SUMOylation results in SUMO-2 specific 
modification of Usp25 and in the inactivation of its hydrolase activity towards tetra-
ubiquitin chains (Meulmeester, 2008). However, whether the paralog-specific 
attachment of SUMO-2 was important for that inactivation or only SUMO modification 
per se was not assessed. Further, investigation of SIM/SUMO paralog specificity in living 
cells might reveal tightly regulated processes similar to the differential signaling 
potential of ubiquitin chains. 
 
4.3 RNF4 is a ubiquitin ligase for SUMO conjugates 
The data presented in sections 3.4 to 3.6 demonstrate that RNF4 is a human SUMO-
dependent ubiquitin ligase involved in the control of PML stability, suggesting that the 
ULS pathway is conserved to humans. While this work was in progress, two other studies 
have confirmed these results in vitro and in cells (Lallemand-Breitenbach, 2008; Tatham, 
2008).  
4.3.1 PML-NBs - a place for SUMO-dependent degradation in mammalian 
cells 
Several studies pointed to the conservation of the ULS pathway in humans (Kosoy, 2007; 
Prudden, 2007; Sun, 2007; Uzunova, 2007; Weißhaar, 2008). This pathway includes an 
upregulation of SUMO conjugation upon diverse stress stimuli and seems to implicate 
SUMO chain formation (Saitoh and Hinchey, 2000; Zhou, 2004). Proteasomal inhibition 
in HeLa cells stabilized specifically SUMO-2/3 conjugates (Uzunova, 2007). 
To investigate the human ULS pathway, HeLa cells transfected with myc-tagged SUMOs 
or their non-conjugatable ΔGG mutants have been treated with the proteasomal 
inhibitor MG132. Conjugates of all three SUMO paralogs accumulated at PML nuclear 
bodies (see section 3.1). Proteasome inhibition was already shown to induce the 
accumulation of SUMO-1 conjugates at PML-NBs (Bailey and O'Hare, 2005) and 
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downregulation of SENP6, the SUMO protease recognizing SUMO-2/3 chains, resulted in 
increased PML-NB size and number (Mukhopadhyay, 2006) which suggests that also 
SUMO-2/3 conjugates and therefore putative ULS substrates accumulate at PML nuclear 
bodies. Together with the fact that PML was probably regulated via the ULS pathway 
upon arsenic trioxide treatment (Lallemand-Breitenbach, 2001; Weißhaar, 2008), it was 
tempting to speculate that PML nuclear bodies might be a place for SUMO-dependent 
degradation in human cells.  
Several PML nuclear body proteins could be identified as putative ULS proteins, among 
them RNF4 (see section 3.3.2) that could be verified as ULS (as discussed in the following 
sections). Further transient transfection studies in human cells could indeed show that 
ATO and RNF4 act synergistically in PML nuclear body dispersal, accompanied by a 
proteasomal degradation of SUMOylated PML species (Lallemand-Breitenbach, 2008; 
Weisshaar, 2008). Conversely, RNAi-mediated depletion of RNF4 abolished ATO induced 
turnover of PML and the dispersal of PML nuclear bodies (Lallemand-Breitenbach, 2008; 
Tatham, 2008). This SUMOylation-dependent turnover is also induced upon ATO 
treatment of APL cells which targets the oncogenic PML-RARα fusion protein for 
degradation and drives the leukemic cells to differentiation (Lallemand-Breitenbach, 
2001; Lallemand-Breitenbach, 2008). However, ATO induced not only the recruitment of 
RNF4 but also of endogenous SUMOs, ubiquitin, the 20S core particle of the 26S 
proteasome as well as Sp100 and Daxx to PML nuclear bodies (Lallemand-Breitenbach, 
2008). Recruitment of ubiquitin and proteasomal subunits has been observed previously 
during several cellular stimuli, including proteasome inhibition and IFN-γ stimulation 
(Fabunmi, 2001; Bailey and O'Hare, 2005).  
Apart from ATO-induced degradation of PML, RNF4 seems to be generally involved in 
the overall stability of PML-NBs as they increase in size and number during RNAi-
mediated RNF4 depletion (Lallemand-Breitenbach, 2008; Tatham, 2008).  
Altogether, this indicates that the SUMO-dependent degradation pathway represents a 
specialized form of post-translational modification that is mediated at PML nuclear 
bodies.  
4.3.2 RNF4 ubiquitylates specifically SUMOylated PML species 
The ULS in vitro assays established in this work (see sections 3.4 to 3.6) clearly 
demonstrate that RNF4 is a specialized ubiquitin ligase that recognizes and modifies 
SUMOylated PML while unmodified PML is not ubiquitylated. The use of the purified in 
E. coli SUMOylated substrates and an efficient ubiquitylation reaction allowed the 
detection of the ubiquitylated species directly by western blotting (see for example 
Figures 3.19 and 3.20).  
In contrast, the ubiquitylation of in vitro SUMO modified PML used in another study 
could only be detected as a smear after γ-counting of I125-ubiquitin (Tatham, 2008). This 
study also demonstrates that RNF4 ubiquitylates only SUMO-modified PML and thus is a 
human ULS. In vitro, a preference of RNF4 for recognizing a site-specific SUMOylation on 
DISCUSSION 
98 
 
PML could not be detected (compare ubiquitylation of PML mutants in Figure 3.21). The 
PML (50-179) K65R and K160R mutants are both ubiquitylated efficiently with a slight 
preference for the SUMOylation on K65 in the K160R mutant. Conversely, studies with 
full length PML-L in human cells showed that SUMOylation at K160 is important for ATO-
induced degradation and suggested that RNF4 is recruited site-specifically to K160-
SUMOylated PML (Lallemand-Breitenbach, 2001; Lallemand-Breitenbach, 2008). The 
latter study also dissected that mutation of K160 completely blocked SUMOylation of 
K65 and that mutation of K65 impairs SUMOylation of K160, pointing to a regulated 
interdependence of these SUMOylation sites in full-lentgh PML isoforms. The authors 
suggested that SUMOylation of K65 recruits Ubc9~SUMO thioesters in order to promote 
SUMO chain formation on K160 on the basis of the previously described mechanism 
(Tatham, 2003; Knipscheer, 2007). Thus, an impaired SUMO chain formation on K160 as 
well as the block of K65 SUMOylation could both result in the loss of RNF4 recruitment 
to PML and therefore to the observed resistance to ATO-induced PML degradation. The 
use of the efficiently SUMOylated PML (50-179) K65R and K160R mutants generated in 
E. coli already demonstrated that at least in vitro, RNF4 is recruited to either 
SUMOylated site of PML. Which of the discussed scenarios is indeed predominant in vivo 
remains to be discovered. 
SENP1/6 treatment showed that RNF4 preferentially ubiquitylated the SUMO moieties 
of SUMOylated PML (50-179) (see Figure 3.22). Lysines 11, 32 and 41 of the SUMO-3 
moiety were identified as attachment sites by mass spectrometry (see Table 3.1) while 
ubiquitylation of the PML (50-179) moiety was not detected. In vitro chain formation 
involving K42 in SUMO-2 or K41 in SUMO-3 has been observed previously to a minor 
extend but whether these lysines are used in vivo remains to be elusive (Jeram, 2010). 
MS analysis performed from in vitro SUMOylated and ubiquitylated PML 560 confirmed 
that the SUMO moiety is indeed ubiquitylated predominantly at these three lysines 
(Tatham, 2008). Ubiquitylation of lysines in a defined region of PML (predominantly 
lysines 380, 400, 401 and 476) have been detected as well. These lysine residues are not 
present in the short PML (50-179) construct applied in the in vitro assays performed in 
this work and at least lysine 401 could also be identified as ubiquitin acceptor site after 
isolation of cells treated with ATO (Lallemand-Breitenbach, 2008). Taken together, these 
data rather point to a mixed ubiquitylation of both the SUMO and the PML moiety of the 
substrate, as long as RNF4 is in proximity of appropriate lysine residues. Yet, there is no 
need of acceptor lysines for ubiquitin attachment in the modified substrate proteins as 
demonstrated by the ubiquitylation of SUMO modified PML (50-179).  
A study in S. cerevisiae showed that the ULS heterodimer Slx5-Slx8 seems to 
predominantly ubiquitylate the N-terminus of the last Smt3 molecule in a SUMO chain 
while neither the other Smt3 molecules nor the tested in vitro substrate were 
significantly ubiquitylated (Mullen and Brill, 2008). Whether this is also the case for 
RNF4-mediated ubiquitylation remains to be elucidated. The closely located ubiquitin 
attachment sites K11, K15 and K19 are also the three acceptor lysines for 
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polySUMOylation in yeast. Attachment of ubiquitin to one of these residues might not 
only result in proteasomal degradation of the substrate but also in a termination of 
further SUMO chain formation due to sterical inhibition of the other attachment sites. 
In contrast to Smt3, the detected ubiquitin acceptor lysines in SUMO-3 are more 
widespread over the sequence (K11, K32 and K41). Still, at least K32 and K41 are in close 
proximity to each other in the native SUMO-3 molecule (or the corresponding residues 
K33 and K42 in the SUMO-2 molecule) and both are part either of the β-sheet or the α-
helix that are involved in SIM binding (see Figure 4.2; Hecker, 2006). Assuming that RNF4 
binding masks K32 and K41 of chain-linked SUMOs and that K11 is used as SUMO 
attachment site within the chains, it is tempting to speculate that RNF4 indeed 
ubiquitylates the last SUMO moiety (see also section 4.2). 
In the model presented in Figure 4.3, the RNF4-mediated ubiquitylation of SUMOylated 
PML is depicted schematically. For simplification, only the variant is depicted in which 
the ubiquitin chain is assembled on top of the SUMO chain.  
 
Figure 4.3: Model of RNF4-mediated ubiquitylation of SUMOylated PML 
PML can be SUMOylated at three lysine residues, K65, K160 and K442/490 (left side). SUMOylation is a 
prerequisite for PML nuclear body formation (not depicted). Upon ATO treatment, RNF4-dependent PML 
turnover is accelerated due to an enhanced SUMO chain formation on PML, most probably at K160. RNF4 
harbors three to four active SIMs which bind to the SUMO chain. The RING domain of RNF4 recruits the 
Ubiquitin E2 (UbE2) bound to an activated ubiquitin. Ubiquitin is then transferred to the K11 side chain of 
the terminal SUMO-2/3 moiety in the SUMO chain. Repeated cycles of ubiquitin attachment forms a K48-
linked chain which serves as recognition signal for the proteasome and leads to the degradation of PML. 
 
The ubiquitin chain targets the SUMO-ubiquitin-substrate hybrid conjugates to the 
proteasome. The mechanism of how these conjugates are unfolded at the proteasome 
and whether SUMO is recycled like ubiquitin by proteasome-associated SENPs or else 
degraded along with the substrate protein remains to be investigated. If it would be 
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degraded along with its substrate the proteasome had to be capable to cleave branched 
proteins which has not been shown yet. 
4.3.3 RNF4 recruitment involves defined SUMO binding properties 
The recruitment of RNF4 to SUMOylated proteins like PML is directed via the SIM 
domain of RNF4, the stretch of up to four SUMO interaction motifs in its N-terminus 
(refer to Figure 3.13 for protein sequence).  
This was demonstrated by a range of experiments in this work as well as in the study of 
(Tatham, 2008). The most intriguing feature was the preference of RNF4 for SUMO 
chains: Both, gel filtration experiments with the N-terminal RNF4 SIM domain (shown in 
section 3.5) as well as binding assays with full length RNF4 performed by (Tatham, 2008) 
revealed that binding to chain-linked SUMOs is much stronger than binding to mono-
SUMOs. While (Tatham, 2008) observed a preference of RNF4 for SUMO chains formed 
of at least three SUMOs, stable binding during gel filtration was already observed with 
di-SUMO chains. In order to elucidate the binding affinities of RNF4 for SUMO chains of 
different lengths, isothermal titration calorimetry has been performed. By applying this 
method, it could be strikingly shown that the biggest difference in binding affinity is 
achieved upon SUMO chain formation per se: The binding affinities of the RNF4 N-
terminus (aa 1-125) to di-SUMOs are ~ 25-fold higher than those of RNF4 (1-125) to 
mono-SUMOs (compare Figures 3.28, 3.29 and see Table 3.2). A further extension of the 
SUMO chain from di- to tetra-SUMOs had no significant effect on the affinity (see 
Figures 3.27, 3.28 and Table 3.2). Moreover, the stoichiometry obtained for mono-
SUMO binding indicates that there may be more than one SUMO binding site in the 
RNF4 SIM domain (see Table 3.2). 
This binding mechanism resembles however the binding properties of some UBDs 
recognizing two ubiquitin molecules of a chain: Ubiquitin chain recognition is either 
conferred by the relative placement of two or more UBDs to each other and to the 
respective ubiquitin chain or by recognizing linkage-specific residues directly (like UBAN 
and NZF domains; (Raasi, 2005; Varadan, 2005; Husnjak, 2008; Schreiner, 2008; 
Komander, 2009c).  
A similar conformational binding mode could be envisioned for RNF4 and its binding to 
SUMO chains: Obviously, as much as two SUMO molecules are sufficient to promote 
efficient binding of RNF4 SIMs. It might also be that the linkage to the lysine side chain is 
recognized by a sterical or another, yet unidentified mechanism. This is indicated by the 
striking difference in ubiquitylation efficiency of proper SUMOylated PML (50-179) and 
the artificial fusion construct of GST-SUMOs. Even the mono-SUMOylated species of 
PML are efficiently ubiquitylated while ubiquitylation of the GST-SUMO fusion is only 
mediated under unspecific low salt conditions (compare Figures 3.18 and 3.19). 
However, the artificial SUMO chains are also N-terminally linked to each other such that 
this theoretical excursion awaits a structural analysis of RNF4 bound to a SUMO chain 
for clarification. 
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Another aspect is the apparently regular arrangement of the SIMs in RNF4: They are 
arranged regularly within a stretch of 40 amino acids, each spaced by six, seven and four 
amino acids (see Figure 3.13), respectively. This arrangement seems to be perfect to 
bind to a tetrameric SUMO chain. Analysis of different single SIM mutants revealed 
however, that the two inner SIMs of this stretch, both of type b, are the most important 
ones for binding to tetra-SUMO-3 (Tatham, 2008). Mutation of the first SIM in the 
stretch (type r SIM) showed no effect on RNF4 binding properties while that of the 
fourth SIM had only minor effects (type a SIM). The mutation of the second RNF4 SIM 
displays the strongest effects on RNF4 binding properties (Tatham, 2008). This is 
somewhat puzzling when assumed that the two outermost SIMs are functional and 
could still bind to for instance the first and the last SUMO of a tetrameric chain. 
Moreover, because binding of two SUMOs seems to be sufficient for RNF4 recruitment 
(as discussed above), this mutant analysis also points to a mechanism where only the 
inner SIMs confer binding to SUMO chains and – at the same time – raises the possibility 
of a linkage-specific recognition.  
On the other hand, the ITC measurements have been performed with the N-terminal 
half of RNF4 lacking the RING domain. Taking into account that RING domains usually 
form dimers or even oligomers, it is also a (if not the most) plausible explanation that 
RNF4 dimers would display an increased binding affinity to polymeric SUMO chains of 
more than two SUMOs. This scenario is similar to the binding of K48-linked tetra-
ubiquitylated proteins to the UBDs of the 19S subunits Rpn10/S5a and Rpn13, both 
recognizing di-ubiquitin (Deveraux, 1994; Groll, 1997; Lam, 2002; Husnjak, 2008; 
Schreiner, 2008). 
Such a coordinated binding mechanism might also explain the observations made in 
binding assays with full length RNF4 where only chains with a minimum of three SUMOs 
bound to RNF4 (Tatham, 2008). In order to address this question in more detail, this 
issue could be further investigated by ITC using full length RNF4 and the respective 
artificial polySUMOs.  
ITC experiments also did not show huge differences in RNF4 (1-125) binding affinities 
regarding the SUMO paralogs investigated. An exception was the addition of tetra-
SUMO-1ΔN15 which gave an odd binding behavior. Also, when mixing artificial tetra-
SUMO-1ΔN15 chains with the shorter RNF4 N-terminal construct (1-105), the proteins 
aggregated and precipitated. Further, the in vitro ubiquitylation with full length RNF4 
showed that also SUMO-1 modified PML (50-179) is recognized and ubiquitylated by 
RNF4. This indicates that at least in vitro, also mono-SUMOylation and multi-
SUMOylation serves as a signal for RNF4 recruitment and subsequent ubiquitylation of 
SUMOylated PML species. It should be noted, however, that due to the dimerization of 
PML, the substrate of the in vitro reaction displays a multi-SUMOylation. 
Nonetheless, RNF4 seems to preferentially ubiquitylate His6-SUMO-3 modified PML (50-
179) over His6-SUMO-1 modified PML (50-179). This can only be explained by an overall 
intrinsic binding preference of RNF4 for SUMO-3 over SUMO-1, even in absence of a 
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SUMO chain. However, ITC experiments as well as other binding assays did not show any 
significant binding preference of the RNF4 SIM domain to one or the other SUMO 
paralog (see Table 3.2 and Figure 3.31). The only hint that RNF4 might prefer binding to 
SUMO-2/3 over SUMO-1 is given by Surface Plasmon Resonance: binding to SUMO-2 
was two-fold stronger than binding to SUMO-1 (see Figure 3.31). A SUMO paralog-
dependent SIM type preference might also play a role in the binding process (as 
discussed in section 4.2). 
4.3.4 Outlook: Are ULS proteins master regulators of stress signaling? 
Stress induction seems to be a key trigger for upregulated SUMO-2/3 modification and 
subsequent ubiquitylation in mammalian cells which can be observed after many 
stresses including heat, oxidative or osmotic stress, an induced unfolded protein 
response and treatment of cells with ethanol or ATO (Saitoh and Hinchey, 2000; 
Weisshaar, 2008; Meyer-Teschendorf, 2010).  
In order to identify further proteins that are regulated via the ULS pathway, the binding 
properties of the RNF4 (1-105) SIM domain construct were used to isolate poly- (or 
multi-) SUMOylated proteins from cells after various stresses (see section 3.7). This 
method was at least partially successful, because peptides for PML, SUMO-2/3 and 
ubiquitin have been identified in isolated samples from MG132 treated cells and cells 
treated with a combination of canavanine and MG132 (see Appendix tables A.2 to A.8). 
Peptides of these proteins served as internal positive controls because PML is a known 
target of the ULS pathway and SUMO-2/3 and ubiquitin are prerequisites of it. 
Moreover, specifically SUMO-2/3 modified proteins could be detected after isolation 
with GST-RNF4 (1-105) (see Figures 3.33 and 3.34). In that respect, the RNF4 (1-105) 
construct could indeed be utilized for specifically isolating poly- or (multi-) SUMOylated 
proteins analogous to the TUBEs isolating ubiquitin chains (Hjerpe, 2009). TUBEs protect 
poly-ubiquitin-conjugated proteins both from proteasomal degradation and de-
ubiquitylating activity in cell extracts (Hjerpe, 2009). Whether this kind of protection is 
also mediated by the RNF4 SIM domain construct is suggestive but remains to be shown.  
Strikingly, many proteins involved in signaling were interacting with the RNF4 N-
terminus. Some of them were found after each of the applied cellular stresses. For 
instance, IKK-1, part of the IκB kinase complex involved in the NFκB pathway (Solt and 
May, 2008), and the N-myc and STAT interactor Nmi, a scaffolding protein important for 
signal transduction of myc and STAT pathways (Shuai, 2000), were found in all stressed 
samples. In some samples, stabilization upon treatment with MG132 could be observed. 
Both molecules are usually localizing to the cytoplasm and if they are indeed ULS 
targets, they might rather be regulated by a ULS protein that resides in the cytoplasm. 
Alternatively, the stressed-induced (yet to be verified) SUMOylation of these proteins 
could induce their shuttling into the nucleus where they might be targets of RNF4-
dependent ubiquitylation. To underline the latter hypothesis, a recent report showed 
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that IKKε shuttles into the nucleus upon genotoxic stress and localizes to PML-NBs 
where it is SUMOylated and phosphorylates target proteins (Renner, 2010).  
Further, many other kinases and transcription factors could be isolated by GST-RNF4 (1-
105), indicating that ULS proteins might be involved in many cellular pathways.  
However, these results are only a first hint towards the identification of other ULS 
substrates. Data have to be validated by assessing the SUMO-dependent ubiquitylation 
of the individual proteins isolated, applying cellular and biochemical techniques. 
It could well be that proteins upregulated by diverse stresses are not regulated by RNF4 
but regulate RNF4: especially the high occurrence of isolated kinases might also reflect a 
phosphorylation induced regulation of RNF4 activity rather than a ULS regulation of 
kinases. Also, the isolation of the SUMO E3 ligase PIAS2 might reflect an indirect 
interaction that is mediated by a SUMO chain to which both, RNF4 (1-105) and PIAS2 
bind to with their individual SIMs.  
Still, some transcription factors were isolated, some of which showed a differential 
isolation pattern depending on the stress applied: Homeobox prospero-like protein 
PROX1, a negative transcriptional regulator involved in the control of energy 
homeostasis (Charest-Marcotte, 2010), has been predominantly found in samples of 
canavanine and canavanine/MG132 treated cells. This emphasizes the idea that upon 
different stress inductions, different signaling pathways and target genes are regulated 
via the ULS pathway, rendering ULS proteins like RNF4 as master regulators of stress 
signaling in human cells. That this might indeed be the case show examples of the 
transcription factors c-myb and BMAL1: C-myb has been shown to be extensively 
modified with SUMO-2/3 after heat stress (Sramko, 2006) but a connection to the ULS 
pathway remains to be shown. Yet, the circadian activated heterodimeric transcription 
factor BMAL1/CLOCK is a first example where the simultaneous modification of SUMO-
2/3 and ubiquitin has been related to a function: BMAL1 (in humans ‘aryl hydrocarbon 
receptor nuclear translocator-like protein 1’ - ARNTL1) is subject to rhythmic conjugation 
with poly-SUMO-2/3, peaking at times of maximum circadian mediated transcription. 
Interestingly, SUMO-2/3 modification of BMAL1 is accompanied by a translocation of 
BMAL1 to PML-NBs while it simultaneously promotes BMAL1 transactivation and 
ubiquitin-dependent degradation (Lee, 2008). Thus, BMAL1 seems to be tightly 
regulated in its activation, probably ensuring a defined circadian transcription profile. 
This renders BMAL1 as another putative ULS substrate though a direct link to a ULS 
protein, for instance RNF4, has not been shown yet. 
A true second RNF4 substrate has been reported recently. The inner kinetochore 
complex protein CENP-I has been found to be regulated by RNF4 in SENP6-depleted cells 
in order to promote proper assembly of the mitotic spindle and the metaphase plate 
(Mukhopadhyay, 2010). A binding partner of CENP-I, CENP-H could be identified by MS 
analysis as a RNF4 (1-105) interactor in canavanine treated cells (see Table 3.3). 
Other SUMOylated proteins like Sp100 are probably not targets of RNF4, at least during 
the stress conditions applied. Sp100 was not identified in any sample isolated with GST-
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RNF4 (1-105). Moreover, SUMOylated Sp100 seemed to be a poor in vitro substrate for 
RNF4 in comparison to PML (see section 3.4.5). 
 
Interestingly, a second human protein, the Von Hippel-Lindau factor (VHL) was shown to 
display ULS activity, in this case towards the α subunit of the hypoxia inducible 
transcription factor (HIF1α) (Cheng, 2007). VHL is part of a ubiquitin ligase complex that 
is responsible for the specific ubiquitylation of prolyl-hydroxylated HIF1α under 
physiological oxygen levels. However, in SENP1-depleted mouse embryonic fibroblasts, 
VHL seem to target SUMOylated HIF1α for ubiquitylation and subsequent degradation. 
This finding is contrasting other reports that observed a SUMO-dependent stabilization 
of HIF1α (Bae, 2004; Carbia-Nagashima, 2007; Berta, 2007; Cai, 2010). These obviously 
contradicting observations might be solved by assuming a similar regulatory mechanism 
underlying the regulation of BMAL1, namely a consecutive cycle of SUMOylation and 
deSUMOylation and/or ubiquitylation in order to promote and deactivate a certain 
cellular trigger or stress signal, in this case during oxygen shortage. 
 
In yeast, ULS proteins have been implicated in DNA damage control and chromosome 
maintenance, although the respective targets are still missing (Uzunova, 2007; Xie, 2007; 
Mullen and Brill, 2008; Wang and Prelich, 2009). The first in vivo target identified for the 
yeast ULS Slx5-Slx8 was Mot1, a transcriptional regulator (Wang and Prelich, 2009). This 
study also suggested a role for ULS proteins in the quality control system as an increased 
degradation of a Mot1 mutant protein as well as of wt Mot1 after canavanine treatment 
was observed. This parallels the finding in mammalian cells, where canavanine is a 
potent inducer of SUMO-2/3 conjugation (Meyer-Teschendorf, 2010). Furthermore, 
there are hints that also mating type switch is regulated by Slx5-Sxl8, targeting the 
alpha-1 transcriptional activator for degradation (Nixon, 2010). 
 
Taken together, ULS proteins seem to be involved in many cellular processes, ensuring 
the fine-tuned balance of SUMOylated proteins. Upon stress induction, the balance 
between SUMOylation and deSUMOylation is obviously shifted towards SUMOylation. 
ULS proteins target hyperSUMOylated proteins for degradation, indicating that it is 
important for the cell to eliminate these proteins rapidly. This might be explained by the 
assumption that SUMO chains are toxic by-products for the cell (Geoffroy and Hay, 
2009). However, the fact that SUMO chains are assembled in vivo points towards a 
functional requirement for them and the example of BMAL1 illustrated that this is 
indeed the case. 
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APPENDIX 
 
Oligonucleotides 
 
PCR and mutation primer used to generate expression constructs  
(numbers are according to the Oligonucleotide database of AG Praefcke): 
 
17:  
0017 - mUbc9-3'-XhoI 
PCR Primer for XhoI-site insertion in MCS 2 of pRSF 
CCGCTCGAGTTATGAGGGGGCAAACTTCTTCGCTTG 
 
49:  
0049 - hSP100 5' (aa 1) BamHI 
PCR primer for insertion into pETDuet-GST-Tev and pGex-4T 
CGGGATCCATGGCAGGTGGGGGCGGCGAC 
 
55:  
0055 - hSP100 5' (aa 274) BamHI 
PCR primer for insertion into pETDuet-GST-Tev and pGex-4T 
CGGGATCCCCAGAGGCAGAGCTACACAACCATGG 
 
61:  
0061 - hSP100 3' (aa 332) STOP EcoRI 
PCR primer for insertion into pETDuet-GST-Tev and pGex-4T 
GGAATTCATTCAGAGTCCTCACTGCTGATGACTATTATG 
 
62:  
0062 - hSP100 3' (aa 480) STOP EcoRI 
PCR primer for insertion into pETDuet-GST-Tev and pGex-4T- end of ORF 
GGAATTCTAATCTTCTTTACCTGACCCTCTTCTTAGGG 
 
65:  
0065 - hPML11 5' (aa 1) BamHI 
PCR primer for insertion into pETDuet-GST-Tev and pGex-4T 
CGGGATCCATGGAGCCTGCACCCGCC 
 
66:  
0066 - hPML11 5' (aa 50) BamHI 
PCR primer for insertion into pETDuet-GST-Tev and pGex-4T 
CGGGATCCGAGGAGTTCCAGTTTCTGCGCTGCC 
 
79:  
0079 - hPML11 5' K65R 
Mutation primer for aa change Sumoylation site Lysine 65 to Arginine 
CAGGCGGAAGCCAGGTGCCCGAAGCTG 
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80:  
0080 - hPML11 3' K65R 
Mutation primer for aa change Sumoylation site Lysine 65 to Arginine reverse 
CAGCTTCGGGCACCTGGCTTCCGCCTG 
 
81:  
0081 - hPML11 5' K160R 
Mutation primer for aa change Sumoylation site Lysine 160 to Arginine 
CAGTGGTTCCTCAGGCACGAGGCCCGG 
 
82:  
0082 - hPML11 3' K160R 
Mutation primer for aa change Sumoylation site Lysine 160 to Arginine reverse 
CCGGGCCTCGTGCCTGAGGAACCACTG 
 
97:  
0097 - hSAE2 5' (aa 4) Bgl II 
PCR primer for insertion into pETDuet-GST-Tev and pGex-4T 
GAAGATCTGTCGCGGGGGCTGCCCCGGG 
 
98:  
0098 - hSAE2 3' (aa 641) XhoI 
PCR primer for insertion into pETDuet-GST-Tev and pGex-4T 
CCGCTCGAGGCGGCCGCTCAATCTAATGCTATGAC 
 
99:  
0099 - hSAE1 5' (aa 1) BamHI 
PCR primer for insertion into pETDuet-GST-Tev and pGex-4T 
CGGGATCCATGGTGGAGAAGGAGGAGGCTGGCGG 
 
117:  
0117 - hPML11 5' (aa 419) BamHI 
PCR primer for insertion into pETDuet-GST-Tev and pGex-4T  
(+ additional GS from BamHI) 
CGGGATCCGATGTCTCCAATACAACGACAGCCCAGAAGAGG 
 
118:  
0118 - hPML11 3' (aa 503) STOP EcoRI 
PCR primer for insertion into pETDuet-GST-Tev and pGex-4T 
GGAATTCACTCCCCGGCGCCACTGGCCACGTGG 
 
119:  
0119 - hPML11 3' (aa 522) STOP EcoRI 
PCR primer for insertion into pETDuet-GST-Tev and pGex-4T 
GGAATTCACGAGTTTTCGGCATCTGAGTCTTCCGAGCTG 
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131:  
0131 - hPIAS4 5' (aa1) -NdeI 
NdeI primer for insertion into pETDUET-TEV-N v B 2.MCS (E3 enzyme) 
GGAATTCCATATGGCGGCGGAGCTGGTGG 
 
132:  
0132 - hPIAS4 3' (aa 510) STOP-BglII 
STOP-BglII 3 ' primer for insertion into pETDUET-TEV-N v B 2.MCS (E3 enzyme) 
GAAGATCTCAGCAGGCCGGCACCAGG 
 
137:  
0137 - hTIF1-1 5' (aa 1) NcoI 
PCR primer for insertion into pETDuet-GST-TevN and pGex-4TN  
(ATG from Nco-site, 2. codon starts with G!!) 
CATGCCATGGAGGTGGCGGTGGAGAAGGC 
 
138:  
0138 - hTIF1-1 3' (aa 1050) STOP NotI 
PCR primer for insertion into pETDuet-GST-Tev and pGex-4T 
ATAGTTTAGCGGCCGCTATTTAAGCAACTGGCGTTCTTCAATGCTTTTGAGGCG 
 
220:  
0220 - hDaxx 3' (aa 740) EcoRI 
PCR primer for insertion into pETDuet-GST-Tev and pGex-4T 
GGAATTCTAATCAGAGTCTGAGAGCACG 
 
222:  
0222 - hDaxx 5' (aa 625) BamHI 
PCR primer for insertion into pETDuet-GST-Tev and pGex-4T 
CGGGATCCTCTGGTCCCCCCTGCAAAAAATCTCG 
 
234:  
0234 - hPIAS4 5' (aa1) -NcoI 
NcoI primer for insertion into pGEX TN 
CATGCCATGGCGGCGGAGCTGGTGG 
 
255:  
0255 - hPIAS4 3' (aa 510) STOP-BamHI 
STOP-BamHI 3 ' primer for insertion into pETDUET-TEV-N v B 2.MCS (E3 enzyme) 
CGGGATCCTCAGCAGGCCGGCACCAGGC 
 
343:  
0343 - pGEX-TN-hSENP1 5' cat domain 
5' - Mutation primer for generation of SENP1's catalytical domain only (deletion of N-
terminus, aa1-414) 
GGCGGATCCGAATTCATGGATAGTGAAGATGAATTTCCTG 
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344:  
0344 - pGEX-TN-hSENP1 3' cat domain 
3' - Mutation primer for generation of SENP1's catalytical domain only  
(deletion of N-terminus, aa1-414) 
CAGGAAATTCATCTTCACTATCCATGAATTCGGATCCGCC 
 
417:  
0417 - 3´SENP6 PCR primer (aa1112) 
3' SENP6 PCR primer (aa1112) 
CCGCTCGAGTCAATCTGAGATACTATTGACAC 
 
419:  
0419 - 5´SENP6-dN (SUSP1-Cat, aa625-1112) 
5' SENP6-dN (aa625-1112) PCR primer (bp1900) 
CGGGATCCATGAGAAGCAAACAAGAATTTCAG 
 
431:  
0431 - 5´ZNF198 PCR primer BamHI 
PCR primer with BamHI-cut 
CGGGATCCATGGACACAAGTTCAGTGGGAGGA 
 
432:  
0432 - 3´ZNF198 PCR primer NotI 
PCR primer with NotI-cut 
ATAGTTTAGCGGCCGCTTAGTCTGTGTCTTCATCC 
 
447:  
0447 - 5´RNF4 BamHI 
PCR Primer for insertion into pETDuet-GST-Tev and pGEX (!without methionine!) 
CGGGATCCACAAGAAAGCGTCGTGGTGGAGC 
 
448:  
0448 - 3´RNF4 EcoRI 
PCR Primer for insertion into pETDuet-GST-Tev and pGEX  
TCGAATTCATATATAAATGGGGTGGTACCG 
 
471:  
0471 - 5´Ubiquitin EcoRI 
CCTGGTATACGCTAACAGGTCAAAGAATTCATGCAGATCTTCG 
 
472:  
0472 - 3´Ubiquitin XhoI 
CCGCTCGAGTCAACCACCTCTCAGACGCAGGACCAGG 
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614:  
0614 - 3' PML-RB1 with STOP (aa 179) 
EcoRI-PCR-Primer for insertion in pET-Duet und pGEX 
GGAATTCAGTCCAGGAACTCACGCACCGACTGGTTGCGC 
 
620:  
0620 - 3'-RNF4 (1-105)  
3' EcoRI-Primer for cloning of RNF4 aa1-105 
GGAATTCAGTCCCTGTCCCTGGACAACTCCTCATCGTC 
 
622:  
0622 - 5' - PIAS4 SIM BamHI-Primer  
for cloning of PIAS4 aa 445 - 510 
CGGGATCCACGGGTGGCGGCGGCC 
 
623:  
0623 - 3' - PIAS4 SIM EcoRI-Primer  
for cloning of PIAS4 aa 445 - 510 
GGAATTCAGCAGGCCGGCACCAGGCC 
 
624:  
0624 - 3' - PIAS3 SIM EcoRI-Primer  
for cloning of PIAS3 aa 394 - 470 
GGAATTCAAGGTAGGGCCGGGATGGCAGC 
 
625:  
0625 - 5' - SUMO2-dN11 BamHI-Primer 
for cloning of polySUMO2 
CGGGATCCACTGAGAACAACGATCATATTAATTTGAAGGTGGCG 
 
626:  
0626 - 3' - SUMO2-dN11 Bgl II-Primer 
for cloning of polySUMO2 
GAAGATCTACCTCCCGTCTGCTGTTGGAACACATC 
 
627:  
0627 - 5' - SUMO3-dN11 BamHI-Primer 
for cloning of polySUMO3 
CGGGATCCACAGAGAATGACCACATCAACCTGAAGGTGG 
 
628:  
0628 - 3' - SUMO3-dN11 Bgl II-Primer 
for cloning of polySUMO3 
GAAGATCTACCTCCCGTCTGCTGCTGGAACACG 
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629:  
0629 - 5' - SUMO1-dN15 BamHI-Primer 
for cloning of polySUMO1 
CGGGATCCAAGAAGGAAGGTGAATATATTAAACTCAAAGTCATTGGAC 
 
630:  
0630 - 3' - SUMO1-dN15 Bgl II-Primer 
for cloning of polySUMO1 
GAAGATCTACCCCCCGTTTGTTCCTGATAAACTTCAATCACATC 
 
635:  
0635 - 5' mutagenesis S517A in PML 
Mutagenesis primer for S517A  
GATCAGCAGCTCGGAAGACGCAGATGCCGAAAACTCG 
 
636:  
0636 - 3' mutagenesis S517A in PML 
Mutagenesis primer for S517A  
CGAGTTTTCGGCATCTGCGTCTTCCGAGCTGCTGATC 
 
734:  
734 - 5'- PML 11 SSS 512-514 DDD  
Mutagenesis primer for SSS 512-514 DDD SIM mutation 
GGAACGCGTTGTGGTGATCGACGACGATGAAGACTCAGATGCCG 
 
735:  
735 - 3'- PML 11 SSS 512-514 DDD  
Mutagenesis primer for SSS 512-514 DDD SIM mutation 
CGGCATCTGAGTCTTCATCGTCGTCGATCACCACAACGCGTTCC 
 
736:  
736 - 5'- PML 11 S 517 D 
Mutagenesis primer for S 517 D SIM mutation  
GGTGATCGACGACGATGAAGACGATGATGCCGAAAACTCGTG 
 
737:  
737 - 3'- PML 11 S 517 D 
Mutagenesis primer for S 517 D SIM mutation  
CACGAGTTTTCGGCATCATCGTCTTCATCGTCGTCGATCACC 
 
738:  
738 - 5'- PML 11 SSS 512-514 AAA 
Mutagenesis primer for SSS 512-514 AAA SIM mutation into PML S517A 
GGAACGCGTTGTGGTGATCGCCGCCGCGGAAGACGCAGATGCCG 
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739:  
739 - 3'- PML 11 SSS 512-514 AAA 
Mutagenesis primer for SSS 512-514 AAA SIM mutation into PML S517A 
CGGCATCTGCGTCTTCCGCGGCGGCGATCACCACAACGCGTTCC 
 
782: 
782-3'- EcoRI-Primer for cloning of RNF4 aa1-125 
GGAATTCACCTGAGGCCTGTAGCGCCC 
 
 
 
ZNF198 zinc fingers (present in one ‘domain’ from aa 330-795) 
 
KVTCANCKKPLQKGQTAYQRKGSAHLF--CSTTCLSSFSHKPA----PKKLCVMCKKDITTMKGTIVAQVDSSESFQEFCSTSCLSL 
KSRCTICGKLTEIRHEVSFKNMTHKL---CSDHCFNRYRMANG---LIMNCCEQCGEYLPS-KGAGNNVLVIDGQQKRFCCQSCVSE 
LTTCTGCRTQCRFFDMTQCIGPNGYMEPYCSTACMNSHKTKYAKSQSLGIICHFCKRNSLP----QYQATMPDGKLYNFCNSSCVAK 
QLKCNYCKNSFCSKPEILEWENKVHQF--CSKTCSDDYKKLHC----IVTYCEYCQEEKT-----LHETVNFSGVKRPFCSEGCKLL 
GLRCVTCNYCSQLCKKGATKELDGVVRDFCSEDCCKKFQDWYY----KAARCDCCKSQGT-----LKERVQWRGEMKHFCDQHCLLR 
 
Figure A.1: Zinc finger alignment of ZNF198  
Zinc chelating residues in the RING domains are depicted in gold. 
 
In the follwoing Tables A.2-A.8, the results of mass spectrometry results are summarized 
after isolation of cellular proteins binding to GST-RNF4 (1-105). Protein hits with more 
than two peptides found/protein and an ion score of > 20 have been assessed for 
possible SUMOylation sites by using a prediction program. Proteins with high probability 
motifs are listed in black, proteins with a low probability of being SUMOylated are listed 
in grey. 
 
 112 
 
Ta
bl
e 
A
.1
: U
bi
qu
it
in
-li
ke
 m
od
ifi
ca
tio
n 
sy
st
em
s 
 
 113 
 
Ta
bl
e 
A
.2
: S
um
m
ar
y 
of
 m
as
s 
sp
ec
tr
om
et
ry
 a
na
ly
si
s 
of
 is
ol
at
ed
 p
ro
te
in
s 
in
te
ra
ct
in
g 
w
ith
 G
ST
-R
N
F4
 (1
-1
05
) f
ro
m
 M
G
13
2 
tr
ea
te
d 
ce
lls
 
 114 
 
 115 
 
Ta
bl
e 
A
.3
: S
um
m
ar
y 
of
 m
as
s 
sp
ec
tr
om
et
ry
 a
na
ly
si
s 
of
 is
ol
at
ed
 p
ro
te
in
s 
in
te
ra
ct
in
g 
w
ith
 G
ST
-R
N
F4
 (1
-1
05
) f
ro
m
 A
TO
 tr
ea
te
d 
ce
lls
 
 116 
 
 117 
 
Ta
bl
e 
A
.4
: S
um
m
ar
y 
of
 m
as
s 
sp
ec
tr
om
et
ry
 a
na
ly
si
s 
of
 is
ol
at
ed
 p
ro
te
in
s 
in
te
ra
ct
in
g 
w
ith
 G
ST
-R
N
F4
 (1
-1
05
) f
ro
m
 A
TO
 a
nd
 M
G
13
2 
tr
ea
te
d 
ce
lls
 
 118 
 
 119 
 
Ta
bl
e 
A
.5
: S
um
m
ar
y 
of
 m
as
s 
sp
ec
tr
om
et
ry
 a
na
ly
si
s 
of
 is
ol
at
ed
 p
ro
te
in
s 
in
te
ra
ct
in
g 
w
ith
 G
ST
-R
N
F4
 (1
-1
05
) f
ro
m
 S
or
bi
to
l t
re
at
ed
 c
el
ls
 
 120 
 
 121 
 
 122 
 
Ta
bl
e 
A
.6
: S
um
m
ar
y 
of
 m
as
s 
sp
ec
tr
om
et
ry
 a
na
ly
si
s 
of
 is
ol
at
ed
 p
ro
te
in
s 
in
te
ra
ct
in
g 
w
ith
 G
ST
-R
N
F4
 (1
-1
05
) f
ro
m
 S
or
bi
to
l a
nd
 M
G
13
2 
tr
ea
te
d 
ce
lls
 
tr
ea
tm
en
t 
 123 
 
 124 
 
 125 
 
Ta
bl
e 
A
.7
: S
um
m
ar
y 
of
 m
as
s 
sp
ec
tr
om
et
ry
 a
na
ly
si
s 
of
 is
ol
at
ed
 p
ro
te
in
s 
in
te
ra
ct
in
g 
w
ith
 G
ST
-R
N
F4
 (1
-1
05
) f
ro
m
 c
an
av
an
in
e 
tr
ea
te
d 
ce
lls
 
 126 
 
 127 
 
 128 
 
 129 
 
Ta
bl
e 
A
.8
: S
um
m
ar
y 
of
 m
as
s 
sp
ec
tr
om
et
ry
 a
na
ly
si
s 
of
 is
ol
at
ed
 p
ro
te
in
s 
in
te
ra
ct
in
g 
w
ith
 G
ST
-R
N
F4
 (1
-1
05
) f
ro
m
 c
an
va
ni
ne
 a
nd
 M
G
13
2 
tr
ea
te
d 
ce
lls
  
 130 
 
 131 
 
 132 
 
 133 
 
REFERENCES 
 
 
Acconcia, F., Sigismund, S. & Polo, S. (2009) Ubiquitin in trafficking: the network at work. Exp Cell Res, 315, 
1610-8. 
Alcalay, M., Zangrilli, D., Pandolfi, P. P., Longo, L., Mencarelli, A., Giacomucci, A., Rocchi, M., Biondi, A., 
Rambaldi, A., Lo Coco, F. & et al. (1991) Translocation breakpoint of acute promyelocytic 
leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci U S A, 88, 1977-81. 
Alkuraya, F. S., Saadi, I., Lund, J. J., Turbe-Doan, A., Morton, C. C. & Maas, R. L. (2006) SUMO1 
haploinsufficiency leads to cleft lip and palate. Science, 313, 1751. 
Allton, K., Jain, A. K., Herz, H. M., Tsai, W. W., Jung, S. Y., Qin, J., Bergmann, A., Johnson, R. L. & Barton, M. 
C. (2009) Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci U S A, 106, 11612-6. 
Aravind, L. & Koonin, E. V. (2000) The U box is a modified RING finger - a common domain in 
ubiquitination. Curr Biol, 10, R132-4. 
Arnason, T. & Ellison, M. J. (1994) Stress resistance in Saccharomyces cerevisiae is strongly correlated with 
assembly of a novel type of multiubiquitin chain. Mol Cell Biol, 14, 7876-83. 
Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A. & Struhl, K. (2010) 
Current Protocols in Molecular Biology. pp. ~ 5300. John Wiley & Sons, Somerset, NJ, USA. 
Azfer, A., Niu, J., Rogers, L. M., Adamski, F. M. & Kolattukudy, P. E. (2006) Activation of endoplasmic 
reticulum stress response during the development of ischemic heart disease. Am J Physiol Heart 
Circ Physiol, 291, H1411-20. 
Azuma, Y., Tan, S. H., Cavenagh, M. M., Ainsztein, A. M., Saitoh, H. & Dasso, M. (2001) Expression and 
regulation of the mammalian SUMO-1 E1 enzyme. FASEB J, 15, 1825-7. 
Baboshina, O. V. & Haas, A. L. (1996) Novel multiubiquitin chain linkages catalyzed by the conjugating 
enzymes E2EPF and RAD6 are recognized by 26 S proteasome subunit 5. J Biol Chem, 271, 2823-
31. 
Bae, S. H., Jeong, J. W., Park, J. A., Kim, S. H., Bae, M. K., Choi, S. J. & Kim, K. W. (2004) Sumoylation 
increases HIF-1alpha stability and its transcriptional activity. Biochem Biophys Res Commun, 324, 
394-400. 
Bailey, D. & O'Hare, P. (2004) Characterization of the localization and proteolytic activity of the SUMO-
specific protease, SENP1. J Biol Chem, 279, 692-703. 
Bailey, D. & O'Hare, P. (2005) Comparison of the SUMO1 and ubiquitin conjugation pathways during the 
inhibition of proteasome activity with evidence of SUMO1 recycling. Biochem J, 392, 271-81. 
Bailly, V., Lauder, S., Prakash, S. & Prakash, L. (1997) Yeast DNA repair proteins Rad6 and Rad18 form a 
heterodimer that has ubiquitin conjugating, DNA binding, and ATP hydrolytic activities. J Biol 
Chem, 272, 23360-5. 
Barlow, P. N., Luisi, B., Milner, A., Elliott, M. & Everett, R. (1994) Structure of the C3HC4 domain by 1H-
nuclear magnetic resonance spectroscopy. A new structural class of zinc-finger. J Mol Biol, 237, 
201-11. 
Bayer, P., Arndt, A., Metzger, S., Mahajan, R., Melchior, F., Jaenicke, R. & Becker, J. (1998) Structure 
determination of the small ubiquitin-related modifier SUMO-1. J Mol Biol, 280, 275-86. 
Bencsath, K. P., Podgorski, M. S., Pagala, V. R., Slaughter, C. A. & Schulman, B. A. (2002) Identification of a 
multifunctional binding site on Ubc9p required for Smt3p conjugation. J Biol Chem, 277, 47938-
45. 
Benoit, G., Roussel, M., Pendino, F., Segal-Bendirdjian, E. & Lanotte, M. (2001) Orchestration of multiple 
arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another 
vision of t(15;17) preleukemic blast and APL-cell maturation. Oncogene, 20, 7161-77. 
Bergink, S. & Jentsch, S. (2009) Principles of ubiquitin and SUMO modifications in DNA repair. Nature, 458, 
461-7. 
Bernardi, R. & Pandolfi, P. P. (2007) Structure, dynamics and functions of promyelocytic leukaemia nuclear 
bodies. Nat Rev Mol Cell Biol, 8, 1006-16. 
Bernardi, R., Papa, A. & Pandolfi, P. P. (2008) Regulation of apoptosis by PML and the PML-NBs. Oncogene, 
27, 6299-312. 
REFERENCES  
134 
 
Bernardi, R., Scaglioni, P. P., Bergmann, S., Horn, H. F., Vousden, K. H. & Pandolfi, P. P. (2004) PML 
regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol, 6, 665-72. 
Bernier-Villamor, V., Sampson, D. A., Matunis, M. J. & Lima, C. D. (2002) Structural basis for E2-mediated 
SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and 
RanGAP1. Cell, 108, 345-56. 
Berta, M. A., Mazure, N., Hattab, M., Pouyssegur, J. & Brahimi-Horn, M. C. (2007) SUMOylation of hypoxia-
inducible factor-1alpha reduces its transcriptional activity. Biochem Biophys Res Commun, 360, 
646-52. 
Bloom, J., Amador, V., Bartolini, F., DeMartino, G. & Pagano, M. (2003) Proteasome-mediated degradation 
of p21 via N-terminal ubiquitinylation. Cell, 115, 71-82. 
Boddy, M. N., Howe, K., Etkin, L. D., Solomon, E. & Freemont, P. S. (1996) PIC 1, a novel ubiquitin-like 
protein which interacts with the PML component of a multiprotein complex that is disrupted in 
acute promyelocytic leukaemia. Oncogene, 13, 971-82. 
Borden, K. L. (1998) RING fingers and B-boxes: zinc-binding protein-protein interaction domains. Biochem 
Cell Biol, 76, 351-8. 
Borden, K. L., Boddy, M. N., Lally, J., O'Reilly, N. J., Martin, S., Howe, K., Solomon, E. & Freemont, P. S. 
(1995) The solution structure of the RING finger domain from the acute promyelocytic leukaemia 
proto-oncoprotein PML. EMBO J, 14, 1532-41. 
Borodovsky, A., Kessler, B. M., Casagrande, R., Overkleeft, H. S., Wilkinson, K. D. & Ploegh, H. L. (2001) A 
novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome 
association of USP14. EMBO J, 20, 5187-96. 
Borrow, J., Goddard, A. D., Sheer, D. & Solomon, E. (1990) Molecular analysis of acute promyelocytic 
leukemia breakpoint cluster region on chromosome 17. Science, 249, 1577-80. 
Bourdeau, V., Baudry, D. & Ferbeyre, G. (2009) PML links aberrant cytokine signaling and oncogenic stress 
to cellular senescence. Front Biosci, 14, 475-85. 
Bremm, A. & Komander, D. (2009) New insights into K11-linked ubiquitin chains. EMBO conference 
"Ubiquitin and ubiquitin-like modifiers in health and disease". Riva del Garda, Italy. 
Brouwer, A. K., Schimmel, J., Wiegant, J. C., Vertegaal, A. C., Tanke, H. J. & Dirks, R. W. (2009) Telomeric 
DNA mediates de novo PML body formation. Mol Biol Cell, 20, 4804-15. 
Brzovic, P. S. & Klevit, R. E. (2006) Ubiquitin transfer from the E2 perspective: why is UbcH5 so 
promiscuous? Cell Cycle, 5, 2867-73. 
Brzovic, P. S., Rajagopal, P., Hoyt, D. W., King, M. C. & Klevit, R. E. (2001) Structure of a BRCA1-BARD1 
heterodimeric RING-RING complex. Nat Struct Biol, 8, 833-7. 
Burns, K. E. & Darwin, K. H. (2010) Pupylation vs. Ubiquitylation: Tagging for Proteasome-Dependent 
Degradation. Cell Microbiol, 4, 424-31 
Burroughs, A. M., Balaji, S., Iyer, L. M. & Aravind, L. (2007) Small but versatile: the extraordinary functional 
and structural diversity of the beta-grasp fold. Biol Direct, 2, 18. 
Burroughs, A. M., Jaffee, M., Iyer, L. M. & Aravind, L. (2008) Anatomy of the E2 ligase fold: implications for 
enzymology and evolution of ubiquitin/Ub-like protein conjugation. J Struct Biol, 162, 205-18. 
Bylebyl, G. R., Belichenko, I. & Johnson, E. S. (2003) The SUMO isopeptidase Ulp2 prevents accumulation 
of SUMO chains in yeast. J Biol Chem, 278, 44113-20. 
Cadwell, K. & Coscoy, L. (2005) Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase. Science, 
309, 127-30. 
Cai, Q., Verma, S. C., Kumar, P., Ma, M. & Robertson, E. S. (2010) Hypoxia inactivates the VHL tumor 
suppressor through PIASy-mediated SUMO modification. PLoS One, 5, e9720. 
Carbia-Nagashima, A., Gerez, J., Perez-Castro, C., Paez-Pereda, M., Silberstein, S., Stalla, G. K., Holsboer, F. 
& Arzt, E. (2007) RSUME, a small RWD-containing protein, enhances SUMO conjugation and 
stabilizes HIF-1alpha during hypoxia. Cell, 131, 309-23. 
Chang, K. S., Stass, S. A., Chu, D. T., Deaven, L. L., Trujillo, J. M. & Freireich, E. J. (1992) Characterization of 
a fusion cDNA (RARA/myl) transcribed from the t(15;17) translocation breakpoint in acute 
promyelocytic leukemia. Mol Cell Biol, 12, 800-10. 
Chang, P. C., Izumiya, Y., Wu, C. Y., Fitzgerald, L. D., Campbell, M., Ellison, T. J., Lam, K. S., Luciw, P. A. & 
Kung, H. J. Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a SUMO E3 ligase that is SIM-
dependent and SUMO-2/3-specific. J Biol Chem, 285, 5266-73. 
Charest-Marcotte, A., Dufour, C. R., Wilson, B. J., Tremblay, A. M., Eichner, L. J., Arlow, D. H., Mootha, V. K. 
& Giguere, V. (2010) The homeobox protein Prox1 is a negative modulator of ERR{alpha}/PGC-
1{alpha} bioenergetic functions. Genes Dev, 24, 537-42. 
REFERENCES 
135 
 
Chastagner, P., Israel, A. & Brou, C. (2006) Itch/AIP4 mediates Deltex degradation through the formation 
of K29-linked polyubiquitin chains. EMBO Rep, 7, 1147-53. 
Chau, V., Tobias, J. W., Bachmair, A., Marriott, D., Ecker, D. J., Gonda, D. K. & Varshavsky, A. (1989) A 
multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science, 243, 
1576-83. 
Chelbi-Alix, M. K. & de The, H. (1999) Herpes virus induced proteasome-dependent degradation of the 
nuclear bodies-associated PML and Sp100 proteins. Oncogene, 18, 935-41. 
Chen, A., Mannen, H. & Li, S. S. (1998) Characterization of mouse ubiquitin-like SMT3A and SMT3B cDNAs 
and gene/pseudogenes. Biochem Mol Biol Int, 46, 1161-74. 
Chen, G. Q., Shi, X. G., Tang, W., Xiong, S. M., Zhu, J., Cai, X., Han, Z. G., Ni, J. H., Shi, G. Y., Jia, P. M., Liu, M. 
M., He, K. L., Niu, C., Ma, J., Zhang, P., Zhang, T. D., Paul, P., Naoe, T., Kitamura, K., Miller, W., 
Waxman, S., Wang, Z. Y., de The, H., Chen, S. J. & Chen, Z. (1997) Use of arsenic trioxide (As2O3) 
in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual 
effects on APL cells. Blood, 89, 3345-53. 
Chen, G. Q., Zhu, J., Shi, X. G., Ni, J. H., Zhong, H. J., Si, G. Y., Jin, X. L., Tang, W., Li, X. S., Xong, S. M., Shen, 
Z. X., Sun, G. L., Ma, J., Zhang, P., Zhang, T. D., Gazin, C., Naoe, T., Chen, S. J., Wang, Z. Y. & Chen, 
Z. (1996) In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the 
treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with 
downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood, 88, 
1052-61. 
Cheng, J., Kang, X., Zhang, S. & Yeh, E. T. (2007) SUMO-specific protease 1 is essential for stabilization of 
HIF1alpha during hypoxia. Cell, 131, 584-95. 
Cheung, W. L., Briggs, S. D. & Allis, C. D. (2000) Acetylation and chromosomal functions. Curr Opin Cell Biol, 
12, 326-33. 
Ching, R. W., Dellaire, G., Eskiw, C. H. & Bazett-Jones, D. P. (2005) PML bodies: a meeting place for 
genomic loci? J Cell Sci, 118, 847-54. 
Chiu, Y. H., Sun, Q. & Chen, Z. J. (2007) E1-L2 activates both ubiquitin and FAT10. Mol Cell, 27, 1014-23. 
Cho, G., Lim, Y. & Golden, J. A. (2009) SUMO interaction motifs in Sizn1 are required for promyelocytic 
leukemia protein nuclear body localization and for transcriptional activation. J Biol Chem, 284, 
19592-600. 
Christensen, D. E., Brzovic, P. S. & Klevit, R. E. (2007) E2-BRCA1 RING interactions dictate synthesis of 
mono- or specific polyubiquitin chain linkages. Nat Struct Mol Biol, 14, 941-8. 
Chung, C. D., Liao, J., Liu, B., Rao, X., Jay, P., Berta, P. & Shuai, K. (1997) Specific inhibition of Stat3 signal 
transduction by PIAS3. Science, 278, 1803-5. 
Ciechanover, A. (2005) Intracellular protein degradation: from a vague idea thru the lysosome and the 
ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ, 12, 
1178-90. 
Ciechanover, A., Elias, S., Heller, H. & Hershko, A. (1982) "Covalent affinity" purification of ubiquitin-
activating enzyme. J Biol Chem, 257, 2537-42. 
Ciechanover, A., Heller, H., Katz-Etzion, R. & Hershko, A. (1981) Activation of the heat-stable polypeptide 
of the ATP-dependent proteolytic system. Proc Natl Acad Sci U S A, 78, 761-5. 
Cohen, P. (2001) The role of protein phosphorylation in human health and disease. The Sir Hans Krebs 
Medal Lecture. Eur J Biochem, 268, 5001-10. 
Condemine, W., Takahashi, Y., Zhu, J., Puvion-Dutilleul, F., Guegan, S., Janin, A. & de The, H. (2006) 
Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res, 66, 6192-8. 
Daniel, M. T., Koken, M., Romagne, O., Barbey, S., Bazarbachi, A., Stadler, M., Guillemin, M. C., Degos, L., 
Chomienne, C. & de The, H. (1993) PML protein expression in hematopoietic and acute 
promyelocytic leukemia cells. Blood, 82, 1858-67. 
Dasso, M. (2008) Emerging roles of the SUMO pathway in mitosis. Cell Div, 3, 5. 
Dawlaty, M. M., Malureanu, L., Jeganathan, K. B., Kao, E., Sustmann, C., Tahk, S., Shuai, K., Grosschedl, R. 
& van Deursen, J. M. (2008) Resolution of sister centromeres requires RanBP2-mediated 
SUMOylation of topoisomerase IIalpha. Cell, 133, 103-15. 
de Stanchina, E., Querido, E., Narita, M., Davuluri, R. V., Pandolfi, P. P., Ferbeyre, G. & Lowe, S. W. (2004) 
PML is a direct p53 target that modulates p53 effector functions. Mol Cell, 13, 523-35. 
de The, H., Chomienne, C., Lanotte, M., Degos, L. & Dejean, A. (1990) The t(15;17) translocation of acute 
promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. 
Nature, 347, 558-61. 
REFERENCES  
136 
 
de The, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L. & Dejean, A. (1991) The PML-RAR alpha fusion 
mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a 
functionally altered RAR. Cell, 66, 675-84. 
Dellaire, G. & Bazett-Jones, D. P. (2004) PML nuclear bodies: dynamic sensors of DNA damage and cellular 
stress. Bioessays, 26, 963-77. 
Dellaire, G., Eskiw, C. H., Dehghani, H., Ching, R. W. & Bazett-Jones, D. P. (2006) Mitotic accumulations of 
PML protein contribute to the re-establishment of PML nuclear bodies in G1. J Cell Sci, 119, 1034-
42. 
Deng, L., Wang, C., Spencer, E., Yang, L., Braun, A., You, J., Slaughter, C., Pickart, C. & Chen, Z. J. (2000) 
Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating 
enzyme complex and a unique polyubiquitin chain. Cell, 103, 351-61. 
Deshaies, R. J. & Joazeiro, C. A. (2009) RING domain E3 ubiquitin ligases. Annu Rev Biochem, 78, 399-434. 
Desterro, J. M., Rodriguez, M. S. & Hay, R. T. (1998) SUMO-1 modification of IkappaBalpha inhibits NF-
kappaB activation. Mol Cell, 2, 233-9. 
Desterro, J. M., Thomson, J. & Hay, R. T. (1997) Ubch9 conjugates SUMO but not ubiquitin. FEBS Lett, 417, 
297-300. 
Deveraux, Q., Ustrell, V., Pickart, C. & Rechsteiner, M. (1994) A 26 S protease subunit that binds ubiquitin 
conjugates. J Biol Chem, 269, 7059-61. 
Di Bacco, A., Ouyang, J., Lee, H. Y., Catic, A., Ploegh, H. & Gill, G. (2006) The SUMO-specific protease SENP5 
is required for cell division. Mol Cell Biol, 26, 4489-98. 
Dikic, I., Wakatsuki, S. & Walters, K. J. (2009) Ubiquitin-binding domains - from structures to functions. Nat 
Rev Mol Cell Biol, 10, 659-71. 
Dohmen, R. J., Stappen, R., McGrath, J. P., Forrova, H., Kolarov, J., Goffeau, A. & Varshavsky, A. (1995) An 
essential yeast gene encoding a homolog of ubiquitin-activating enzyme. J Biol Chem, 270, 18099-
109. 
Duprez, E., Saurin, A. J., Desterro, J. M., Lallemand-Breitenbach, V., Howe, K., Boddy, M. N., Solomon, E., 
de The, H., Hay, R. T. & Freemont, P. S. (1999) SUMO-1 modification of the acute promyelocytic 
leukaemia protein PML: implications for nuclear localisation. J Cell Sci, 112 ( Pt 3), 381-93. 
Dyck, J. A., Maul, G. G., Miller, W. H., Jr., Chen, J. D., Kakizuka, A. & Evans, R. M. (1994) A novel 
macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. 
Cell, 76, 333-43. 
Dye, B. T. & Schulman, B. A. (2007) Structural mechanisms underlying posttranslational modification by 
ubiquitin-like proteins. Annu Rev Biophys Biomol Struct, 36, 131-50. 
Eddins, M. J., Varadan, R., Fushman, D., Pickart, C. M. & Wolberger, C. (2007) Crystal structure and 
solution NMR studies of Lys48-linked tetraubiquitin at neutral pH. J Mol Biol, 367, 204-11. 
Elsasser, S. & Finley, D. (2005) Delivery of ubiquitinated substrates to protein-unfolding machines. Nat Cell 
Biol, 7, 742-9. 
Eng, J. K., McCormack, A. L. & Yates, J. R. I. (1994) An approach to correlate tandem mass spectral data of 
peptides with amino acid sequences in a protein database. Journal of the American Society for 
Mass Spectrometry, 5, 976-989  
Engelhardt, O. G., Boutell, C., Orr, A., Ullrich, E., Haller, O. & Everett, R. D. (2003) The homeodomain-
interacting kinase PKM (HIPK-2) modifies ND10 through both its kinase domain and a SUMO-1 
interaction motif and alters the posttranslational modification of PML. Exp Cell Res, 283, 36-50. 
Eskiw, C. H., Dellaire, G. & Bazett-Jones, D. P. (2004) Chromatin contributes to structural integrity of 
promyelocytic leukemia bodies through a SUMO-1-independent mechanism. J Biol Chem, 279, 
9577-85. 
Eskiw, C. H., Dellaire, G., Mymryk, J. S. & Bazett-Jones, D. P. (2003) Size, position and dynamic behavior of 
PML nuclear bodies following cell stress as a paradigm for supramolecular trafficking and 
assembly. J Cell Sci, 116, 4455-66. 
Estey, E., Garcia-Manero, G., Ferrajoli, A., Faderl, S., Verstovsek, S., Jones, D. & Kantarjian, H. (2006) Use of 
all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute 
promyelocytic leukemia. Blood, 107, 3469-73. 
Evans, J. D. & Hearing, P. (2005) Relocalization of the Mre11-Rad50-Nbs1 complex by the adenovirus E4 
ORF3 protein is required for viral replication. J Virol, 79, 6207-15. 
Evdokimov, E., Sharma, P., Lockett, S. J., Lualdi, M. & Kuehn, M. R. (2008) Loss of SUMO1 in mice affects 
RanGAP1 localization and formation of PML nuclear bodies, but is not lethal as it can be 
compensated by SUMO2 or SUMO3. J Cell Sci, 121, 4106-13. 
REFERENCES 
137 
 
Everett, R. D. & Chelbi-Alix, M. K. (2007) PML and PML nuclear bodies: implications in antiviral defence. 
Biochimie, 89, 819-30. 
Everett, R. D. & Murray, J. (2005) ND10 components relocate to sites associated with herpes simplex virus 
type 1 nucleoprotein complexes during virus infection. J Virol, 79, 5078-89. 
Everett, R. D., Parada, C., Gripon, P., Sirma, H. & Orr, A. (2008) Replication of ICP0-null mutant herpes 
simplex virus type 1 is restricted by both PML and Sp100. J Virol, 82, 2661-72. 
Fabunmi, R. P., Wigley, W. C., Thomas, P. J. & DeMartino, G. N. (2001) Interferon gamma regulates 
accumulation of the proteasome activator PA28 and immunoproteasomes at nuclear PML bodies. 
J Cell Sci, 114, 29-36. 
Fagioli, M., Alcalay, M., Pandolfi, P. P., Venturini, L., Mencarelli, A., Simeone, A., Acampora, D., Grignani, F. 
& Pelicci, P. G. (1992) Alternative splicing of PML transcripts predicts coexpression of several 
carboxy-terminally different protein isoforms. Oncogene, 7, 1083-91. 
Figueroa-Romero, C., Iniguez-Lluhi, J. A., Stadler, J., Chang, C. R., Arnoult, D., Keller, P. J., Hong, Y., 
Blackstone, C. & Feldman, E. L. (2009) SUMOylation of the mitochondrial fission protein Drp1 
occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycle. 
FASEB J, 23, 3917-27. 
Finley, D. (2002) Ubiquitin chained and crosslinked. Nat Cell Biol, 4, E121-3. 
Fogal, V., Gostissa, M., Sandy, P., Zacchi, P., Sternsdorf, T., Jensen, K., Pandolfi, P. P., Will, H., Schneider, C. 
& Del Sal, G. (2000) Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO 
J, 19, 6185-95. 
Freemont, P. S., Hanson, I. M. & Trowsdale, J. (1991) A novel cysteine-rich sequence motif. Cell, 64, 483-4. 
Galanty, Y., Belotserkovskaya, R., Coates, J., Polo, S., Miller, K. M. & Jackson, S. P. (2009) Mammalian 
SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature, 462, 
935-9. 
Gan-Erdene, T., Nagamalleswari, K., Yin, L., Wu, K., Pan, Z. Q. & Wilkinson, K. D. (2003) Identification and 
characterization of DEN1, a deneddylase of the ULP family. J Biol Chem, 278, 28892-900. 
Gao, C., Ho, C. C., Reineke, E., Lam, M., Cheng, X., Stanya, K. J., Liu, Y., Chakraborty, S., Shih, H. M. & Kao, 
H. Y. (2008) Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear 
body formation. Mol Cell Biol, 28, 5658-67. 
Garcia-Dominguez, M. & Reyes, J. C. (2009) SUMO association with repressor complexes, emerging routes 
for transcriptional control. Biochim Biophys Acta, 1789, 451-9. 
Geng, J. & Klionsky, D. J. (2008) The Atg8 and Atg12 ubiquitin-like conjugation systems in 
macroautophagy. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep, 9, 
859-64. 
Geoffroy, M. C. & Hay, R. T. (2009) An additional role for SUMO in ubiquitin-mediated proteolysis. Nat Rev 
Mol Cell Biol, 10, 564-8. 
Gill, G. (2005) Something about SUMO inhibits transcription. Curr Opin Genet Dev, 15, 536-41. 
Glickman, M. H. & Ciechanover, A. (2002) The ubiquitin-proteasome proteolytic pathway: destruction for 
the sake of construction. Physiol Rev, 82, 373-428. 
Goddard, A. D., Borrow, J., Freemont, P. S. & Solomon, E. (1991) Characterization of a zinc finger gene 
disrupted by the t(15;17) in acute promyelocytic leukemia. Science, 254, 1371-4. 
Goldknopf, I. L. & Busch, H. (1977) Isopeptide linkage between nonhistone and histone 2A polypeptides of 
chromosomal conjugate-protein A24. Proc Natl Acad Sci U S A, 74, 864-8. 
Golebiowski, F., Matic, I., Tatham, M. H., Cole, C., Yin, Y., Nakamura, A., Cox, J., Barton, G. J., Mann, M. & 
Hay, R. T. (2009) System-wide changes to SUMO modifications in response to heat shock. Sci 
Signal, 2, ra24. 
Gong, L., Millas, S., Maul, G. G. & Yeh, E. T. (2000) Differential regulation of sentrinized proteins by a novel 
sentrin-specific protease. J Biol Chem, 275, 3355-9. 
Gong, L. & Yeh, E. T. (2006) Characterization of a family of nucleolar SUMO-specific proteases with 
preference for SUMO-2 or SUMO-3. J Biol Chem, 281, 15869-77. 
Goodson, M. L., Hong, Y., Rogers, R., Matunis, M. J., Park-Sarge, O. K. & Sarge, K. D. (2001) Sumo-1 
modification regulates the DNA binding activity of heat shock transcription factor 2, a 
promyelocytic leukemia nuclear body associated transcription factor. J Biol Chem, 276, 18513-8. 
Gregoire, S. & Yang, X. J. (2005) Association with class IIa histone deacetylases upregulates the 
sumoylation of MEF2 transcription factors. Mol Cell Biol, 25, 2273-87. 
 
REFERENCES  
138 
 
Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., 
Ferrara, F. F., Zamir, I., Seiser, C., Lazar, M. A., Minucci, S. & Pelicci, P. G. (1998) Fusion proteins of 
the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature, 
391, 815-8. 
Groettrup, M., Pelzer, C., Schmidtke, G. & Hofmann, K. (2008) Activating the ubiquitin family: UBA6 
challenges the field. Trends Biochem Sci, 33, 230-7. 
Groll, M., Ditzel, L., Lowe, J., Stock, D., Bochtler, M., Bartunik, H. D. & Huber, R. (1997) Structure of 20S 
proteasome from yeast at 2.4 A resolution. Nature, 386, 463-71. 
Guldner, H. H., Szostecki, C., Grotzinger, T. & Will, H. (1992) IFN enhance expression of Sp100, an 
autoantigen in primary biliary cirrhosis. J Immunol, 149, 4067-73. 
Guo, D., Li, M., Zhang, Y., Yang, P., Eckenrode, S., Hopkins, D., Zheng, W., Purohit, S., Podolsky, R. H., Muir, 
A., Wang, J., Dong, Z., Brusko, T., Atkinson, M., Pozzilli, P., Zeidler, A., Raffel, L. J., Jacob, C. O., 
Park, Y., Serrano-Rios, M., Larrad, M. T., Zhang, Z., Garchon, H. J., Bach, J. F., Rotter, J. I., She, J. X. 
& Wang, C. Y. (2004) A functional variant of SUMO4, a new I kappa B alpha modifier, is associated 
with type 1 diabetes. Nat Genet, 36, 837-41. 
Gurrieri, C., Capodieci, P., Bernardi, R., Scaglioni, P. P., Nafa, K., Rush, L. J., Verbel, D. A., Cordon-Cardo, C. 
& Pandolfi, P. P. (2004) Loss of the tumor suppressor PML in human cancers of multiple histologic 
origins. J Natl Cancer Inst, 96, 269-79. 
Haas, A. L. & Bright, P. M. (1988) The resolution and characterization of putative ubiquitin carrier protein 
isozymes from rabbit reticulocytes. J Biol Chem, 263, 13258-67. 
Haas, T. L., Emmerich, C. H., Gerlach, B., Schmukle, A. C., Cordier, S. M., Rieser, E., Feltham, R., Vince, J., 
Warnken, U., Wenger, T., Koschny, R., Komander, D., Silke, J. & Walczak, H. (2009) Recruitment of 
the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is 
required for TNF-mediated gene induction. Mol Cell, 36, 831-44. 
Haglund, K., Di Fiore, P. P. & Dikic, I. (2003) Distinct monoubiquitin signals in receptor endocytosis. Trends 
Biochem Sci, 28, 598-603. 
Haindl, M., Harasim, T., Eick, D. & Müller, S. (2008) The nucleolar SUMO-specific protease SENP3 reverses 
SUMO modification of nucleophosmin and is required for rRNA processing. EMBO Rep, 9, 273-9. 
Häkli, M., Karvonen, U., Janne, O. A. & Palvimo, J. J. (2005) SUMO-1 promotes association of SNURF (RNF4) 
with PML nuclear bodies. Exp Cell Res, 304, 224-33. 
Häkli, M., Lorick, K. L., Weissman, A. M., Janne, O. A. & Palvimo, J. J. (2004) Transcriptional coregulator 
SNURF (RNF4) possesses ubiquitin E3 ligase activity. FEBS Lett, 560, 56-62. 
Haluska, P., Jr., Saleem, A., Rasheed, Z., Ahmed, F., Su, E. W., Liu, L. F. & Rubin, E. H. (1999) Interaction 
between human topoisomerase I and a novel RING finger/arginine-serine protein. Nucleic Acids 
Res, 27, 2538-44. 
Hang, J. & Dasso, M. (2002) Association of the human SUMO-1 protease SENP2 with the nuclear pore. J 
Biol Chem, 277, 19961-6. 
Hannich, J. T., Lewis, A., Kroetz, M. B., Li, S. J., Heide, H., Emili, A. & Hochstrasser, M. (2005) Defining the 
SUMO-modified proteome by multiple approaches in Saccharomyces cerevisiae. J Biol Chem, 280, 
4102-10. 
Hashizume, R., Fukuda, M., Maeda, I., Nishikawa, H., Oyake, D., Yabuki, Y., Ogata, H. & Ohta, T. (2001) The 
RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived 
mutation. J Biol Chem, 276, 14537-40. 
Hatakeyama, S. & Nakayama, K. I. (2003) U-box proteins as a new family of ubiquitin ligases. Biochem 
Biophys Res Commun, 302, 635-45. 
Hayakawa, F., Abe, A., Kitabayashi, I., Pandolfi, P. P. & Naoe, T. (2008) Acetylation of PML is involved in 
histone deacetylase inhibitor-mediated apoptosis. J Biol Chem, 283, 24420-5. 
Hayakawa, F. & Privalsky, M. L. (2004) Phosphorylation of PML by mitogen-activated protein kinases plays 
a key role in arsenic trioxide-mediated apoptosis. Cancer Cell, 5, 389-401. 
Hecker, C. M., Rabiller, M., Haglund, K., Bayer, P. & Dikic, I. (2006) Specification of SUMO1- and SUMO2-
interacting motifs. J Biol Chem, 281, 16117-27. 
Hershko, A. (1983) Ubiquitin: roles in protein modification and breakdown. Cell, 34, 11-2. 
Hershko, A. (1991) The ubiquitin pathway of protein degradation and proteolysis of ubiquitin-protein 
conjugates. Biochem Soc Trans, 19, 726-9. 
Hershko, A. & Ciechanover, A. (1998) The ubiquitin system. Annu Rev Biochem, 67, 425-79. 
REFERENCES 
139 
 
Hershko, A., Ciechanover, A., Heller, H., Haas, A. L. & Rose, I. A. (1980) Proposed role of ATP in protein 
breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent 
proteolysis. Proc Natl Acad Sci U S A, 77, 1783-6. 
Hershko, A., Ciechanover, A. & Rose, I. A. (1981) Identification of the active amino acid residue of the 
polypeptide of ATP-dependent protein breakdown. J Biol Chem, 256, 1525-8. 
Heun, P. (2007) SUMOrganization of the nucleus. Curr Opin Cell Biol, 19, 350-5. 
Hietakangas, V., Ahlskog, J. K., Jakobsson, A. M., Hellesuo, M., Sahlberg, N. M., Holmberg, C. I., Mikhailov, 
A., Palvimo, J. J., Pirkkala, L. & Sistonen, L. (2003) Phosphorylation of serine 303 is a prerequisite 
for the stress-inducible SUMO modification of heat shock factor 1. Mol Cell Biol, 23, 2953-68. 
Hietakangas, V., Anckar, J., Blomster, H. A., Fujimoto, M., Palvimo, J. J., Nakai, A. & Sistonen, L. (2006) 
PDSM, a motif for phosphorylation-dependent SUMO modification. Proc Natl Acad Sci U S A, 103, 
45-50. 
Hjerpe, R., Aillet, F., Lopitz-Otsoa, F., Lang, V., England, P. & Rodriguez, M. S. (2009) Efficient protection 
and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. EMBO Rep, 10, 
1250-8. 
Ho, J. C. & Watts, F. Z. (2003) Characterization of SUMO-conjugating enzyme mutants in 
Schizosaccharomyces pombe identifies a dominant-negative allele that severely reduces SUMO 
conjugation. Biochem J, 372, 97-104. 
Hochstrasser, M. (2006) Lingering mysteries of ubiquitin-chain assembly. Cell, 124, 27-34. 
Hochstrasser, M. (2009) Origin and function of ubiquitin-like proteins. Nature, 458, 422-9. 
Hoege, C., Pfander, B., Moldovan, G. L., Pyrowolakis, G. & Jentsch, S. (2002) RAD6-dependent DNA repair 
is linked to modification of PCNA by ubiquitin and SUMO. Nature, 419, 135-41. 
Hoeller, D., Hecker, C. M., Wagner, S., Rogov, V., Dotsch, V. & Dikic, I. (2007) E3-independent 
monoubiquitination of ubiquitin-binding proteins. Mol Cell, 26, 891-8. 
Hoemme, C., Peerzada, A., Behre, G., Wang, Y., McClelland, M., Nieselt, K., Zschunke, M., Disselhoff, C., 
Agrawal, S., Isken, F., Tidow, N., Berdel, W. E., Serve, H. & Müller-Tidow, C. (2008) Chromatin 
modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by 
ChIP-Chip. Blood, 111, 2887-95. 
Hofmann, R. M. & Pickart, C. M. (1999) Noncanonical MMS2-encoded ubiquitin-conjugating enzyme 
functions in assembly of novel polyubiquitin chains for DNA repair. Cell, 96, 645-53. 
Hsiao, H. H., Meulmeester, E., Frank, B. T., Melchior, F. & Urlaub, H. (2009) "ChopNSpice," a mass 
spectrometric approach that allows identification of endogenous small ubiquitin-like modifier-
conjugated peptides. Mol Cell Proteomics, 8, 2664-75. 
Hu, J., Liu, Y. F., Wu, C. F., Xu, F., Shen, Z. X., Zhu, Y. M., Li, J. M., Tang, W., Zhao, W. L., Wu, W., Sun, H. P., 
Chen, Q. S., Chen, B., Zhou, G. B., Zelent, A., Waxman, S., Wang, Z. Y., Chen, S. J. & Chen, Z. (2009) 
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly 
diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A, 106, 3342-7. 
Huang, D. T., Ayrault, O., Hunt, H. W., Taherbhoy, A. M., Duda, D. M., Scott, D. C., Borg, L. A., Neale, G., 
Murray, P. J., Roussel, M. F. & Schulman, B. A. (2009) E2-RING expansion of the NEDD8 cascade 
confers specificity to cullin modification. Mol Cell, 33, 483-95. 
Huang, D. T., Walden, H., Duda, D. & Schulman, B. A. (2004) Ubiquitin-like protein activation. Oncogene, 
23, 1958-71. 
Huang, T. T., Wuerzberger-Davis, S. M., Wu, Z. H. & Miyamoto, S. (2003) Sequential modification of 
NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. 
Cell, 115, 565-76. 
Huang, W. C., Ko, T. P., Li, S. S. & Wang, A. H. (2004) Crystal structures of the human SUMO-2 protein at 
1.6 A and 1.2 A resolution: implication on the functional differences of SUMO proteins. Eur J 
Biochem, 271, 4114-22. 
Huibregtse, J. M., Scheffner, M., Beaudenon, S. & Howley, P. M. (1995) A family of proteins structurally 
and functionally related to the E6-AP ubiquitin-protein ligase. Proc Natl Acad Sci U S A, 92, 5249. 
Husnjak, K., Elsasser, S., Zhang, N., Chen, X., Randles, L., Shi, Y., Hofmann, K., Walters, K. J., Finley, D. & 
Dikic, I. (2008) Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature, 453, 481-8. 
Hutschenreiter, S., Tinazli, A., Model, K. & Tampe, R. (2004) Two-substrate association with the 20S 
proteasome at single-molecule level. EMBO J, 23, 2488-97. 
Ii, T., Fung, J., Mullen, J. R. & Brill, S. J. (2007) The yeast Slx5-Slx8 DNA integrity complex displays ubiquitin 
ligase activity. Cell Cycle, 6, 2800-9. 
REFERENCES  
140 
 
Ikeda, F. & Dikic, I. (2008) Atypical ubiquitin chains: new molecular signals. 'Protein Modifications: Beyond 
the Usual Suspects' review series. EMBO Rep, 9, 536-42. 
Ikegami, H., Noso, S., Babaya, N., Hiromine, Y. & Kawabata, Y. (2008) Genetic Basis of Type 1 Diabetes: 
Similarities and Differences between East and West. Rev Diabet Stud, 5, 64-72. 
Indyk, L. & Fisher, H. F. (1998) Theoretical aspects of isothermal titration calorimetry. Methods Enzymol, 
295, 350-64. 
Ishov, A. M., Sotnikov, A. G., Negorev, D., Vladimirova, O. V., Neff, N., Kamitani, T., Yeh, E. T., Strauss, J. F., 
3rd & Maul, G. G. (1999) PML is critical for ND10 formation and recruits the PML-interacting 
protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol, 147, 221-34. 
Iwai, K. & Tokunaga, F. (2009) Linear polyubiquitination: a new regulator of NF-kappaB activation. EMBO 
Rep, 10, 706-13. 
Iyer, L. M., Burroughs, A. M. & Aravind, L. (2006) The prokaryotic antecedents of the ubiquitin-signaling 
system and the early evolution of ubiquitin-like beta-grasp domains. Genome Biol, 7, R60. 
Jang, M. S., Ryu, S. W. & Kim, E. (2002) Modification of Daxx by small ubiquitin-related modifier-1. 
Biochem Biophys Res Commun, 295, 495-500. 
Jensen, K., Shiels, C. & Freemont, P. S. (2001) PML protein isoforms and the RBCC/TRIM motif. Oncogene, 
20, 7223-33. 
Jeram, S. M., Srikumar, T., Zhang, X. D., Anne Eisenhauer, H., Rogers, R., Pedrioli, P. G., Matunis, M. & 
Raught, B. (2010) An improved SUMmOn-based methodology for the identification of ubiquitin 
and ubiquitin-like protein conjugation sites identifies novel ubiquitin-like protein chain linkages. 
Proteomics, 10, 254-65. 
Jin, J., Li, X., Gygi, S. P. & Harper, J. W. (2007) Dual E1 activation systems for ubiquitin differentially 
regulate E2 enzyme charging. Nature, 447, 1135-8. 
Jing, Y., Wang, L., Xia, L., Chen, G. Q., Chen, Z., Miller, W. H. & Waxman, S. (2001) Combined effect of all-
trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. 
Blood, 97, 264-9. 
Joazeiro, C. A. & Weissman, A. M. (2000) RING finger proteins: mediators of ubiquitin ligase activity. Cell, 
102, 549-52. 
Joazeiro, C. A., Wing, S. S., Huang, H., Leverson, J. D., Hunter, T. & Liu, Y. C. (1999) The tyrosine kinase 
negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science, 286, 309-
12. 
Joe, Y., Jeong, J. H., Yang, S., Kang, H., Motoyama, N., Pandolfi, P. P., Chung, J. H. & Kim, M. K. (2006) ATR, 
PML, and CHK2 play a role in arsenic trioxide-induced apoptosis. J Biol Chem, 281, 28764-71. 
Johnson, E. S. (2004) Protein modification by SUMO. Annu Rev Biochem, 73, 355-82. 
Johnson, E. S. & Blobel, G. (1997) Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p. J 
Biol Chem, 272, 26799-802. 
Johnson, E. S. & Gupta, A. A. (2001) An E3-like factor that promotes SUMO conjugation to the yeast 
septins. Cell, 106, 735-44. 
Johnson, E. S., Ma, P. C., Ota, I. M. & Varshavsky, A. (1995) A proteolytic pathway that recognizes ubiquitin 
as a degradation signal. J Biol Chem, 270, 17442-56. 
Johnson, E. S., Schwienhorst, I., Dohmen, R. J. & Blobel, G. (1997) The ubiquitin-like protein Smt3p is 
activated for conjugation to other proteins by an Aos1p/Uba2p heterodimer. EMBO J, 16, 5509-
19. 
Jones, D., Crowe, E., Stevens, T. A. & Candido, E. P. (2002) Functional and phylogenetic analysis of the 
ubiquitylation system in Caenorhabditis elegans: ubiquitin-conjugating enzymes, ubiquitin-
activating enzymes, and ubiquitin-like proteins. Genome Biol, 3, RESEARCH0002. 
Kakizuka, A., Miller, W. H., Jr., Umesono, K., Warrell, R. P., Jr., Frankel, S. R., Murty, V. V., Dmitrovsky, E. & 
Evans, R. M. (1991) Chromosomal translocation t(15;17) in human acute promyelocytic leukemia 
fuses RAR alpha with a novel putative transcription factor, PML. Cell, 66, 663-74. 
Kamitani, T., Nguyen, H. P. & Yeh, E. T. (1997) Preferential modification of nuclear proteins by a novel 
ubiquitin-like molecule. J Biol Chem, 272, 14001-4.  
Kamitani, T., Nguyen, H. P., Kito, K., Fukuda-Kamitani, T. & Yeh, E. T. (1998a) Covalent modification of PML 
by the sentrin family of ubiquitin-like proteins. J Biol Chem, 273, 3117-20. 
Kamitani, T., Kito, K., Nguyen, H. P., Wada, H., Fukuda-Kamitani, T. & Yeh, E. T. (1998b) Identification of 
three major sentrinization sites in PML. J Biol Chem, 273, 26675-82. 
REFERENCES 
141 
 
Kamura, T., Conrad, M. N., Yan, Q., Conaway, R. C. & Conaway, J. W. (1999) The Rbx1 subunit of SCF and 
VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev, 13, 
2928-33. 
Kang, S. H., Kim, G. R., Seong, M., Baek, S. H., Seol, J. H., Bang, O. S., Ovaa, H., Tatsumi, K., Komatsu, M., 
Tanaka, K. & Chung, C. H. (2007) Two novel ubiquitin-fold modifier 1 (Ufm1)-specific proteases, 
UfSP1 and UfSP2. J Biol Chem, 282, 5256-62. 
Kannouche, P. L., Wing, J. & Lehmann, A. R. (2004) Interaction of human DNA polymerase eta with 
monoubiquitinated PCNA: a possible mechanism for the polymerase switch in response to DNA 
damage. Mol Cell, 14, 491-500. 
Kastner, P., Perez, A., Lutz, Y., Rochette-Egly, C., Gaub, M. P., Durand, B., Lanotte, M., Berger, R. & 
Chambon, P. (1992) Structure, localization and transcriptional properties of two classes of 
retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural 
similarities with a new family of oncoproteins. EMBO J, 11, 629-42. 
Katoh, K. & Toh, H. (2008) Recent developments in the MAFFT multiple sequence alignment program. 
Brief Bioinform, 9, 286-98. 
Kawai, H., Lopez-Pajares, V., Kim, M. M., Wiederschain, D. & Yuan, Z. M. (2007) RING domain-mediated 
interaction is a requirement for MDM2's E3 ligase activity. Cancer Res, 67, 6026-30. 
Kerscher, O., Felberbaum, R. & Hochstrasser, M. (2006) Modification of proteins by ubiquitin and 
ubiquitin-like proteins. Annu Rev Cell Dev Biol, 22, 159-80. 
Kim, H. T., Kim, K. P., Lledias, F., Kisselev, A. F., Scaglione, K. M., Skowyra, D., Gygi, S. P. & Goldberg, A. L. 
(2007) Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) 
synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages. J 
Biol Chem, 282, 17375-86. 
Kim, K. I. & Baek, S. H. (2006) SUMOylation code in cancer development and metastasis. Mol Cells, 22, 
247-53. 
Kim, K. I., Giannakopoulos, N. V., Virgin, H. W. & Zhang, D. E. (2004) Interferon-inducible ubiquitin E2, 
Ubc8, is a conjugating enzyme for protein ISGylation. Mol Cell Biol, 24, 9592-600. 
Kirisako, T., Kamei, K., Murata, S., Kato, M., Fukumoto, H., Kanie, M., Sano, S., Tokunaga, F., Tanaka, K. & 
Iwai, K. (2006) A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J, 25, 
4877-87. 
Kirsh, O., Seeler, J. S., Pichler, A., Gast, A., Müller, S., Miska, E., Mathieu, M., Harel-Bellan, A., Kouzarides, 
T., Melchior, F. & Dejean, A. (2002) The SUMO E3 ligase RanBP2 promotes modification of the 
HDAC4 deacetylase. EMBO J, 21, 2682-91. 
Knipscheer, P., Flotho, A., Klug, H., Olsen, J. V., van Dijk, W. J., Fish, A., Johnson, E. S., Mann, M., Sixma, T. 
K. & Pichler, A. (2008) Ubc9 sumoylation regulates SUMO target discrimination. Mol Cell, 31, 371-
82. 
Knipscheer, P., van Dijk, W. J., Olsen, J. V., Mann, M. & Sixma, T. K. (2007) Noncovalent interaction 
between Ubc9 and SUMO promotes SUMO chain formation. EMBO J, 26, 2797-807. 
Koken, M. H., Puvion-Dutilleul, F., Guillemin, M. C., Viron, A., Linares-Cruz, G., Stuurman, N., de Jong, L., 
Szostecki, C., Calvo, F., Chomienne, C. & et al. (1994) The t(15;17) translocation alters a nuclear 
body in a retinoic acid-reversible fashion. EMBO J, 13, 1073-83. 
Komander, D. (2009a) The emerging complexity of protein ubiquitination. Biochem Soc Trans, 37, 937-53. 
Komander, D., Clague, M. J. & Urbe, S. (2009b) Breaking the chains: structure and function of the 
deubiquitinases. Nat Rev Mol Cell Biol, 10, 550-63. 
Komander, D., Reyes-Turcu, F., Licchesi, J. D., Odenwaelder, P., Wilkinson, K. D. & Barford, D. (2009c) 
Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. 
EMBO Rep, 10, 466-73. 
Komatsu, M., Chiba, T., Tatsumi, K., Iemura, S., Tanida, I., Okazaki, N., Ueno, T., Kominami, E., Natsume, T. 
& Tanaka, K. (2004) A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. 
EMBO J, 23, 1977-86. 
Kosoy, A., Calonge, T. M., Outwin, E. A. & O'Connell, M. J. (2007) Fission yeast Rnf4 homologs are required 
for DNA repair. J Biol Chem, 282, 20388-94. 
Kunapuli, P., Kasyapa, C. S., Chin, S. F., Caldas, C. & Cowell, J. K. (2006) ZNF198, a zinc finger protein 
rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with 
SUMO-1 and PML. Exp Cell Res, 312, 3739-51. 
REFERENCES  
142 
 
Kurepa, J., Walker, J. M., Smalle, J., Gosink, M. M., Davis, S. J., Durham, T. L., Sung, D. Y. & Vierstra, R. D. 
(2003) The small ubiquitin-like modifier (SUMO) protein modification system in Arabidopsis. 
Accumulation of SUMO1 and -2 conjugates is increased by stress. J Biol Chem, 278, 6862-72. 
Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. 
Nature, 227, 680-5. 
Lallemand-Breitenbach, V., Jeanne, M., Benhenda, S., Nasr, R., Lei, M., Peres, L., Zhou, J., Zhu, J., Raught, 
B. & de The, H. (2008) Arsenic degrades PML or PML-RARalpha through a SUMO-triggered 
RNF4/ubiquitin-mediated pathway. Nat Cell Biol, 10, 547-55. 
Lallemand-Breitenbach, V., Zhu, J., Puvion, F., Koken, M., Honore, N., Doubeikovsky, A., Duprez, E., 
Pandolfi, P. P., Puvion, E., Freemont, P. & de The, H. (2001) Role of promyelocytic leukemia (PML) 
sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or 
PML/retinoic acid receptor alpha degradation. J Exp Med, 193, 1361-71. 
Lam, Y. A., DeMartino, G. N., Pickart, C. M. & Cohen, R. E. (1997) Specificity of the ubiquitin isopeptidase in 
the PA700 regulatory complex of 26 S proteasomes. J Biol Chem, 272, 28438-46. 
Lam, Y. A., Lawson, T. G., Velayutham, M., Zweier, J. L. & Pickart, C. M. (2002) A proteasomal ATPase 
subunit recognizes the polyubiquitin degradation signal. Nature, 416, 763-7. 
Lang, M., Jegou, T., Chung, I., Richter, K., Munch, S., Udvarhelyi, A., Cremer, C., Hemmerich, P., Engelhardt, 
J., Hell, S. W. & Rippe, K. (2010) Three-dimensional organization of promyelocytic leukemia 
nuclear bodies. J Cell Sci, 123, 392-400. 
Lapenta, V., Chiurazzi, P., van der Spek, P., Pizzuti, A., Hanaoka, F. & Brahe, C. (1997) SMT3A, a human 
homologue of the S. cerevisiae SMT3 gene, maps to chromosome 21qter and defines a novel 
gene family. Genomics, 40, 362-6. 
Lavau, C., Marchio, A., Fagioli, M., Jansen, J., Falini, B., Lebon, P., Grosveld, F., Pandolfi, P. P., Pelicci, P. G. 
& Dejean, A. (1995) The acute promyelocytic leukaemia-associated PML gene is induced by 
interferon. Oncogene, 11, 871-6. 
Le Roy, C. & Wrana, J. L. (2004) Cell biology: an unexpected social servant. Nature, 431, 142. 
Lee, D. H. & Goldberg, A. L. (1998) Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell 
Biol, 8, 397-403. 
Lee, J., Lee, Y., Lee, M. J., Park, E., Kang, S. H., Chung, C. H., Lee, K. H. & Kim, K. (2008) Dual modification of 
BMAL1 by SUMO2/3 and ubiquitin promotes circadian activation of the CLOCK/BMAL1 complex. 
Mol Cell Biol, 28, 6056-65. 
Leung, J., Pang, A., Yuen, W. H., Kwong, Y. L. & Tse, E. W. (2007) Relationship of expression of 
aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood, 109, 740-6. 
Levkowitz, G., Waterman, H., Ettenberg, S. A., Katz, M., Tsygankov, A. Y., Alroy, I., Lavi, S., Iwai, K., Reiss, Y., 
Ciechanover, A., Lipkowitz, S. & Yarden, Y. (1999) Ubiquitin ligase activity and tyrosine 
phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell, 4, 1029-
40. 
Levkowitz, G., Waterman, H., Zamir, E., Kam, Z., Oved, S., Langdon, W. Y., Beguinot, L., Geiger, B. & 
Yarden, Y. (1998) c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal 
growth factor receptor. Genes Dev, 12, 3663-74. 
Li, S. J. & Hochstrasser, M. (1999) A new protease required for cell-cycle progression in yeast. Nature, 398, 
246-51. 
Li, S. J. & Hochstrasser, M. (2000) The yeast ULP2 (SMT4) gene encodes a novel protease specific for the 
ubiquitin-like Smt3 protein. Mol Cell Biol, 20, 2367-77. 
Li, W., Tu, D., Brunger, A. T. & Ye, Y. (2007) A ubiquitin ligase transfers preformed polyubiquitin chains 
from a conjugating enzyme to a substrate. Nature, 446, 333-7. 
Li, W. & Ye, Y. (2008) Polyubiquitin chains: functions, structures, and mechanisms. Cell Mol Life Sci, 65, 
2397-406. 
Lima, C. D. & Reverter, D. (2008) Structure of the human SENP7 catalytic domain and poly-SUMO 
deconjugation activities for SENP6 and SENP7. J Biol Chem, 283, 32045-55. 
Lin, D. Y., Huang, Y. S., Jeng, J. C., Kuo, H. Y., Chang, C. C., Chao, T. T., Ho, C. C., Chen, Y. C., Lin, T. P., Fang, 
H. I., Hung, C. C., Suen, C. S., Hwang, M. J., Chang, K. S., Maul, G. G. & Shih, H. M. (2006) Role of 
SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of 
sumoylated transcription factors. Mol Cell, 24, 341-54. 
Lin, H. K., Bergmann, S. & Pandolfi, P. P. (2004) Cytoplasmic PML function in TGF-beta signalling. Nature, 
431, 205-11. 
REFERENCES 
143 
 
Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., Jr. & Evans, R. M. (1998) Role of the histone 
deacetylase complex in acute promyelocytic leukaemia. Nature, 391, 811-4. 
Liu, B., Liao, J., Rao, X., Kushner, S. A., Chung, C. D., Chang, D. D. & Shuai, K. (1998) Inhibition of Stat1-
mediated gene activation by PIAS1. Proc Natl Acad Sci U S A, 95, 10626-31. 
Lois, L. M. & Lima, C. D. (2005) Structures of the SUMO E1 provide mechanistic insights into SUMO 
activation and E2 recruitment to E1. EMBO J, 24, 439-51. 
Lois, L. M., Lima, C. D. & Chua, N. H. (2003) Small ubiquitin-like modifier modulates abscisic acid signaling 
in Arabidopsis. Plant Cell, 15, 1347-59. 
Lorick, K. L., Jensen, J. P., Fang, S., Ong, A. M., Hatakeyama, S. & Weissman, A. M. (1999) RING fingers 
mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci U S A, 
96, 11364-9. 
Lorick, K. L., Jensen, J. P. & Weissman, A. M. (2005) Expression, purification, and properties of the Ubc4/5 
family of E2 enzymes. Methods Enzymol, 398, 54-68. 
Löwe, J., Stock, D., Jap, B., Zwickl, P., Baumeister, W. & Huber, R. (1995) Crystal structure of the 20S 
proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science, 268, 533-9. 
Luciani, J. J., Depetris, D., Usson, Y., Metzler-Guillemain, C., Mignon-Ravix, C., Mitchell, M. J., Megarbane, 
A., Sarda, P., Sirma, H., Moncla, A., Feunteun, J. & Mattei, M. G. (2006) PML nuclear bodies are 
highly organised DNA-protein structures with a function in heterochromatin remodelling at the 
G2 phase. J Cell Sci, 119, 2518-31. 
Lukashchuk, V. & Everett, R. D. (2010) Regulation of ICP0 null mutant HSV-1 infection by ND10 
components ATRX and hDaxx. J Virol. 
Mabb, A. M., Wuerzberger-Davis, S. M. & Miyamoto, S. (2006) PIASy mediates NEMO sumoylation and NF-
kappaB activation in response to genotoxic stress. Nat Cell Biol, 8, 986-93. 
Mahajan, R., Delphin, C., Guan, T., Gerace, L. & Melchior, F. (1997) A small ubiquitin-related polypeptide 
involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell, 88, 97-107. 
Mannen, H., Tseng, H. M., Cho, C. L. & Li, S. S. (1996) Cloning and expression of human homolog HSMT3 to 
yeast SMT3 suppressor of MIF2 mutations in a centromere protein gene. Biochem Biophys Res 
Commun, 222, 178-80. 
Marques, A. J., Palanimurugan, R., Matias, A. C., Ramos, P. C. & Dohmen, R. J. (2009) Catalytic mechanism 
and assembly of the proteasome. Chem Rev, 109, 1509-36. 
Martin, M., Kettmann, R. & Dequiedt, F. (2009) Class IIa histone deacetylases: conducting development 
and differentiation. Int J Dev Biol, 53, 291-301. 
Martin, S., Wilkinson, K. A., Nishimune, A. & Henley, J. M. (2007) Emerging extranuclear roles of protein 
SUMOylation in neuronal function and dysfunction. Nat Rev Neurosci, 8, 948-59. 
Mathieu, J. & Besancon, F. (2006) Arsenic trioxide represses NF-kappaB activation and increases apoptosis 
in ATRA-treated APL cells. Ann N Y Acad Sci, 1090, 203-8. 
Matic, I., Macek, B., Hilger, M., Walther, T. C. & Mann, M. (2008) Phosphorylation of SUMO-1 occurs in 
vivo and is conserved through evolution. J Proteome Res, 7, 4050-7. 
Matic, I., van Hagen, M., Schimmel, J., Macek, B., Ogg, S. C., Tatham, M. H., Hay, R. T., Lamond, A. I., Mann, 
M. & Vertegaal, A. C. (2008) In vivo identification of human small ubiquitin-like modifier 
polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy. Mol 
Cell Proteomics, 7, 132-44. 
Matunis, M. J., Coutavas, E. & Blobel, G. (1996) A novel ubiquitin-like modification modulates the 
partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear 
pore complex. J Cell Biol, 135, 1457-70. 
Matunis, M. J., Zhang, X. D. & Ellis, N. A. (2006) SUMO: the glue that binds. Dev Cell, 11, 596-7. 
Maul, G. G., Yu, E., Ishov, A. M. & Epstein, A. L. (1995) Nuclear domain 10 (ND10) associated proteins are 
also present in nuclear bodies and redistribute to hundreds of nuclear sites after stress. J Cell 
Biochem, 59, 498-513. 
Melnick, A. & Licht, J. D. (1999) Deconstructing a disease: RARalpha, its fusion partners, and their roles in 
the pathogenesis of acute promyelocytic leukemia. Blood, 93, 3167-215. 
Meluh, P. B. & Koshland, D. (1995) Evidence that the MIF2 gene of Saccharomyces cerevisiae encodes a 
centromere protein with homology to the mammalian centromere protein CENP-C. Mol Biol Cell, 
6, 793-807. 
Meulmeester, E., Kunze, M., Hsiao, H. H., Urlaub, H. & Melchior, F. (2008) Mechanism and consequences 
for paralog-specific sumoylation of ubiquitin-specific protease 25. Mol Cell, 30, 610-9. 
REFERENCES  
144 
 
Meyer-Teschendorf, K. (2010) Canavanine stress regulation of promyelocytic leukemia protein nuclear 
bodies (PML-NBs) Master Master thesis, University of Cologne, Cologne. 
Michiels, L., Van der Rauwelaert, E., Van Hasselt, F., Kas, K. & Merregaert, J. (1993) fau cDNA encodes a 
ubiquitin-like-S30 fusion protein and is expressed as an antisense sequence in the Finkel-Biskis-
Reilly murine sarcoma virus. Oncogene, 8, 2537-46. 
Mikolajczyk, J., Drag, M., Bekes, M., Cao, J. T., Ronai, Z. & Salvesen, G. S. (2007) Small ubiquitin-related 
modifier (SUMO)-specific proteases: profiling the specificities and activities of human SENPs. J 
Biol Chem, 282, 26217-24. 
Minty, A., Dumont, X., Kaghad, M. & Caput, D. (2000) Covalent modification of p73alpha by SUMO-1. Two-
hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 
interaction motif. J Biol Chem, 275, 36316-23. 
Miteva, M., Keusekotten, K., Hofmann, K., Praefcke, G. J. K. & Dohmen, R. J. (2010) Sumoylation as a Signal 
for Polyubiquitylation and Proteasomal Degradation. Conjugation and Deconjugation of Ubiquitin 
Family Modifiers (ed M. Groettrup). Landes Bioscience and Springer Science+Business Media, 
Austin, TX, USA. 
Möller, A., Sirma, H., Hofmann, T. G., Rueffer, S., Klimczak, E., Droge, W., Will, H. & Schmitz, M. L. (2003) 
PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 
phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. 
Cancer Res, 63, 4310-4. 
Morris, J. R., Boutell, C., Keppler, M., Densham, R., Weekes, D., Alamshah, A., Butler, L., Galanty, Y., 
Pangon, L., Kiuchi, T., Ng, T. & Solomon, E. (2009) The SUMO modification pathway is involved in 
the BRCA1 response to genotoxic stress. Nature, 462, 886-90. 
Mossessova, E. & Lima, C. D. (2000) Ulp1-SUMO crystal structure and genetic analysis reveal conserved 
interactions and a regulatory element essential for cell growth in yeast. Mol Cell, 5, 865-76. 
Müller, S., Matunis, M. J. & Dejean, A. (1998) Conjugation with the ubiquitin-related modifier SUMO-1 
regulates the partitioning of PML within the nucleus. EMBO J, 17, 61-70. 
Mukhopadhyay, D., Arnaoutov, A. & Dasso, M. (2010) The SUMO protease SENP6 is essential for inner 
kinetochore assembly. J Cell Biol, 188, 681-92. 
Mukhopadhyay, D., Ayaydin, F., Kolli, N., Tan, S. H., Anan, T., Kametaka, A., Azuma, Y., Wilkinson, K. D. & 
Dasso, M. (2006) SUSP1 antagonizes formation of highly SUMO2/3-conjugated species. J Cell Biol, 
174, 939-49. 
Mukhopadhyay, D. & Riezman, H. (2007) Proteasome-independent functions of ubiquitin in endocytosis 
and signaling. Science, 315, 201-5. 
Mullen, J. R. & Brill, S. J. (2008) Activation of the Slx5-Slx8 ubiquitin ligase by poly-small ubiquitin-like 
modifier conjugates. J Biol Chem, 283, 19912-21. 
Mullen, J. R., Kaliraman, V., Ibrahim, S. S. & Brill, S. J. (2001) Requirement for three novel protein 
complexes in the absence of the Sgs1 DNA helicase in Saccharomyces cerevisiae. Genetics, 157, 
103-18. 
Nacerddine, K., Lehembre, F., Bhaumik, M., Artus, J., Cohen-Tannoudji, M., Babinet, C., Pandolfi, P. P. & 
Dejean, A. (2005) The SUMO pathway is essential for nuclear integrity and chromosome 
segregation in mice. Dev Cell, 9, 769-79. 
Nasr, R., Guillemin, M. C., Ferhi, O., Soilihi, H., Peres, L., Berthier, C., Rousselot, P., Robledo-Sarmiento, M., 
Lallemand-Breitenbach, V., Gourmel, B., Vitoux, D., Pandolfi, P. P., Rochette-Egly, C., Zhu, J. & de 
The, H. (2008) Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA 
degradation. Nat Med, 14, 1333-42. 
Negorev, D. & Maul, G. G. (2001) Cellular proteins localized at and interacting within ND10/PML nuclear 
bodies/PODs suggest functions of a nuclear depot. Oncogene, 20, 7234-42. 
Ng, S. S., Yue, W. W., Oppermann, U. & Klose, R. J. (2009) Dynamic protein methylation in chromatin 
biology. Cell Mol Life Sci, 66, 407-22. 
Niikura, T., Hashimoto, Y., Tajima, H., Ishizaka, M., Yamagishi, Y., Kawasumi, M., Nawa, M., Terashita, K., 
Aiso, S. & Nishimoto, I. (2003) A tripartite motif protein TRIM11 binds and destabilizes Humanin, 
a neuroprotective peptide against Alzheimer's disease-relevant insults. Eur J Neurosci, 17, 1150-8. 
Nijman, S. M., Luna-Vargas, M. P., Velds, A., Brummelkamp, T. R., Dirac, A. M., Sixma, T. K. & Bernards, R. 
(2005) A genomic and functional inventory of deubiquitinating enzymes. Cell, 123, 773-86. 
Nishida, T., Tanaka, H. & Yasuda, H. (2000) A novel mammalian Smt3-specific isopeptidase 1 (SMT3IP1) 
localized in the nucleolus at interphase. Eur J Biochem, 267, 6423-7. 
REFERENCES 
145 
 
Nisole, S., Stoye, J. P. & Saib, A. (2005) TRIM family proteins: retroviral restriction and antiviral defence. 
Nat Rev Microbiol, 3, 799-808. 
Nixon, C. E., Wilcox, A. J. & Laney, J. D. Degradation of the Saccharomyces cerevisiae Mating-type 
Regulator {alpha}1: Genetic Dissection of Cis-determinants and Trans-acting Pathways. Genetics. 
Ohnishi, K. (2007) PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic 
leukemia. Int J Clin Oncol, 12, 313-7. 
Okura, T., Gong, L., Kamitani, T., Wada, T., Okura, I., Wei, C. F., Chang, H. M. & Yeh, E. T. (1996) Protection 
against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J 
Immunol, 157, 4277-81. 
Owerbach, D., McKay, E. M., Yeh, E. T., Gabbay, K. H. & Bohren, K. M. (2005) A proline-90 residue unique 
to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun, 337, 517-20. 
Palvimo, J. J. (2007) PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications 
and transcription. Biochem Soc Trans, 35, 1405-8. 
Pandolfi, P. P., Grignani, F., Alcalay, M., Mencarelli, A., Biondi, A., LoCoco, F. & Pelicci, P. G. (1991) 
Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and 
characterization of its retinoid-binding and transactivation properties. Oncogene, 6, 1285-92. 
Park, H. J., Zheng, H., Kulkarni, D., Kerrigan, J., Pungaliya, P., Saleem, A. & Rubin, E. H. (2008) Identification 
of phosphorylation sites of TOPORS and a role for serine 98 in the regulation of ubiquitin but not 
SUMO E3 ligase activity. Biochemistry, 47, 13887-96. 
Park, K. C., Woo, S. K., Yoo, Y. J., Wyndham, A. M., Baker, R. T. & Chung, C. H. (1997) Purification and 
characterization of UBP6, a new ubiquitin-specific protease in Saccharomyces cerevisiae. Arch 
Biochem Biophys, 347, 78-84. 
Pedrioli, P. G., Leidel, S. & Hofmann, K. (2008) Urm1 at the crossroad of modifications. 'Protein 
Modifications: Beyond the Usual Suspects' Review Series. EMBO Rep, 9, 1196-202. 
Pedrioli, P. G., Raught, B., Zhang, X. D., Rogers, R., Aitchison, J., Matunis, M. & Aebersold, R. (2006) 
Automated identification of SUMOylation sites using mass spectrometry and SUMmOn pattern 
recognition software. Nat Methods, 3, 533-9. 
Pelzer, C., Kassner, I., Matentzoglu, K., Singh, R. K., Wollscheid, H. P., Scheffner, M., Schmidtke, G. & 
Groettrup, M. (2007) UBE1L2, a novel E1 enzyme specific for ubiquitin. J Biol Chem, 282, 23010-4. 
Peng, J., Schwartz, D., Elias, J. E., Thoreen, C. C., Cheng, D., Marsischky, G., Roelofs, J., Finley, D. & Gygi, S. 
P. (2003) A proteomics approach to understanding protein ubiquitination. Nat Biotechnol, 21, 
921-6. 
Perez, A., Kastner, P., Sethi, S., Lutz, Y., Reibel, C. & Chambon, P. (1993) PMLRAR homodimers: distinct 
DNA binding properties and heteromeric interactions with RXR. EMBO J, 12, 3171-82. 
Pfander, B., Moldovan, G. L., Sacher, M., Hoege, C. & Jentsch, S. (2005) SUMO-modified PCNA recruits Srs2 
to prevent recombination during S phase. Nature, 436, 428-33. 
Pichler, A., Gast, A., Seeler, J. S., Dejean, A. & Melchior, F. (2002) The nucleoporin RanBP2 has SUMO1 E3 
ligase activity. Cell, 108, 109-20. 
Pickart, C. M. & Eddins, M. J. (2004) Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta, 
1695, 55-72. 
Pickart, C. M. & Fushman, D. (2004) Polyubiquitin chains: polymeric protein signals. Curr Opin Chem Biol, 
8, 610-6. 
Pickart, C. M. & Rose, I. A. (1985) Functional heterogeneity of ubiquitin carrier proteins. J Biol Chem, 260, 
1573-81. 
Prudden, J., Pebernard, S., Raffa, G., Slavin, D. A., Perry, J. J., Tainer, J. A., McGowan, C. H. & Boddy, M. N. 
(2007) SUMO-targeted ubiquitin ligases in genome stability. EMBO J, 26, 4089-101. 
Prudden, J., Perry, J. J., Arvai, A. S., Tainer, J. A. & Boddy, M. N. (2009) Molecular mimicry of SUMO 
promotes DNA repair. Nat Struct Mol Biol, 16, 509-16. 
Quimby, B. B., Yong-Gonzalez, V., Anan, T., Strunnikov, A. V. & Dasso, M. (2006) The promyelocytic 
leukemia protein stimulates SUMO conjugation in yeast. Oncogene, 25, 2999-3005. 
Raasi, S., Varadan, R., Fushman, D. & Pickart, C. M. (2005) Diverse polyubiquitin interaction properties of 
ubiquitin-associated domains. Nat Struct Mol Biol, 12, 708-14. 
Rabut, G. & Peter, M. (2008) Function and regulation of protein neddylation. 'Protein modifications: 
beyond the usual suspects' review series. EMBO Rep, 9, 969-76. 
Rajendra, R., Malegaonkar, D., Pungaliya, P., Marshall, H., Rasheed, Z., Brownell, J., Liu, L. F., Lutzker, S., 
Saleem, A. & Rubin, E. H. (2004) Topors functions as an E3 ubiquitin ligase with specific E2 
enzymes and ubiquitinates p53. J Biol Chem, 279, 36440-4. 
REFERENCES  
146 
 
Ravandi, F., Estey, E., Jones, D., Faderl, S., O'Brien, S., Fiorentino, J., Pierce, S., Blamble, D., Estrov, Z., 
Wierda, W., Ferrajoli, A., Verstovsek, S., Garcia-Manero, G., Cortes, J. & Kantarjian, H. (2009) 
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, 
and gemtuzumab ozogamicin. J Clin Oncol, 27, 504-10. 
Reddy, B. A., Etkin, L. D. & Freemont, P. S. (1992) A novel zinc finger coiled-coil domain in a family of 
nuclear proteins. Trends Biochem Sci, 17, 344-5. 
Reineke, E. L., Liu, H., Lam, M., Liu, Y. & Kao, H. Y. (2007) Aberrant association of promyelocytic leukemia 
protein-retinoic acid receptor-alpha with coactivators contributes to its ability to regulate gene 
expression. J Biol Chem, 282, 18584-96. 
Reiss, Y., Heller, H. & Hershko, A. (1989) Binding sites of ubiquitin-protein ligase. Binding of ubiquitin-
protein conjugates and of ubiquitin-carrier protein. J Biol Chem, 264, 10378-83. 
Renart, J., Reiser, J. & Stark, G. R. (1979) Transfer of proteins from gels to diazobenzyloxymethyl-paper 
and detection with antisera: a method for studying antibody specificity and antigen structure. 
Proc Natl Acad Sci U S A, 76, 3116-20. 
Renner, F., Moreno, R. & Schmitz, M. L. SUMOylation-dependent localization of IKKepsilon in PML nuclear 
bodies is essential for protection against DNA-damage-triggered cell death. Mol Cell, 37, 503-15. 
Reverter, D. & Lima, C. D. (2004) A basis for SUMO protease specificity provided by analysis of human 
Senp2 and a Senp2-SUMO complex. Structure, 12, 1519-31. 
Reverter, D. & Lima, C. D. (2005) Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-
Nup358 complex. Nature, 435, 687-92. 
Reymond, A., Meroni, G., Fantozzi, A., Merla, G., Cairo, S., Luzi, L., Riganelli, D., Zanaria, E., Messali, S., 
Cainarca, S., Guffanti, A., Minucci, S., Pelicci, P. G. & Ballabio, A. (2001) The tripartite motif family 
identifies cell compartments. EMBO J, 20, 2140-51. 
Rotin, D. & Kumar, S. (2009) Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol 
Cell Biol, 10, 398-409. 
Rowley, J. D., Golomb, H. M. & Dougherty, C. (1977) 15/17 translocation, a consistent chromosomal 
change in acute promyelocytic leukaemia. Lancet, 1, 549-50. 
Rudolph, M. G. (1998) Kristallstruktur des GTP-bindenden Proteins Cdc42 und dessen Wechselwirkung mit 
dem Wiskott-Aldrich Syndrom Protein. Universität Bayreuth, Bayreuth. 
Sadler, A. J. & Williams, B. R. (2008) Interferon-inducible antiviral effectors. Nat Rev Immunol, 8, 559-68. 
Saitoh, H. & Hinchey, J. (2000) Functional heterogeneity of small ubiquitin-related protein modifiers 
SUMO-1 versus SUMO-2/3. J Biol Chem, 275, 6252-8. 
Saitoh, H., Sparrow, D. B., Shiomi, T., Pu, R. T., Nishimoto, T., Mohun, T. J. & Dasso, M. (1998) Ubc9p and 
the conjugation of SUMO-1 to RanGAP1 and RanBP2. Curr Biol, 8, 121-4. 
Saitoh, N., Uchimura, Y., Tachibana, T., Sugahara, S., Saitoh, H. & Nakao, M. (2006) In situ SUMOylation 
analysis reveals a modulatory role of RanBP2 in the nuclear rim and PML bodies. Exp Cell Res, 
312, 1418-30. 
Sampson, D. A., Wang, M. & Matunis, M. J. (2001) The small ubiquitin-like modifier-1 (SUMO-1) consensus 
sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J Biol Chem, 276, 
21664-9. 
Sarge, K. D. & Park-Sarge, O. K. (2009) Sumoylation and human disease pathogenesis. Trends Biochem Sci, 
34, 200-5. 
Scaglioni, P. P., Yung, T. M., Choi, S., Baldini, C., Konstantinidou, G. & Pandolfi, P. P. (2008) CK2 mediates 
phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor. Mol Cell 
Biochem, 316, 149-54. 
Schlesinger, D. H., Goldstein, G. & Niall, H. D. (1975) The complete amino acid sequence of ubiquitin, an 
adenylate cyclase stimulating polypeptide probably universal in living cells. Biochemistry, 14, 
2214-8. 
Schreiner, P., Chen, X., Husnjak, K., Randles, L., Zhang, N., Elsasser, S., Finley, D., Dikic, I., Walters, K. J. & 
Groll, M. (2008) Ubiquitin docking at the proteasome through a novel pleckstrin-homology 
domain interaction. Nature, 453, 548-52. 
Schulman, B. A. & Harper, J. W. (2009) Ubiquitin-like protein activation by E1 enzymes: the apex for 
downstream signalling pathways. Nat Rev Mol Cell Biol, 10, 319-31. 
Schwartz, D. C., Felberbaum, R. & Hochstrasser, M. (2007) The Ulp2 SUMO protease is required for cell 
division following termination of the DNA damage checkpoint. Mol Cell Biol, 27, 6948-61. 
REFERENCES 
147 
 
Schwarz, S. E., Matuschewski, K., Liakopoulos, D., Scheffner, M. & Jentsch, S. (1998) The ubiquitin-like 
proteins SMT3 and SUMO-1 are conjugated by the UBC9 E2 enzyme. Proc Natl Acad Sci U S A, 95, 
560-4. 
Schwienhorst, I., Johnson, E. S. & Dohmen, R. J. (2000) SUMO conjugation and deconjugation. Mol Gen 
Genet, 263, 771-86. 
Seeler, J. S., Marchio, A., Losson, R., Desterro, J. M., Hay, R. T., Chambon, P. & Dejean, A. (2001) Common 
properties of nuclear body protein SP100 and TIF1alpha chromatin factor: role of SUMO 
modification. Mol Cell Biol, 21, 3314-24. 
Seeler, J. S., Marchio, A., Sitterlin, D., Transy, C. & Dejean, A. (1998) Interaction of SP100 with HP1 
proteins: a link between the promyelocytic leukemia-associated nuclear bodies and the 
chromatin compartment. Proc Natl Acad Sci U S A, 95, 7316-21. 
Sekiyama, N., Ikegami, T., Yamane, T., Ikeguchi, M., Uchimura, Y., Baba, D., Ariyoshi, M., Tochio, H., Saitoh, 
H. & Shirakawa, M. (2008) Structure of the small ubiquitin-like modifier (SUMO)-interacting motif 
of MBD1-containing chromatin-associated factor 1 bound to SUMO-3. J Biol Chem, 283, 35966-
75. 
Seufert, W., Futcher, B. & Jentsch, S. (1995) Role of a ubiquitin-conjugating enzyme in degradation of S- 
and M-phase cyclins. Nature, 373, 78-81. 
Seufert, W. & Jentsch, S. (1992) In vivo function of the proteasome in the ubiquitin pathway. EMBO J, 11, 
3077-80. 
Shang, F., Deng, G., Liu, Q., Guo, W., Haas, A. L., Crosas, B., Finley, D. & Taylor, A. (2005) Lys6-modified 
ubiquitin inhibits ubiquitin-dependent protein degradation. J Biol Chem, 280, 20365-74. 
Sharp, D. A., Kratowicz, S. A., Sank, M. J. & George, D. L. (1999) Stabilization of the MDM2 oncoprotein by 
interaction with the structurally related MDMX protein. J Biol Chem, 274, 38189-96. 
Shen, T. H., Lin, H. K., Scaglioni, P. P., Yung, T. M. & Pandolfi, P. P. (2006) The mechanisms of PML-nuclear 
body formation. Mol Cell, 24, 331-9. 
Shen, Z., Pardington-Purtymun, P. E., Comeaux, J. C., Moyzis, R. K. & Chen, D. J. (1996) UBL1, a human 
ubiquitin-like protein associating with human RAD51/RAD52 proteins. Genomics, 36, 271-9. 
Shen, Z. X., Chen, G. Q., Ni, J. H., Li, X. S., Xiong, S. M., Qiu, Q. Y., Zhu, J., Tang, W., Sun, G. L., Yang, K. Q., 
Chen, Y., Zhou, L., Fang, Z. W., Wang, Y. T., Ma, J., Zhang, P., Zhang, T. D., Chen, S. J., Chen, Z. & 
Wang, Z. Y. (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic 
leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89, 3354-60. 
Shen, Z. X., Shi, Z. Z., Fang, J., Gu, B. W., Li, J. M., Zhu, Y. M., Shi, J. Y., Zheng, P. Z., Yan, H., Liu, Y. F., Chen, 
Y., Shen, Y., Wu, W., Tang, W., Waxman, S., De The, H., Wang, Z. Y., Chen, S. J. & Chen, Z. (2004) 
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly 
diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A, 101, 5328-35. 
Shimoda, K., Kamesaki, K., Numata, A., Aoki, K., Matsuda, T., Oritani, K., Tamiya, S., Kato, K., Takase, K., 
Imamura, R., Yamamoto, T., Miyamoto, T., Nagafuji, K., Gondo, H., Nagafuchi, S., Nakayama, K. & 
Harada, M. (2002) Cutting edge: tyk2 is required for the induction and nuclear translocation of 
Daxx which regulates IFN-alpha-induced suppression of B lymphocyte formation. J Immunol, 169, 
4707-11. 
Shuai, K. (2000) Modulation of STAT signaling by STAT-interacting proteins. Oncogene, 19, 2638-44. 
Skilton, A., Ho, J. C., Mercer, B., Outwin, E. & Watts, F. Z. (2009) SUMO chain formation is required for 
response to replication arrest in S. pombe. PLoS One, 4, e6750. 
Solt, L. A. & May, M. J. (2008) The IkappaB kinase complex: master regulator of NF-kappaB signaling. 
Immunol Res, 42, 3-18. 
Song, J., Durrin, L. K., Wilkinson, T. A., Krontiris, T. G. & Chen, Y. (2004) Identification of a SUMO-binding 
motif that recognizes SUMO-modified proteins. Proc Natl Acad Sci U S A, 101, 14373-8. 
Song, J., Zhang, Z., Hu, W. & Chen, Y. (2005) Small ubiquitin-like modifier (SUMO) recognition of a SUMO 
binding motif: a reversal of the bound orientation. J Biol Chem, 280, 40122-9. 
Song, M. S., Salmena, L., Carracedo, A., Egia, A., Lo-Coco, F., Teruya-Feldstein, J. & Pandolfi, P. P. (2008) 
The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature, 
455, 813-7. 
Sramko, M., Markus, J., Kabat, J., Wolff, L. & Bies, J. (2006) Stress-induced inactivation of the c-Myb 
transcription factor through conjugation of SUMO-2/3 proteins. J Biol Chem, 281, 40065-75. 
Stadler, M., Chelbi-Alix, M. K., Koken, M. H., Venturini, L., Lee, C., Saib, A., Quignon, F., Pelicano, L., 
Guillemin, M. C., Schindler, C. & et al. (1995) Transcriptional induction of the PML growth 
REFERENCES  
148 
 
suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene, 11, 
2565-73. 
Stehmeier, P. & Müller, S. (2009) Phospho-regulated SUMO interaction modules connect the SUMO 
system to CK2 signaling. Mol Cell, 33, 400-9. 
Stelter, P. & Ulrich, H. D. (2003) Control of spontaneous and damage-induced mutagenesis by SUMO and 
ubiquitin conjugation. Nature, 425, 188-91. 
Sternsdorf, T., Jensen, K., Reich, B. & Will, H. (1999) The nuclear dot protein sp100, characterization of 
domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-
like modifiers. J Biol Chem, 274, 12555-66. 
Sternsdorf, T., Jensen, K. & Will, H. (1997) Evidence for covalent modification of the nuclear dot-associated 
proteins PML and Sp100 by PIC1/SUMO-1. J Cell Biol, 139, 1621-34. 
Sternsdorf, T., Phan, V. T., Maunakea, M. L., Ocampo, C. B., Sohal, J., Silletto, A., Galimi, F., Le Beau, M. M., 
Evans, R. M. & Kogan, S. C. (2006) Forced retinoic acid receptor alpha homodimers prime mice for 
APL-like leukemia. Cancer Cell, 9, 81-94. 
Sun, H., Leverson, J. D. & Hunter, T. (2007) Conserved function of RNF4 family proteins in eukaryotes: 
targeting a ubiquitin ligase to SUMOylated proteins. EMBO J, 26, 4102-12. 
Sung, P., Berleth, E., Pickart, C., Prakash, S. & Prakash, L. (1991) Yeast RAD6 encoded ubiquitin conjugating 
enzyme mediates protein degradation dependent on the N-end-recognizing E3 enzyme. EMBO J, 
10, 2187-93. 
Takahashi, Y., Mizoi, J., Toh, E. A. & Kikuchi, Y. (2000) Yeast Ulp1, an Smt3-specific protease, associates 
with nucleoporins. J Biochem, 128, 723-5. 
Tanaka, K., Nishide, J., Okazaki, K., Kato, H., Niwa, O., Nakagawa, T., Matsuda, H., Kawamukai, M. & 
Murakami, Y. (1999) Characterization of a fission yeast SUMO-1 homologue, pmt3p, required for 
multiple nuclear events, including the control of telomere length and chromosome segregation. 
Mol Cell Biol, 19, 8660-72. 
Tao, H., Simmons, B. N., Singireddy, S., Jakkidi, M., Short, K. M., Cox, T. C. & Massiah, M. A. (2008) 
Structure of the MID1 tandem B-boxes reveals an interaction reminiscent of intermolecular ring 
heterodimers. Biochemistry, 47, 2450-7. 
Tarkanyi, I., Dudognon, C., Hillion, J., Pendino, F., Lanotte, M., Aradi, J. & Segal-Bendirdjian, E. (2005) 
Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-
dependent cell death. Leukemia, 19, 1806-11. 
Tarrade, A., Bastien, J., Bruck, N., Bauer, A., Gianni, M. & Rochette-Egly, C. (2005) Retinoic acid and arsenic 
trioxide cooperate for apoptosis through phosphorylated RXR alpha. Oncogene, 24, 2277-88. 
Tatham, M. H., Geoffroy, M. C., Shen, L., Plechanovova, A., Hattersley, N., Jaffray, E. G., Palvimo, J. J. & 
Hay, R. T. (2008) RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced 
PML degradation. Nat Cell Biol, 10, 538-46. 
Tatham, M. H., Jaffray, E., Vaughan, O. A., Desterro, J. M., Botting, C. H., Naismith, J. H. & Hay, R. T. (2001) 
Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and 
Ubc9. J Biol Chem, 276, 35368-74. 
Tatham, M. H., Kim, S., Yu, B., Jaffray, E., Song, J., Zheng, J., Rodriguez, M. S., Hay, R. T. & Chen, Y. (2003) 
Role of an N-terminal site of Ubc9 in SUMO-1, -2, and -3 binding and conjugation. Biochemistry, 
42, 9959-69. 
Tatsumi, K., Sou, Y. S., Tada, N., Nakamura, E., Iemura, S. I., Natsume, T., Kang, S. H., Chung, C. H., 
Kasahara, M., Kominami, E., Yamamoto, M., Tanaka, K. & Komatsu, M. (2010) A novel type of E3-
ligase for the Ufm1-conjugation system. J Biol Chem, 285, 5417-27. 
Tempe, D., Piechaczyk, M. & Bossis, G. (2008) SUMO under stress. Biochem Soc Trans, 36, 874-8. 
Thompson, L. H. & Hinz, J. M. (2009) Cellular and molecular consequences of defective Fanconi anemia 
proteins in replication-coupled DNA repair: mechanistic insights. Mutat Res, 668, 54-72. 
Thornton, B. R. & Toczyski, D. P. (2006) Precise destruction: an emerging picture of the APC. Genes Dev, 
20, 3069-78. 
Towbin, H., Staehelin, T. & Gordon, J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels 
to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A, 76, 4350-4. 
Trockenbacher, A., Suckow, V., Foerster, J., Winter, J., Krauss, S., Ropers, H. H., Schneider, R. & Schweiger, 
S. (2001) MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 
2A for degradation. Nat Genet, 29, 287-94. 
REFERENCES 
149 
 
Uchimura, Y., Nakao, M. & Saitoh, H. (2004a) Generation of SUMO-1 modified proteins in E. coli: towards 
understanding the biochemistry/structural biology of the SUMO-1 pathway. FEBS Lett, 564, 85-
90. 
Uchimura, Y., Nakamura, M., Sugasawa, K., Nakao, M. & Saitoh, H. (2004b) Overproduction of eukaryotic 
SUMO-1- and SUMO-2-conjugated proteins in Escherichia coli. Anal Biochem, 331, 204-6. 
Ulrich, H. D. (2005) Mutual interactions between the SUMO and ubiquitin systems: a plea of no contest. 
Trends Cell Biol, 15, 525-32. 
Urano, T., Saito, T., Tsukui, T., Fujita, M., Hosoi, T., Muramatsu, M., Ouchi, Y. & Inoue, S. (2002) Efp targets 
14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature, 417, 871-5. 
Uzunova, K., Gottsche, K., Miteva, M., Weisshaar, S. R., Glanemann, C., Schnellhardt, M., Niessen, M., 
Scheel, H., Hofmann, K., Johnson, E. S., Praefcke, G. J. & Dohmen, R. J. (2007) Ubiquitin-
dependent proteolytic control of SUMO conjugates. J Biol Chem, 282, 34167-75. 
Van Damme, E., Laukens, K., Dang, T. H. & Van Ostade, X. (2010) A manually curated network of the PML 
nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics. Int J 
Biol Sci, 6, 51-67. 
van Wageningen, S., Breems-de Ridder, M. C., Nigten, J., Nikoloski, G., Erpelinck-Verschueren, C. A., 
Lowenberg, B., de Witte, T., Tenen, D. G., van der Reijden, B. A. & Jansen, J. H. (2008) Gene 
transactivation without direct DNA binding defines a novel gain-of-function for PML-RARalpha. 
Blood, 111, 1634-43. 
van Wijk, S. J. & Timmers, M. H. T. (2009) The family of ubiquitin-conjugating enzymes (E2s): deciding 
between life and death of proteins. FASEB J. 
VanDemark, A. P., Hofmann, R. M., Tsui, C., Pickart, C. M. & Wolberger, C. (2001) Molecular insights into 
polyubiquitin chain assembly: crystal structure of the Mms2/Ubc13 heterodimer. Cell, 105, 711-
20. 
Varadan, R., Assfalg, M., Raasi, S., Pickart, C. & Fushman, D. (2005) Structural determinants for selective 
recognition of a Lys48-linked polyubiquitin chain by a UBA domain. Mol Cell, 18, 687-98. 
Verma, R., Aravind, L., Oania, R., McDonald, W. H., Yates, J. R., 3rd, Koonin, E. V. & Deshaies, R. J. (2002) 
Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. 
Science, 298, 611-5. 
Vichi, A., Payne, D. M., Pacheco-Rodriguez, G., Moss, J. & Vaughan, M. (2005) E3 ubiquitin ligase activity of 
the trifunctional ARD1 (ADP-ribosylation factor domain protein 1). Proc Natl Acad Sci U S A, 102, 
1945-50. 
Voges, D., Zwickl, P. & Baumeister, W. (1999) The 26S proteasome: a molecular machine designed for 
controlled proteolysis. Annu Rev Biochem, 68, 1015-68. 
Walsh, C. T. (2007) Posttranslational Modification of Proteins. Roberts & Company Publishers, Greenwood 
Village, USA. 
Wang, H., Matsuzawa, A., Brown, S. A., Zhou, J., Guy, C. S., Tseng, P. H., Forbes, K., Nicholson, T. P., 
Sheppard, P. W., Hacker, H., Karin, M. & Vignali, D. A. (2008) Analysis of nondegradative protein 
ubiquitylation with a monoclonal antibody specific for lysine-63-linked polyubiquitin. Proc Natl 
Acad Sci U S A, 105, 20197-202. 
Wang, J., Lee, B., Cai, S., Fukui, L., Hu, W. & Chen, Y. (2009) Conformational transition associated with E1-
E2 interaction in small ubiquitin-like modifications. J Biol Chem, 284, 20340-8. 
Wang, J. C. & Dick, J. E. (2005) Cancer stem cells: lessons from leukemia. Trends Cell Biol, 15, 494-501. 
Wang, Z. & Prelich, G. (2009) Quality control of a transcriptional regulator by SUMO-targeted degradation. 
Mol Cell Biol, 29, 1694-706. 
Wang, Z. Y. & Chen, Z. (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood, 
111, 2505-15. 
Weger, S., Hammer, E. & Heilbronn, R. (2005) Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in 
vivo. FEBS Lett, 579, 5007-12. 
Weidtkamp-Peters, S., Lenser, T., Negorev, D., Gerstner, N., Hofmann, T. G., Schwanitz, G., Hoischen, C., 
Maul, G., Dittrich, P. & Hemmerich, P. (2008) Dynamics of component exchange at PML nuclear 
bodies. J Cell Sci, 121, 2731-43. 
Weiner, M. P., Anderson, C., Jerpseth, B., Johnson-Browne, B. and Vaillancourt, P. (1994) Strategies. pp. 
41-43. 
Weis, K., Rambaud, S., Lavau, C., Jansen, J., Carvalho, T., Carmo-Fonseca, M., Lamond, A. & Dejean, A. 
(1994) Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute 
promyelocytic leukemia cells. Cell, 76, 345-56. 
REFERENCES  
150 
 
Weißhaar, S. R. (2008) Proteolytische Kontrolle des Proteins der promyelozytischen Leukämie (PML) durch 
Modifikation mit dem Ubiquitin-verwandten Protein SUMO. dissertation, University of Cologne, 
Cologne. 
Weisshaar, S. R., Keusekotten, K., Krause, A., Horst, C., Springer, H. M., Göttsche, K., Dohmen, R. J. & 
Praefcke, G. J. (2008) Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-
dependent proteolytic targeting of PML. FEBS Lett, 582, 3174-8. 
Wertz, I. E., O'Rourke, K. M., Zhou, H., Eby, M., Aravind, L., Seshagiri, S., Wu, P., Wiesmann, C., Baker, R., 
Boone, D. L., Ma, A., Koonin, E. V. & Dixit, V. M. (2004) De-ubiquitination and ubiquitin ligase 
domains of A20 downregulate NF-kappaB signalling. Nature, 430, 694-9. 
Wiborg, O., Pedersen, M. S., Wind, A., Berglund, L. E., Marcker, K. A. & Vuust, J. (1985) The human 
ubiquitin multigene family: some genes contain multiple directly repeated ubiquitin coding 
sequences. EMBO J, 4, 755-9. 
Wilkinson, C. R., Dittmar, G. A., Ohi, M. D., Uetz, P., Jones, N. & Finley, D. (2004) Ubiquitin-like protein 
Hub1 is required for pre-mRNA splicing and localization of an essential splicing factor in fission 
yeast. Curr Biol, 14, 2283-8. 
Williamson, A., Wickliffe, K. E., Mellone, B. G., Song, L., Karpen, G. H. & Rape, M. (2009) Identification of a 
physiological E2 module for the human anaphase-promoting complex. Proc Natl Acad Sci U S A, 
106, 18213-8. 
Wiseman, T., Williston, S., Brandts, J. F. & Lin, L. N. (1989) Rapid measurement of binding constants and 
heats of binding using a new titration calorimeter. Anal Biochem, 179, 131-7. 
Woodcock, D. M., Crowther, P. J., Doherty, J., Jefferson, S., DeCruz, E., Noyer-Weidner, M., Smith, S. S., 
Michael, M. Z. & Graham, M. W. (1989) Quantitative evaluation of Escherichia coli host strains for 
tolerance to cytosine methylation in plasmid and phage recombinants. Nucleic Acids Res, 17, 
3469-78. 
Wotton, D. & Merrill, J. C. (2007) Pc2 and SUMOylation. Biochem Soc Trans, 35, 1401-4. 
Wu, J., Matunis, M. J., Kraemer, D., Blobel, G. & Coutavas, E. (1995) Nup358, a cytoplasmically exposed 
nucleoporin with peptide repeats, Ran-GTP binding sites, zinc fingers, a cyclophilin A homologous 
domain, and a leucine-rich region. J Biol Chem, 270, 14209-13. 
Xia, Y., Pao, G. M., Chen, H. W., Verma, I. M. & Hunter, T. (2003) Enhancement of BRCA1 E3 ubiquitin 
ligase activity through direct interaction with the BARD1 protein. J Biol Chem, 278, 5255-63. 
Xie, Y., Kerscher, O., Kroetz, M. B., McConchie, H. F., Sung, P. & Hochstrasser, M. (2007) The yeast 
Hex3.Slx8 heterodimer is a ubiquitin ligase stimulated by substrate sumoylation. J Biol Chem, 282, 
34176-84. 
Xu, P., Duong, D. M., Seyfried, N. T., Cheng, D., Xie, Y., Robert, J., Rush, J., Hochstrasser, M., Finley, D. & 
Peng, J. (2009) Quantitative proteomics reveals the function of unconventional ubiquitin chains in 
proteasomal degradation. Cell, 137, 133-45. 
Xu, Z. & Au, S. W. (2005) Mapping residues of SUMO precursors essential in differential maturation by 
SUMO-specific protease, SENP1. Biochem J, 386, 325-30. 
Xu, Z., Chan, H. Y., Lam, W. L., Lam, K. H., Lam, L. S., Ng, T. B. & Au, S. W. (2009) SUMO proteases: redox 
regulation and biological consequences. Antioxid Redox Signal, 11, 1453-84. 
Yamaguchi, T., Sharma, P., Athanasiou, M., Kumar, A., Yamada, S. & Kuehn, M. R. (2005) Mutation of 
SENP1/SuPr-2 reveals an essential role for desumoylation in mouse development. Mol Cell Biol, 
25, 5171-82. 
Yamauchi, K., Wada, K., Tanji, K., Tanaka, M. & Kamitani, T. (2008) Ubiquitination of E3 ubiquitin ligase 
TRIM5 alpha and its potential role. FEBS J, 275, 1540-55. 
Yang, S., Jeong, J. H., Brown, A. L., Lee, C. H., Pandolfi, P. P., Chung, J. H. & Kim, M. K. (2006) Promyelocytic 
leukemia activates Chk2 by mediating Chk2 autophosphorylation. J Biol Chem, 281, 26645-54. 
Yang, S., Kuo, C., Bisi, J. E. & Kim, M. K. (2002) PML-dependent apoptosis after DNA damage is regulated by 
the checkpoint kinase hCds1/Chk2. Nat Cell Biol, 4, 865-70. 
Yang, X. J. & Gregoire, S. (2006) A recurrent phospho-sumoyl switch in transcriptional repression and 
beyond. Mol Cell, 23, 779-86. 
Yang, X. J. & Seto, E. (2008) Lysine acetylation: codified crosstalk with other posttranslational 
modifications. Mol Cell, 31, 449-61. 
Yashiroda, H. & Tanaka, K. (2004) Hub1 is an essential ubiquitin-like protein without functioning as a 
typical modifier in fission yeast. Genes Cells, 9, 1189-97. 
Ye, Y. & Rape, M. (2009) Building ubiquitin chains: E2 enzymes at work. Nat Rev Mol Cell Biol, 10, 755-64. 
REFERENCES 
151 
 
Yokoyama, N., Hayashi, N., Seki, T., Pante, N., Ohba, T., Nishii, K., Kuma, K., Hayashida, T., Miyata, T., Aebi, 
U. & et al. (1995) A giant nucleopore protein that binds Ran/TC4. Nature, 376, 184-8. 
Yunus, A. A. & Lima, C. D. (2009) Structure of the Siz/PIAS SUMO E3 ligase Siz1 and determinants required 
for SUMO modification of PCNA. Mol Cell, 35, 669-82. 
Zachariae, W., Shevchenko, A., Andrews, P. D., Ciosk, R., Galova, M., Stark, M. J., Mann, M. & Nasmyth, K. 
(1998) Mass spectrometric analysis of the anaphase-promoting complex from yeast: 
identification of a subunit related to cullins. Science, 279, 1216-9. 
Zhang, F. P., Mikkonen, L., Toppari, J., Palvimo, J. J., Thesleff, I. & Janne, O. A. (2008) Sumo-1 function is 
dispensable in normal mouse development. Mol Cell Biol, 28, 5381-90. 
Zhang, X. W., Yan, X. J., Zhou, Z. R., Yang, F. F., Wu, Z. Y., Sun, H. B., Liang, W. X., Song, A. X., Lallemand-
Breitenbach, V., Jeanne, M., Zhang, Q. Y., Yang, H. Y., Huang, Q. H., Zhou, G. B., Tong, J. H., Zhang, 
Y., Wu, J. H., Hu, H. Y., de The, H., Chen, S. J. & Chen, Z. (2010) Arsenic trioxide controls the fate of 
the PML-RARalpha oncoprotein by directly binding PML. Science, 328, 240-3. 
Zhao, J. (2007) Sumoylation regulates diverse biological processes. Cell Mol Life Sci, 64, 3017-33. 
Zhao, Q., Tao, J., Zhu, Q., Jia, P. M., Dou, A. X., Li, X., Cheng, F., Waxman, S., Chen, G. Q., Chen, S. J., 
Lanotte, M., Chen, Z. & Tong, J. H. (2004) Rapid induction of cAMP/PKA pathway during retinoic 
acid-induced acute promyelocytic leukemia cell differentiation. Leukemia, 18, 285-92. 
Zhao, X., Sternsdorf, T., Bolger, T. A., Evans, R. M. & Yao, T. P. (2005) Regulation of MEF2 by histone 
deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications. Mol Cell Biol, 25, 8456-64. 
Zheng, M., Gu, X., Zheng, D., Yang, Z., Li, F., Zhao, J., Xie, Y., Ji, C. & Mao, Y. (2008) UBE1DC1, an ubiquitin-
activating enzyme, activates two different ubiquitin-like proteins. J Cell Biochem, 104, 2324-34. 
Zheng, N., Wang, P., Jeffrey, P. D. & Pavletich, N. P. (2000) Structure of a c-Cbl-UbcH7 complex: RING 
domain function in ubiquitin-protein ligases. Cell, 102, 533-9. 
Zheng, Y., Yamaguchi, H., Tian, C., Lee, M. W., Tang, H., Wang, H. G. & Chen, Q. (2005) Arsenic trioxide 
(As(2)O(3)) induces apoptosis through activation of Bax in hematopoietic cells. Oncogene, 24, 
3339-47. 
Zhong, S., Müller, S., Ronchetti, S., Freemont, P. S., Dejean, A. & Pandolfi, P. P. (2000) Role of SUMO-1-
modified PML in nuclear body formation. Blood, 95, 2748-52. 
Zhou, R., Wen, H. & Ao, S. Z. (1999) Identification of a novel gene encoding a p53-associated protein. 
Gene, 235, 93-101. 
Zhou, W., Ryan, J. J. & Zhou, H. (2004) Global analyses of sumoylated proteins in Saccharomyces 
cerevisiae. Induction of protein sumoylation by cellular stresses. J Biol Chem, 279, 32262-8. 
Zhu, J., Chen, Z., Lallemand-Breitenbach, V. & de The, H. (2002) How acute promyelocytic leukaemia 
revived arsenic. Nat Rev Cancer, 2, 705-13. 
Zhu, J., Koken, M. H., Quignon, F., Chelbi-Alix, M. K., Degos, L., Wang, Z. Y., Chen, Z. & de The, H. (1997) 
Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute 
promyelocytic leukemia. Proc Natl Acad Sci U S A, 94, 3978-83. 
Zhu, J., Lallemand-Breitenbach, V. & de The, H. (2001) Pathways of retinoic acid- or arsenic trioxide-
induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. 
Oncogene, 20, 7257-65. 
Zhu, J., Nasr, R., Peres, L., Riaucoux-Lormiere, F., Honore, N., Berthier, C., Kamashev, D., Zhou, J., Vitoux, 
D., Lavau, C. & de The, H. (2007) RXR is an essential component of the oncogenic PML/RARA 
complex in vivo. Cancer Cell, 12, 23-35. 
Zhu, J., Zhou, J., Peres, L., Riaucoux, F., Honore, N., Kogan, S. & de The, H. (2005) A sumoylation site in 
PML/RARA is essential for leukemic transformation. Cancer Cell, 7, 143-53. 
Zhu, S., Goeres, J., Sixt, K. M., Bekes, M., Zhang, X. D., Salvesen, G. S. & Matunis, M. J. (2009) Protection 
from isopeptidase-mediated deconjugation regulates paralog-selective sumoylation of RanGAP1. 
Mol Cell, 33, 570-80. 
Zou, W. & Zhang, D. E. (2006) The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also 
functions as an ISG15 E3 ligase. J Biol Chem, 281, 3989-94. 
Zunino, R., Schauss, A., Rippstein, P., Andrade-Navarro, M. & McBride, H. M. (2007) The SUMO protease 
SENP5 is required to maintain mitochondrial morphology and function. J Cell Sci, 120, 1178-88. 
 
 152 
 
ABSTRACT 
 
Ubiquitin and the small ubiquitin related modifier (SUMO) belong to a group of small 
proteins that can be covalently attached to lysine side chains of other proteins, thereby 
changing their function, localization, interaction partners or stability. The conjugation 
reactions are mediated by an enzymatic cascade of specific activating, conjugating and 
ligating enzymes. A ubiquitin chain of at least four K48-linked ubiquitin molecules target 
substrate proteins for degradation by the proteasome.  
Several interconnections exist between the ubiquitin and SUMO system, with the latest 
discoveries made in yeast by identifying E3 ubiquitin ligases that target SUMO 
conjugates for ubiquitylation and subsequent degradation by the proteasome. These 
ubiquitin ligases for SUMO conjugates (ULS) recognize especially high molecular weight 
SUMO conjugates, probably modified with SUMO chains. 
In mammals, out of the three conjugatable SUMO paralogs, only SUMO-2/3 are able to 
form chains. Upon stress induction, the free pool of SUMO-2/3 is rapidly conjugated to 
cellular target proteins. These conjugates are under proteasomal control, implicating 
that the ULS pathway is conserved in humans.  
This work identified the RING finger protein RNF4 as a human ULS protein, confirming 
previous observations in which RNF4 complemented yeast ULS deletion phenotypes. 
RNF4 comprises a RING domain which is present in many E3 ligases and a stretch of up 
to four SUMO interaction motifs (SIMs) that confer binding to SUMO. 
In order to demonstrate ULS activity for RNF4, an in vitro ubiquitylation assay for SUMO 
conjugates has been developed. For that purpose, SUMOylated proteins were generated 
and purified as in vitro substrates from E. coli.  
RNF4 efficiently in vitro ubiquitylated SUMO modified PML while unmodified PML was 
not recognized as a substrate. This result is in line with recent studies in cells 
demonstrating that RNF4 targets PML in a SUMO-dependent manner after arsenic 
trioxide treatment, a drug which is applied in acute promyelocytic leukemia (APL).  
By investigating the SUMO binding properties of the RNF4 SIM domain, it became 
apparent that the interaction was especially enhanced by the presence of SUMO chains 
of more than two SUMOs. In addition, a SIM type specific recognition was noticed for 
different SUMO paralogs, which emphasizes the idea that there is also a SUMO paralogs 
specific regulation. Finally, in an attempt to find other ULS regulated cellular proteins, an 
RNF4 SIM domain construct was used to isolate poly- or multi-SUMOylated proteins 
from cells subjected to diverse cell stresses.  
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ZUSAMMENFASSUNG 
 
Die zwei verwandten Proteine Ubiquitin und SUMO gehören zu einer Gruppe kleiner 
Proteine, die kovalent an die Seitenketten von Lysinen anderer Proteine (Substrate) 
konjugiert werden können. Dies kann zu Veränderungen der Proteinfunktion, -
lokalisation, -interaktion oder -stabilität führen. Die Konjugation erfolgt über spezifische 
Enzymkaskaden von aktivierenden, konjugierenden und ligierenden Enzymen. Ubiquitin-
Ketten, die über K48 geknüpft werden, dienen als Signal für den proteasomalen Abbau 
von Substratproteinen. Die Ubiquitin- und SUMO-Systeme sind auf vielerlei Art 
miteinander verbunden, wobei die neueste Entdeckung in der Hefe zur Identifizierung 
spezialisierter Ubiquitin E3-Ligasen führte. Diese ubiquitylieren SUMO-modifizierte 
Proteine und bewirken dadurch deren proteasomalen Abbau. Diese sogenannten 
Ubiquitin-Ligasen für SUMO-Konjugate (ULS) erkennen vor allem hochmolekulare 
SUMO-Konjugate, die wahrscheinlich mit SUMO-Ketten modifiziert sind. In Säugern sind 
von den drei konjugierbaren SUMOs nur SUMO-2 und -3 in der Lage, Ketten auszubilden. 
Freie SUMO-2/3-Moleküle werden durch mehrere Arten von Zellstressen relativ schnell 
an Substrate konjugiert. Diese Konjugate stehen unter proteasomaler Kontrolle, was 
darauf schließen lässt, dass der ULS-Abbauweg bis zum Menschen konserviert ist.  
In dieser Arbeit konnte das RING-Finger Protein RNF4 als humanes ULS-Protein 
identifiziert werden. Dies bestätigte vorangegangene Beobachtungen, in denen RNF4 die 
Deletionsphänotypen von Hefe-ULS-Proteinen komplementiert. 
RNF4 enthält eine für viele E3-Ligasen typische RING-Domäne sowie einen Bereich von 
bis zu vier SUMO-Interaktionsmotiven (SIMs), welche die Bindung an SUMO 
ermöglichen. 
Um die ULS-Aktivität von RNF4 eindeutig zeigen zu können, wurde ein in vitro-Versuch 
entwickelt, in dem SUMO-Konjugate ubiquityliert werden. Dazu wurden gereinigte 
SUMO-modifizierte Proteine benötigt, die in E. coli hergestellt wurden.  
RNF4 ubiquityliert effizient und spezifisch SUMO-modifiziertes PML, während nicht-
modifiziertes PML nicht ubiquityliert wird. Dieses Ergebnis wird durch aktuelle Studien 
bestätigt, in denen gezeigt wurde, dass RNF4 nach Arsentrioxid (ATO)-Zugabe den 
SUMO-abhängigen Abbau von PML induziert. ATO wird zur Behandlung der akuten 
promyelozytischen Leukämie eingesetzt.  
Untersuchungen der SUMO-bindenden Eigenschaften des SIM-haltigen RNF4-Bereichs 
zeigten, dass RNF4 bevorzugt an SUMO-Ketten mit mindestens zwei SUMO-Molekülen 
bindet. Zusätzlich wurde eine unterschiedliche SIM-Typ-Präferenz verschiedener SUMOs 
festgestellt, was die Frage nach einer SUMO-spezifischen Regulation aufwirft. Schließlich 
wurde der SIM-haltige Bereich von RNF4 dazu eingesetzt, poly- oder multi-SUMOylierte 
Proteine als potentielle ULS-Substrate aus Zellen zu isolieren, die zuvor verschiedenen 
Stressarten ausgesetzt wurden. 
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